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  Introduction   I.
I.1 Multiple sclerosis 
The description of multiple sclerosis (MS) goes back to the 13th century, when Jean-Martin 
Charcot first described MS as a distinct neurological entity, terming it sclerosé en plaques 
disseminées in 1868 [1]. Today, MS is known as a progressive and multifactorial autoimmune 
disease that affects the central nervous system (CNS). MS is pathologically and clinically 
heterogeneous in different patients [2], and according to its transitory nature, the diagnosis is 
often delayed until the stage at which the progressive phase of the disease develops. MS is 
initiated by malfunctioning of the immune system, wherein autoimmune antibodies are 
produced against myelin-derived proteins, such as myelin basic protein (MBP), myelin 
oligodendrocyte glycoprotein (MOG), and proteolipid protein (PLP) [3]. Thereafter, 
antibodies and autoimmune cells attack myelin and promote demyelination and axonal 
damage, followed by plaque formation that correlates with permanent clinical deficiency.  
MS begins with lesions or patches in the CNS, as the inflammation caused by infiltrates 
assists the destruction of myelin. Myelin, which consists of a fatty layer covering nerve fibers, 
is damaged due to the demyelination process, resulting in multiple patches of hard and scarred 
tissues called plaques. Some young lesions might be remyelinated by oligodendrocytes prior 
to plaque formation, while others convert to permanent visible scars. Studying the pathology 
of the disease, MS develops following the breakdown of the blood brain barrier (BBB) [4], 
allowing massive cellular infiltrates and attacking the myelin layer. There is a growing body 
of evidence suggesting the involvement of macrophages and microglia [5]-[7] as major 
initiators of the lesion formation. Macrophages phagocytose myelin and secrete soluble 
inflammatory mediators that assist in the deterioration of the disease [8]. Today, MS is 
considered the most common disabling neurological disorder of the CNS.  
I.1.1 Disease classification 
MS is classified into four subtypes according to relapses rates and clinical disorders [9], as 
follows (Figure 1). Benign MS: This type of MS is diagnosed in 5% of patients and is 
characterized by minimal relapses followed by complete recovery. The diagnosis of benign 
MS is made when a patient experiences minor disabilities for a period of 10–15 years. Benign 
MS can further progress to the next stage, relapsing remitting MS (RRMS). 
RRMS: 85% of MS patients are initially diagnosed with RRMS. In this stage, patients 
experience relapses or attacks followed by remission (a period of recovery). After each attack, 
the patient might recover partially or completely, leading to minor or major exacerbations. 
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The majority of RRMS patients develop secondary progressive MS (SPMS) a few years after 
RRMS diagnosis.  
SPMS: On average, 65% of patients diagnosed with RRMS develop SPMS within 15 years of 
diagnosis. Patients with SPMS suffer from a continuous worsening of the disease and increase 
in disabilities as a result of the development of neurological dysfunction. To determine 
progression of the disease from RRMS to SPMS, a steady deterioration for at least six months 
should be observed.  
 Primary progressive MS (PPMS): PPMS is usually diagnosed in people older than 40 years 
of age. PPMS patients experience gradually worsening symptoms and an accelerated increase 
in disability. Approximately 10% of patients suffer from PPMS. Unlike RRMS, men are as 
likely as women to develop this type of MS [10]. 
 
 
 Multiple sclerosis (MS) is classified according to developed clinical signs. From left to right and top Figure 1.
to bottom: Benign MS, relapsing remitting MS (RRMS), secondary progressive MS (SPMS), and primary 
progressive MS (PPMS). The red peaks represent relapses (Image by Eric Aslanian). 
I.1.2 Prognosis and epidemiology 
It is estimated that approximately 2.5 million people are affected worldwide by MS [11], 
500,000 of whom are in Western Europe. Women outnumber men by a ratio of almost 2:1; 
however, the ratio of PPMS patients is nearly equal. The prevalence rate in Germany is 149.1 
per 100,000 inhabitants [12], excluding the diagnostic category of “possible multiple 
sclerosis” [13]. In addition, 200 new cases are diagnosed weekly in the USA. The prevalence 
of MS varies between 60–200 persons (per 100,000) in Northern Europe and America and 6–
20 persons (per 100,000) in low-risk areas, such as Japan [2].  
MS is five times more prevalent in temperate climates, such as the northern United States, 
Canada, and Europe, compared to tropical regions (Figure 2) [14], [15]. 
I.1.1 Etiology  
The etiology of MS is poorly understood, as the reason for its onset is not exactly known. 
There are two alternative hypotheses supporting the initiation of MS. Rodriguez’s theory 
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describes MS as a disease that begins with damage to the oligodendrocytes in the brain [16], 
[17], called the “inside-out” theory. 
 
 
 Total number of people affected by MS globally and global MS prevalence (www.atlasofms.org) Figure 2.
Normally, oligodendrocytes are responsible for the production of the fatty myelin layer 
around the axons. In MS, as these myelin-forming oligodendrocytes undergo apoptosis for 
unknown reasons, degradation of the myelin is initiated, blocking the transmission of 
electrical impulses through nerve cells. This process triggers an immune response and 
inflammation that affects the CNS and attracts immune cells through the cerebrospinal fluid 
and blood. However, the inside-out theory [18]-[20] has lost its attraction, as in a similar 
situation, the disease could only develop as a progressive form. Because only 10% of patients 
suffer from PPMS, with the majority diagnosed with relapsing forms of MS, with partial or 
total remission, relapses cannot be explained by this theory.  
In contrast, the “outside-in” theory describes MS as a disease that starts from the peripheral 
bloodstream upon entrance of the immune cells to the CNS through the BBB, as in an 
inflamed situation the structure of the BBB is disrupted and becomes penetrable compared to 
its normal condition. It is believed that the primary inflammation is initiated by a viral or 
chemical stimulation that triggers the immune cells, breaks down the BBB, and sends an 
influx of immune cells to attack the myelin layer of the neuronal cells [21], [22]. Furthermore, 
Ransohoff (the describer of the outside-in theory) has shown that innate immune cells are 
present in the biopsies of early MS patients, thus contradicting Rodriguez’s inside-out theory 
[23], [24]. Despite the differences between these theories, researchers share a common belief 
that the disease develops as a result of an immune system malfunction, and that it contains 
immunological components against its own substances, such as myelinated neurons. 
Recent studies have suggested that people who live closer to the equator and get more 
sunshine, and therefore have higher levels of vitamin D, are at low risk of contracting MS. In 
addition, people who live in colder regions or have had a previous Epstein Barr virus [25], 
[26] or Varicella Zoster virus [27], [28] infection have a higher risk of developing the disease. 
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It is also agreed that certain genes increase the susceptibility of developing MS [29], [30]. 
I.1.2 Myelin proteins  
The dry mass of the myelin layer is mostly composed of lipids (70–85%), and only 15–30% is 
protein. The white appearing myelinated axons contribute to the formation of the “white 
matter.” The myelin layer of the axons contains several known immunogenic proteins. Myelin 
basic protein (MBP) is a myelin antigen that, when injected into an animal, elicits a cellular 
immune response and develops a CNS autoimmune disease called experimental allergic 
encephalomyelitis (EAE) [31], [32]. Proteolipid protein (PLP), known as Folch–Lees protein, 
is the most abundant protein in the CNS [33], [34]. In some animal species, EAE is induced 
by injection of PLP supplemented by an adjuvant [35], [36]. Finally, the 26 kDa 
transmembrane, myelin oligodendrocyte glycoprotein (MOG), contains an Ig-like domain and 
N-linked glycosylation site, localized on the outer surface of the myelin sheath and 
oligodendrocytes [37], [38]. MOG has been considered the most significant target of antigens 
in demyelinating autoimmune diseases of the CNS [39], [40], as its surface location suggests 
that it might have a role in signal transduction, transmitting information from the extracellular 
matrix or adjoining myelin sheaths to oligodendrocytes, which are responsible for myelin 
regeneration [41], [42].   
I.1.3 Pathogenesis of MS 
Inflammation is the main trigger of events leading to CNS tissue damage, followed by 
demyelination and axonal destruction that leads to gliosis and permanent scars [43], [44]. In 
MS, an immune response is developed upon antigen presentation by antigen presenting cells 
(APCs). This process involves the engagement of major histocompatibility complex (MHC II) 
and B7 molecules present on the APCs, together with T cell receptor (TCR) and CD28. These 
interactions activate T helper type 1 (Th1) cells, promoting secretion of inflammatory 
cytokines, such as interferon INFγ, lymphotoxin, interleukin 2 (IL-2), and tumor necrosis 
factor alpha (TNFα), breaking down the BBB. Furthermore, activated Th1 cells bind to the 
vascular cell adhesion molecule (VCAM-I) of the BBB via very late antigen-4 (VLA-4), 
composed of CD29 and CD49, and infiltrate the BBB and CNS [45], [46].  
The secretion of inflammatory agents by T cells subsequently attracts macrophages and B 
cells, while antigen particles are presented by macrophages to immune cells. B cells 
differentiate to plasma cells and start to produce antibodies against the myelin proteins. 
Macrophages complete the process by stripping the myelin sheath directly off the nerves and 
releasing TNFα, which is believed to damage the myelin-producing oligodendrocytes, thus 
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making the damage irreparable [47], [48]. Finally, continuous and increased permeability of 
the BBB and the influx of auto reactive immune cells further assists in the formation of 
plaque following lesion development [49], [50]. 
I.1.4 Immunopathology of a lesion structure  
Because the infiltrated immune cells attack the fatty myelin layer around the axons, lesions 
are formed in those areas of the brain and spinal cord [51], [52]. According to the outside-in 
theory, in MS, a lesion develops from myelin layer to axon, as myelin is the immunogenic 
target (Figure 3) [53], [54]. Recent studies have suggested that an active lesion is composed of 
different layers, and that macrophages are the most abundant population present within a 
lesion [55], [56]. In the MS brain, the normal appearing white matter (NAWM) is the 
myelinated area that contains activated macrophages, oligodendrocytes, and dendritic cells 
along the blood vessels. Two types of active and inactive lesions can be found in an MS brain, 
and the cell population of each lesion is determined according to the lesion’s activation phase 
and layer.  
Lesions are composed of four different layers: outer layer, inactive layer, recently 
demyelinated layer, and active layer. In an active lesion on NAWM, the outer layer is where 
the number of oligodendrocytes is considerably reduced, the myelin layer is damaged, and a 
small number of T cells are found. However, in an inactive, already demyelinated layer, a 
small number of activated microglia and macrophages can be found around the blood vessels 
[57], [58],[43], [59], cleaning the environment through phagocytosis. The number of myelin-
containing phagocytes is noticeably increased in the recently demyelinated layer as a sign of 
fresh demyelination. In addition, a small number of oligodendrocytes implementing 
remyelination together with T cells, B cells, and other immune cells are concentrated around 
the blood vessels. In the active layer, the macrophages are infiltrated from blood, while local 
microglia and larger T cell populations are present, attacking the myelin or the demyelinated 
axons. This structure could be described as an ongoing and developed lesion, while a newly 
formed lesion consists of only an active layer or an active layer plus a recently demyelinated 
layer. Old lesions are inactive, due to irreversible damage assisting plaque formation. 
Regardless of lesion layers, various types of lesion patterns are additionally classified based 
on different conditions. For example, lesions with an antibody-mediated phagocytosis profile 
are composed of a diverse cell population compared to lesions with a macrophage-mediated 
phagocytosis profile [60], [61]. Generally, MS lesions develop due to the involvement of 
various immune cells in specified areas of the CNS.  
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 A sample of lesion structure developed on a demyelinated axon. A lesion is composed of different Figure 3.
layers including; outer layer, inactive layer, recently demyelinated layer and active layer (image was adapted 
after; www.adapaonline.org) 
I.2 Multiple sclerosis therapeutics 
In order to develop effective immunotherapies, it is necessary to understand the complicated 
pathogenesis of the disease. According to recent pharmaceutical studies, some progress has 
been made in discovering drugs that reduce attacks and slow down the progress of the disease. 
Currently, the multiple sclerosis (MS) market is focused on disease-modifying, anti-
inflammatory drugs that can reduce the clinical symptoms of MS and be partially effective 
during the relapsing-remitting (RRMS) phase of the disease. Additionally, symptom-
controlling drugs, including anti-depressants, spasmolytics or drugs for managing pain, 
fatigue, and inflammation, can be co-prescribed [62], [63]. However, there are still no 
approved therapies that target the progressive state of the disease.  
According to the immunopathology of the disease [64], [65], a wide range of therapeutics, 
disturbing the circulation of the immune cells or their mechanism of action, are being 
developed against T-cells, B-cells and leukocytes. Macrophages are the cells that require 
more consideration, in terms of drug development, since no effective therapy has yet been 
introduced to target these cells (Figure 4) [62], [66]. Recent studies, especially in the area of 
therapeutic development, explain the role of infiltrating macrophages and endogenous 
microglia as actual effector cells that promote inflammation and demyelination [39], [67]. 
These data suggest that targeting macrophages would be an essential step in controlling the 
relapse and progress of the disease. Further, the studies suggest that depleting macrophages in 
the early phase of the disease, thereby altering their activity, would also be beneficial [68], 
[69]. 
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 Immune pathology and therapeutics of MS; There is a wide range of therapeutics against different Figure 4.
cells, in and outside of the inflamed CNS. Presented in this figure, there are current therapies to inhibit the 
entrance of the immune cells to the CNS by altering the adhesion pathway of VLA-4 to VCAM1 or some 
could react against B cells (Alemtuzumab and Rituximab) or T cells (Daclizumab) and block their activity. 
Macrophages are the only cells that have been left outside the interest of MS market (image by Eric Aslanian) 
I.2.1 Disease modifying drugs  
Disease modifying drugs are designed and produced for patients suffering from RRMS; they 
are capable of reducing the number and severity of the relapses. Interferon beta (IFN-β) is the 
first drug with immune-modulatory properties; it regulates the expression of the adhesion 
molecules and matrix metalloproteinase [70], [71], inhibiting the interruption of the blood-
brain barrier (BBB). It also potentially induces a shift from a cellular immune response to an 
anti-inflammatory Th2 response, while inhibiting the major histocompatibility (MHC) 
expression, in a pro-inflammatory environment [70], [72]. The range of anti-inflammatory 
drugs, in the INF-β family, includes Avonex, Betaseron, Extavia, Rebif and the recently 
launched Copaxone, Tysabri, Ampyra and Gilenya (first oral drug), each have reducing 
effects on the relapse rates of multiple sclerosis [23], [73].  
Glatiramer acetate (GA) is the second major therapeutic, available since 2007, with immune-
modulatory and neuro-protective effects that reduce the relapse frequency, modulate 
microglial activation, and inhibit the release of inflammatory TNFα [74], [75]. GA blocks the 
antigen presentation of PLP, MBP and MOG particles to T-cells, and importantly, induces a 
shift from Th1 to Th2 cytokines. However, even though IFNβ and GA are the major MS 
therapies, they are only moderately effective. They can reduce the disease exacerbation by 30 
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percent or postpone the progressive phase [76], [77]. Additionally, some oral therapies, such 
as fingolimod (FTY720), are approved to facilitate drug usage and are determined to be one 
of the most effective therapeutics for MS. The FTY720 therapy retains T-cells in the lymph 
nodes, therefore preventing relapses and the outbreak of BBB, and keeping T-cells away from 
antigen presenting cells (Figure 4) [23], [78]. 
 
I.2.2 Antibody based therapeutics  
A wide range of therapeutics are being evaluated in phase II/III clinical trials, including oral 
treatments, cytotoxic agents, antibodies and antigen-specific therapies, of which monoclonal 
antibody and protein-based therapeutics provide the most cutting-edge [79], [80]. 
Alemtuzumab, is a recombinant humanized monoclonal antibody (h-mAb), against CD52, 
expressed on T and B-cells, that depletes lymphocytes in circulation and develops 
lymphopenia [14], [81]. Another h-mAb, daclizumab, targets CD25, the IL-2 alpha receptor. 
IL-2 is crucial for the expansion and viability of activated T-cells; therefore daclizumab was 
designed to selectively inhibit T-cell activation and expansion [16], [82]. These two drugs 
were initially used to prevent organ rejection after transplantation, but today they are also 
used to inhibit MS progression. Moreover, natalizumab is used against integrin α4 to reduce 
the cell traffic through the BBB and prevent relapses [18], [83]. Finally, rituximab is a 
chimeric mAb used against CD20 to destroy B-cells, that is now a candidate for MS treatment 
[21], [84]. Recent therapeutics were all aimed at improving the patient’s condition and disease 
outcome, through inhibition of T-cells (alemtuzumab and daclizumab) or B-cells (rituximab 
and ocrelizumab) [23], [59], [85], [86]. Conclusively, we would focus on a treatment via 
immunotoxin, targeting macrophages, one of the key elements in MS. 
I.2.3 Immunotoxins 
Immunotoxins (ITs) are antigen-specific immune-conjugates, used for targeted delivery of 
toxins in life-threatening diseases. The targeting moiety has a specific affinity to an indicated 
target (e.g. a receptor) that assists the IT to bind, internalize and undergo endosomal 
processing. Thereafter, the toxin is released into the cytosol, where it can induce apoptosis.  
Immunotoxins have either toxic or modulatory effects, depending on the peptide, cloned next 
to the binding moiety. To achieve an optimal effect, possible side effects of the immunotoxins 
are minimized through size reduction, humanization of the antibodies and reduction of the 
immunogenicity. Immunotoxins are produced in mice, using monoclonal antibody 
technology, therefore prior to use, the antibodies should be modified and humanized. 
Subsequently, the variable regions are cloned into bacterial plasmid and further expressed as 
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a single chain [27], [87]. The original 150 kDa anti-CD64 antibody (M22), was reduced to 
~30 kDa single chain (H22). This indeed made the IT to perform a faster and easier 
internalization into the target cell, in comparison to the full-size antibody.  
The toxin moiety was changed from the original bacterial origin [Pseudomonas exotoxin A 
(ETAʹ′)] or plant origin (Ricin A), to an enzyme of human origin (Granzyme B) [29], [88]. 
And were further modified to Tau protein [31], [89] or other human toxins, to achieve a non-
immunogenic [33], [90], human based immunotoxin or a protein-based immunotherapeutic. 
Furthermore, upon immunogenic reaction, the antibodies will naturalize the immunotoxin 
immediately, prior to internalization. Therefore to reduce the immune response, the potential 
immunogenic, T and B-cell epitopes are identified and mutated [35], [91], [37], [92]. 
Additionally, in some ITs, such as H22-angiogenin, a small cleavable adaptor sequence is 
introduced, to improve the stability and the toxicity of the IT [39], [59], [23], [41]. 
Subsequently, the improvements are applied to promote the increase of the administration 
dose and frequency, and also for “non-life-threatening” diseases, such as multiple sclerosis.  
I.2.4 FcγRI Receptor (CD64)  
The FcγRI receptor (CD64) is comprised of three immunoglobulin superfamily domains 
(EC1, EC2, and EC3), a single transmembrane spanning region and a short cytoplasmic tail. 
CD64 is a 72 kDa high-affinity receptor for IgG (FcγRI), and is expressed on monocytic cells 
of the myeloid lineage, such as macrophages [43], [86]. CD64 has some unique properties 
that describe the receptor as a suitable target for immunotherapy; it binds and internalizes the 
monomeric IgG-immune complexes [45], [93], and is highly expressed on activated 
macrophages and their progenitors [47], [94]. Binding of monomeric IgG-complexes 
(antibody-antigen) triggers endocytosis, and increase CD64 expression on inflammatory 
macrophages, in inflamed areas [49], [95]. Moreover, CD64 enhances antigen presentation 
and therefore T-cell activation, through internalization of antigen-IgG complexes, in addition, 
it releases cytokines and reactive oxygen intermediates [51], [96]. Regarding these unique 
specifications, CD64 is the targeted molecule for selective therapy of immunotoxins, directed 
against macrophages. 
The human and murine Fcγ receptors have identical nomenclatures, however they vary with 
regard to binding and expression patterns. Since the entire human Fcγ receptors have affinity 
for human IgG1 [53], [97], while in mice, only FcγRI and FcγRIII have affinity for mouse 
IgG1 [55], [98], [99]. Therefore, FcγR homologs are defined regarding their ligand binding, 
rather than amino acid similarity. Conclusively, the importance of Fc receptors [43], [70], 
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especially CD64, and their role in the promotion of EAE, the corresponding autoimmune 
disease of MS in animals, has been confirmed extensively [60],	  [100].  
I.2.5 H22-ETAʹ′  immunotoxin as a therapeutic 
Considering the significant role of macrophages in MS and the available therapeutics on the 
market, there is an essential need for development of therapeutics directed against 
inflammatory macrophages, in order to modify or deplete them [62], [101]. Previously, 
Thepen et al., eliminated infiltrating activated macrophages, and resolved the chronic 
cutaneous inflammation in CD64 transgenic mice, using H22-RicinA IT [64], [102]. 
Thereafter, CD64-expressing activated macrophages were eliminated, in the rheumatoid 
arthritis (RA) model of the hCD64 transgenic rat, leading to significant inhibition of the 
disease [62], [103].  
Afterwards, H22-ETAʹ′ immunotoxin was generated upon fusion of the H22 single chain with 
truncated Pseudomonas exotoxin A (ETAʹ′). The efficiency of the modified IT was further 
established for diverse chronic inflammatory diseases [104], [68], [105], [70], [106]. 
H22(scFv)-ETAʹ′ considerably reduced the CD64-expressing macrophages in the cutaneous 
inflammation model of transgenic mice [70], [88]. Moreover, Tur et al., established the 
efficiency of H22(scFv)-ETA′ for treatment of human Acute Myeloid Leukemia (AML), 
while providing evidence for the elimination of human CD64-expressing tumor cells in mouse 
organs [73], [107]. Additionally, anti-CD64 immunofusions (H22-scFv) [74], [87], together 
with Granzyme B (human serine protease), were confirmed to be a potent trigger of apoptosis, 
in CD64-expressing AML cells [76], [108].  
Conclusively, CD64-directed immunotherapy was described as a specified method that 
successfully eliminated the macrophages, upon delivery of ETAʹ′ into the CD64-presenting 
cells, in many chronic disease models. 
I.3 Monocytic cell population 
Metchnikoff discovered phagocytes and introduced the “phagocytic theory” as the basis of 
natural cellular immunity [109], [110], [111], [112]. Nowadays, the ability of macrophages to 
clear pathogens is widely accepted. Monocytes and macrophages are the critical effectors and 
regulators of inflammation during innate immune response. These remarkable plastic cells 
recruit immediately to inflamed and damaged tissues and then polarize to different functional 
phenotypes in response to variable microenvironmental signals. In addition, these cells can 
instruct other immune cells, while contributing to the pathogenesis of inflammatory and 
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degenerative diseases [113], [114]. 
The rapidly recruited inflammatory monocytes could sometimes not only delay the resolution 
of the inflammation, but also further be the hallmark of numerous diseases. Thus, targeting 
these cells in different disease models could present a therapeutic value [92], [115]. 
I.3.1 Tissue resident microglia  
Brain lesions of MS patients consist of variable immune cell infiltrates, of which microglia 
and macrophages are the significant ones. Microglia are the bone marrow-derived ramified, 
resident cells of the brain that are recruited to the neural tissues during early postnatal 
development [116], [117]. They constitute 10–15% of the total glial cell population [118], 
[119], which is the non-neuron, supporting cell population of the CNS, such as 
oligodendrocytes and astrocytes.  
Microglia (or parenchymal microglia) are the defenders of the brain parenchyma (Figure 5), 
where the neurons and glial cell population of the brain are located. Therefore, any infectious 
agent in the brain parenchyma is immediately detected by the microglia and destroyed. 
However, microglia can also contribute to tissue damage and destruction through indirect 
inflammatory attack [120],	   [121]. Once activated, whether chronically or pathologically by 
the presence of other inflammatory cells [122],	  [123], especially macrophages, they display a 
behavior comparable to that of inflammatory macrophages. In addition, their shape is 
reformed from a ramified to a rounded structure when presenting antigens to T cells, 
producing inflammatory agents, and phagocytosing debris.  
I.3.2 Activated microglia in multiple sclerosis  
Normally, the resident microglia produce mediators to protect the brain against invasive, 
infectious agents. However, in chronic neuronal diseases such as MS, the microglia remain 
activated continuously [92], [124] and produce neurotoxic mediators, causing neuronal death 
[125], [126]. Furthermore, they are the vital cells in lesion formation [127], [128] and have an 
active role in the pathogenesis of EAE and MS [129], [130]. 
Microglia are distinguishable from infiltrated macrophages, depending on their expression 
profile [129], [131]. Studies have confirmed that activated microglial cells comprise 37% of 
the total macrophage population in the brain, localized together with infiltrating leukocytes in 
the inflammatory lesions. Reactive microglia exhibit an increased expression of Fc receptors, 
including CD64, in MS lesions upon inflammation [66], [132]. Therefore, they could also be a 
target for pharmacological approaches to inhibit progressive neurodegenerative diseases 
[133], [134]. Despite the role of microglia in EAE progression, it is important to mention that 
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once the entrance of blood-derived monocytes to the CNS is blocked, the microglia can no 
longer trigger the EAE progress [124],	  [135]. Thus, the presence of the inflammatory active 
macrophages is essential to proliferate the microglia to the inflammatory phase.  
I.3.3 Perivascular macrophages 
The term “perivascular” refers to the location of these cells rather than their function. 
Perivascular macrophages are located between endothelial cells of brain–blood vessels and 
the perivascular basal membrane [136], [137]. Perivascular macrophages are originally 
derived from bone marrow precursor cells, and they react strongly to macrophage-
differentiating antigens [138], [139]. Immuno-phenotypically, they present markers such as 
MHC II, B7, CD40, and FcγR, and are activated in a similar manner as macrophages and 
microglia [140], [141]. Inflammations of the CNS lead to the formation of large perivascular 
infiltrates and the entry of perivascular macrophages into the brain parenchyma from the basal 
membrane (Figure 5). 
 
 Macrophages and microglia in an inflamed brain (Raivich et al., 2004). The brain has two monocytic Figure 5.
populations: the ramified resident cells of the brain parenchyma, called microglia, and the perivascular 
macrophages, located between the basal membrane and the blood vessel (thick dotted line). The basal 
membrane is the border between the perivascular and parenchymal compartments, and it is part of the blood–
brain barrier. Inflammation leads to the entrance of perivascular macrophages into the parenchymal area, 
together with blood-derived macrophages (circulating monocytes that maturate and enter the sites of 
inflammation). Later, these cells (both macrophages and microglia) react with T cells, present antigens, and 
secrete inflammatory agents. They can also convert to foamy macrophages, phagocyte the myelin, and clean 
the environment [153], [154]. 
I.3.4 Blood-derived peripheral macrophages 
Macrophages are monocytes that are recruited from the blood vessels to the sites of 
inflammation (Figure 5) [142],	   [143] when facing particular chemokines and cytokines in 
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the CNS [144], [145]. These cells undergo a diverse program of differentiation, depending on 
the presence of environmental chemoattractants [146], [147]. An early event in the 
development of inflammatory lesions during MS is the formation of cellular infiltrates 
consisting mainly of blood-derived peripheral macrophages. In particular, the presence of 
these infiltrating macrophages is essential for the process of myelin degradation and tissue 
damage that characterizes MS. No macrophages are typically detected in the normal adult rat 
brain [148], [149]; however, following inflammation, macrophages enter the CNS and 
immediately polarize in response to the available cytokines [150],	  [151].  
According to our research, macrophage kinetic studies have confirmed the early entrance of 
these cells to the CNS at the beginning of inflammation and prior to the onset of disease. 
Floris et al., demonstrated a promising treatment strategy, tested in mice, involving the 
prevention of monocyte-derived macrophages into the CNS [4], [152]. 
I.3.5 Macrophage polarization in the immune system 
Macrophages can undergo a diverse program of differentiation, depending on the 
microenvironment, ultimately dictating their effector functions [147], [155]. They reflect 
plasticity or polarize to the inflammatory M1 or regulatory M2 profile [148], [156]. 
Macrophages differentiate to the M1 profile, upon encountering microbial products (LPS) or 
inflammatory cytokines (IFNγ). During autoimmune diseases, M1 macrophages cause 
damage and attract inflammatory cells while producing IL-12, reactive nitrogen, and oxygen 
intermediates. The hallmarks of M1 macrophages are CD32, CD64, CD68 [157], [158], and 
CD14 [148], [159], which are highly expressed during classical activation.  
Alternatively activated macrophages (M2) are further classified into different subsets (M2a, 
M2b, and M2c) based on the type of stimulation and the subsequent expression of the surface 
molecules and cytokines. The M2a profile is induced in response to IL-4 or IL-13, displaying 
a wound-healing effect and exhibiting tissue repair during the adaptive immune response by 
Th-2 cells [145], [160]. Regulatory M2b macrophages similarly exhibit anti-inflammatory 
activity and appear upon activation by regulatory T-cells and various stimuli, such as 
immuno-complexes and glucocorticoids [161], [162]. Finally, M2c macrophages are induced 
by IL-10 and are mostly related to the suppression of immune responses and tissue 
remodeling [163], [164]. CD206, CD163 [166], CD301 [167], [168], and CD273 are 
overexpressed from M2 markers upon alternative activation, while CD273 is expressed on 
both dendritic cells and alternatively activated macrophages through IL-4 secretions [142], 
[169]. 
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I.3.6 Activated M1 and M2 macrophages in MS 
In general multifunctional macrophages [158], [170] have an important role at different stages 
of MS development (Figure 6). In an early MS phase, macrophages trigger inflammation and 
worsen the disease when the immune infiltrates cross into the brain parenchyma upon 
disruption of the BBB. Thereafter, the macrophages develop an autoimmune reaction against 
myelin particles and perform macrophage-mediated demyelination [157], [171], [172].  
In MS lesions, inflammatory macrophages (M1) can destroy the nerves by producing 
oxidative metabolites, neurotoxins, and proinflammatory cytokines, while attracting 
inflammatory cell populations [163], [170]. They also release nitric oxide, which blocks 
signal conduction in demyelinated axons. M1 macrophages present myelin particles to T cells 
and produce cytokines and toxic radicals that lead to the destruction of myelin, thus assisting 
the progress of inflammation [171],	   [173]. In addition, M1 macrophages produce 
inflammatory agents that destroy the oligodendrocytes, which are the myelin protecting cells 
responsible for remyelination [174], [175]. Production of these inflammatory neurotoxic 
mediators leads to immune cell attraction, microglial activation, and exacerbation of the 
disease. Once remyelination is inhibited (upon damage to oligodendrocytes), the axons are 
injured and signal conduction is blocked, therefore enabling the formation of plaque (Figure 
6) [58], [140].  
This inflammatory characteristic is comparable in all monocytic cell populations, as described 
previously, including microglia, perivascular macrophages, and peripheral macrophages that 
are blood-derived, BBB passed, infiltrated macrophages (here called “macrophages”).  
 
 
 Inflammatory M1 macrophages have an extremely significant role in the pathogenesis of MS. This Figure 6.
chart describes how these activities are combined to exacerbate the disease. These actions are all related to 
each other, from top to bottom and left to right (chart by E. Aslanian).  
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During these inflammatory processes, antigens and T cells additionally activate B cells. They 
then convert to plasma cells and produce large amounts of antibodies against myelin particles 
[176]. These antibodies assist the macrophages to phagocyte and attack the myelin layer 
through their Fc receptors (Figure 7).  
M2 macrophages might take a part in remyelination of MS lesions [178], [179], as 
macrophages shift to the M2 profile in the presence of regulatory mediators during the 
remission phase, phagocytosing the degraded myelin particles and cleaning up the chaos 
[143], [180]. As mentioned previously, activated inflammatory microglia might assist in the 
initiation of EAE, but infiltration of blood-derived M1 macrophages is necessary for both 
progress of the disease and polarization of the microglia. In addition, blocking the entrance of 
cytokine-activated, blood-derived inflammatory macrophages to the CNS prevents the 
severity of the disease from increasing in its animal model [87], [130].  
According to different studies, macrophage depletion through silica dust or liposomes 
containing dichloromethylene diphosphonate suppresses clinical signs, and thus, EAE scoring 
[181]-[183]. Because the increase of infiltrated monocytes directly correlates with the 
intensity and severity of relapses in EAE and leads to decline of the disease [130], [184], the 
depletion of M1 macrophages could have a reducing influence on disease severity.  
 
  
 Activated microglia/macrophages present antigen to T cells. Microglia and Mph’s can produce nitric Figure 7.
oxide, therefor attack the myelin layer via FcγR, through antibodies produced by B cells (Compstone et al.,) 
[10], [177]. 
I.3.7 Macrophages in MS lesions 
Upon initiation of this thesis, very little was known about the M1 and M2 macrophage 
subtypes and their role in the pathogenesis of MS lesions. However, it is now clear that 
macrophages play a dual role in MS lesion pathology [132], [158]. 
There is evidence showing the presence of M2 macrophages in the center of a lesion, 
suggesting that they phagocyte the myelin debris and potentially repair the peripheral nerves 
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[170],	   [185], while the outer rim of the lesion is mostly occupied by M1 macrophages, 
attacking the myelin layer [124],	  [180]. Therefore, not only inhibiting M1 activity, but also 
altering the M1 profile toward M2, could have a great beneficial effect on exacerbation of the 
disease [69],	  [186].  
Expression of the Fc receptor (FcγR) is highly upregulated within active MS lesions 
compared to FcγR expression on cells located outside the demyelinating area of a lesion [132],	   [187]. Fc receptors are one of the inflammatory profile indicators, which might 
explain the presence and activation of M1 macrophages inside MS lesions. Various data have 
demonstrated the presence of M1 markers, including Fc receptors (CD64 and CD32), on 
activated microglia and macrophages [139],	   [188], [145],	   [189], [158],	   [190]. Recently, 
Vogel et al., demonstrated CD64 as a M1 marker, expressed abundantly by activated 
microglia and macrophages in the NAWM of active demyelinating MS lesions [191], [192].  
I.4 Experimental autoimmune encephalomyelitis (EAE) 
Since the 1980s, EAE models have been used extensively to investigate potential therapeutics 
for MS [78], [193], [194], and the majority of the upcoming or already approved drugs have 
been initially tested in these models (Table 1). EAE mimics many neuropathological and 
immunological aspects of human MS [181], [195], and it is induced in animals by 
immunization with the appropriate immunogenic sequences of myelin components, such as 
MBP, PLP, or MOG supplemented with Freund’s adjuvant [3], [196] and pertussis toxin (PT) 
[158], [197]. In addition, different encephalitogenic regions of the extracellular domain of 
MOG could further be used for EAE induction. MOG 35–55 is the epitope that corresponds to 
EAE induction in C57BL/6 mice [198], [199], while MOG 91–110 induces EAE in SJL mice 
[78], [186] and MOG 79–96 induces EAE in DBA1 mice [170], [200]. EAE in C57BL/6 mice 
is known as a progressive chronic disease [201]-[205], and it has long been studied for 
macrophage-related MS therapeutics [180], [194], [202]. The main advantage of chronic EAE 
in C57BL/6 is its similarity to the pathogenesis of progressive MS, as the clinical disabilities 
progress continuously [169], [206]. In contrast to the EAE chronic model, the relapsing model 
induced in SJL and DBA1 strains are used for T cell-mediated demyelination and 
pathogenesis studies [207], [208], [209]. According to this data, animals could develop either 
a relapsing–remitting or progressive (chronic) model of the disease, depending on their strain 
(SJL, DBA1, C57BL/6) and the antigen used for immunization  [3], [48], [64], [145], [194] 
[195].  
Clinically, EAE is characterized by the development of disability signs, such as weight loss 
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and paralysis, starting after the second week of immunization (day 14). EAE score is 
determined according to the balance of pro- and anti-inflammatory agents, which are in direct 
correlation with variable degrees of demyelination [6], [79], [156]. A severe EAE score is 
achieved with the development of large demyelinated areas and the presence of a great 
number of myelomonocytic infiltrates [42], [124]. 
MS and EAE share certain immunopathogenesis characteristics, such as association of the 
disease with MHC II, higher susceptibility in females, and presence of several autoreactive 
cell populations, including T cells, B cells, macrophages, and accumulated antibodies in the 
lesions. In addition, demyelination and degeneration of the axons and further inflammation of 
the optic nerves, spinal cord, and periventricular white matter are considered similarities of 
MS and EAE [2], [170].  
 
Table 1. Developed therapeutics of MS that are derived from in vivo studies of EAE models (collected by E. 
Aslanian). 
 
 
I.4.1 Transgenic EAE and development of therapeutics 
The development of transgenic technology and widespread contribution of EAE models in the 
area of MS research have had a major impact on the increase of effective antigen-specific 
therapeutics [210], [211]. Indeed, the development of transgenic models adds validity to 
therapeutics in the developing stages [179], [194], [212], [213].  
The history of generating human FcγRI transgenic mice dates back to 1996 [180], [214], when 
Heijnen et al., evaluated the role of FcγRI in antigen presentation in vivo. They generated a 
human CD64 mouse model in which the receptor was selectively expressed on murine 
myeloid cells under the control of its promoter. It was essential to closely resemble the same 
  
23 
condition of humans in mice, so that reliable outcomes could be expected once the clinical 
phase was completed [138], [215]. Smith et al., compared the immune response of humanized 
FcγRI C57BL/6 and wild type mice to antigens. Both were immunized with LPS-based 
antigens, and the IgG levels measured seven and 14 days after immunization presented similar 
immune responses [216], [217]. The transgenic hCD64 mice model had the additional 
advantage of expressing human receptor via murine macrophages, thus binding to human IgG 
and mediating IgG complex internalization (IT). 
The immunohistochemical and flow cytometry examinations of transgenic FVB/N mice 
established that hCD64 expression was restricted to the monocytes, macrophages, and 
polymorphonuclear neutrophils of myeloid cells, whereas the lymphocytes and mast cells 
lacked expression. By selecting FcγRI transgenic mice, the effect of human CD64 elimination 
as an indicator of M1 macrophage activation in MS and EAE was analyzed. 
I.4.2 EAE immune pathogenesis 
Despite the similarities between MS and EAE models, there is a major difference upon 
initiation of the disease. In the EAE model, disease development requires an external 
immunization step, whereas in humans, the response to auto antigens is obviously not 
artificially induced [218], [219], [220], [221], but unknown. Thus, the disease-inducing 
antigens are already known in EAE, while the identity of the MS initiator antigens is still in 
question. In the EAE model, autoreactive T cell response is actively induced through 
peripheral immunization with myelin proteins [156], [195], which initiates the migration of 
myelin-specific T cells (primed by APCs), from the lymph nodes to the sites of inflammation. 
At the same time, the proinflammatory cytokines IFNγ and IL17 are produced [167], [186] 
and macrophages are activated, further enhancing the production of inflammatory agents. 
These T cells cross the disrupted BBB (upon the presence of proinflammatory chemokines) 
and encounter the CNS’s APCs. The T cells and APCs further develop the autoimmune 
reactions, leading to perivascular inflammation. In addition, the activated macrophages 
influence neuroinflammation by secreting toxic material, cytokines, and chemokines, and 
stimulating the production of complement proteins. They also activate the resident microglia 
and produce factors that further attract the inflammatory cells to the CNS. Many 
neuroimmunological processes are directly dictated through activated macrophages in the 
CNS [170], [222]. In this inflammatory cascade, antibodies and B cells also enter the CNS, 
and plasma cells produce antibodies against self-myelin proteins. Finally, antibody-mediated 
damage contributes to demyelination and neurodegeneration.  
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EAE primarily affects the white matter of the spinal cord and other CNS areas such as the 
cerebellum and the brainstem [223], [224]. Histopathologically, EAE is characterized by 
lymphocyte and macrophage infiltrates in lesions formed in the CNS [48], [225]. The 
infiltrate size, demyelinated area, inflammation degree, and pro/anti-inflammatory agents 
basically determine the clinical EAE score [226], [227], as there is a strong expression of 
proinflammatory cytokines in the acute phase of the disease, while anti-inflammatory agents 
are dominant during the recovery phase [6],	  [228].  
Herein, we will focus on the role that macrophages might have in MS, using the EAE mice 
model. In addition, the effect of depleting the significant macrophages from the initial stages 
of the disease will be established by using the recent version of truncated H22-ETAʹ′ 
immunotoxin. 
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I.5 Aims and objectives 
Multiple sclerosis is a complicated autoimmune disease of the CNS that is developed and 
exacerbated upon inflammatory infiltrated immune cell activities and subsequent growth of 
demyelinated lesions. From the cellular infiltrates, the inflammatory macrophages have a 
distinct role in the pathogenesis of MS through production of inflammatory mediators and 
stimulation of the immuno-inflammatory cascade against the myelin antigens. To date, several 
therapeutics have been introduced to modify or inhibit single or multiple reactions in this 
autoimmune cascade. However, treatment of the disease is still the most significant concern, 
as none of the available therapies on the market, have been able to cure the disease. 
The majority of MS therapeutics were originally developed through experiments performed in 
EAE, the animal model of MS. The heterogeneity of MS compared to EAE suggests the 
necessity for diverse animal models, representing different disease characteristics [180], 
[229]. Therefore, the human FcγRI (CD64) transgenic C57BL/6 mouse is suitable for 
targeting human CD64 receptor in the MS mouse model. 
Considering the need for the development of an effective therapeutic and the diverse role of 
the inflammatory macrophages in MS, it will be valuable to determine whether elimination of 
these cells interrupts the autoimmune-reactive cascade against the neuronal myelin proteins. 
We investigated whether depletion of the M1 inflammatory macrophages in the EAE model 
affects the progression of the disease and reduces the clinical scores. The effect of M1 
macrophage depletion on both regulatory and inflammatory cell populations will also be 
determined. We further demonstrated whether targeting M1 macrophages through the FcγRI 
receptor, using H22-ETAʹ′ as a CD64-directed immunotoxin, efficiently eliminates the 
activated CD64-expressing macrophages from EAE brain lesions.  
To answer related questions, MOG, MOG-ETAʹ′, and H22-ETAʹ′ recombinant proteins were 
cloned, expressed, purified, and characterized for EAE induction and treatment. Macrophages 
were isolated from human blood and polarized to M1 and M2 subtypes, and the expression 
profile of CD64 were established in both populations. In addition, as a prerequisite for 
designing the treatment schedule, macrophage kinetics, effect of complete Freund’s adjuvant 
and H22-ETAʹ′ were investigated. Finally, the immunohistochemistry data of B and T cells, 
dendritic cells, and M1/M2 macrophages were processed for statistical evaluation (figure 8).  
 
 
 
  
26 
 
 
 The flow scheme of the Ph.D. thesis. As a prerequisite, the required proteins were expressed and Figure 8.
characterized for the experiments. CD64 expression status was studied on M1 and M2 polarized macrophages. 
And EAE induction and immunohistochemistry protocols were optimized, while the suitable C57BL/6 mice 
were breeded for the major experiments. EAE inductions were carried out and the proper treatment strategy 
was established after development of the macrophage kinetics and CFA effect. Finally the binding of H22 
(scFv) to human brain was shown, according to the IHC of brain. 
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 Materials and Methods II.
II.1 Materials  
II.1.1 Chemicals and consumables 
Unless otherwise mentioned, chemicals and consumables were purchased from Amersham 
Pharmacia (Freiburg), Becton Dickinson Bioscience (Franklin Lakes, USA), Biochrom 
(Berlin), BioRad (München), Biozym (Oldendorf), Calbiochem (Darmstadt), Clontech 
(Heidelberg), Corning Inc. (Schiphol-Rijk, Nederland), Cytogen (Obermörlen), Dharmacon 
(Lafayette, USA), eBioscience (Frankfurt), Eppendorf (Hamburg), Fluka (Neu-Ulm), Gibco 
BRL (Eggstein), Greiner (Solingen), Hampton Research (Aliso Viejo), Hewlett-Packard 
(München), ICN (Eschwege), Invitrogen (Eggenstein),  KMF Laborchemie (St. Augustin), 
kodak (Stuttgart), Menzel GmbH (Braunschweig), Millipore (Eschborn), MWG-Biotech 
(Ebersberg), New England Biolabs (Schwalbach), Nunc (Wiesbaden), Novagen (Madison, 
USA), Pall Filtron (Northborough, USA), Perkin-Elmer (Applied Biosystems, Foster City, 
USA), Pierce (Rockford), Promega (Mannheim), Qiagen (Hilden), Roche Molecular 
Biochemicals (Mannheim), Roth (Karlsruhe), Sarstedt (Nümbrecht), Serva (Heidelberg), 
Sigma-Aldrich (Steinheim), Starlab (Ahrensburg), Thermo scientific (Braunschweig), 
Whatman (Maidstone, England) and VWR (Darmstadt).  
II.1.2 Equipment and applications 
All the experiments were carried out using the listed equipments. 
Table 2. List of equipment and the provider companies. 
Application Equipment Origin 
Bioreactor BioFlo 110 New Brunswick Scientific 
Centrifuges Avanti J-25I centrifuge,  
Multifuge 3 S-R/1S   
Rotina 420 R  
Table centrifuge 5415R, 5415D 
Beckman Coulter 
Heraeus Instruments 
Hettich zentrifuge 
Eppendrof 
Clean benches Biowizard 2 Kojair  
Cryostat Leica CM3050 S Leica microsystems 
Cell counter Casy1 Schaerfe-system 
Cell washer  Dade Serocent Cell Washer  Baxter 
Electrophoresis  Mini Sub Cell Electrophoresis System  BioRad 
ELISA reader  ELx808 Bio-TEK 
Flow cytometer FACSCalibur Becton Dickinson 
Chromatography ÄKTA-FPLC GE Healthcare 
Gel electrophoresis Mini Protean Electrophoresis System  BioRad 
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Laminar flow hoods Hera Safe HS12 Kendro 
Incubators Thermomixer Compact 
Function line type UT12 
Incubator Innova 4430 shaker 
Eppendorf  
Heraeus Instruments 
New Brunswick Scientific 
Microscopes DM2000 
DMIL Inverted Microscope 
Leica 
Leica 
PCR Thermocyclers Primus 96 Plus MWG-Biotech 
Photometer Bio-Photometer  Eppendorf 
Pipettes  Pipetman starter kit  
Transfer pipettes 8-12  
Gilson 
Eppendorf 
Rotors JA-10, JLA-16.250 Beckman 
Scales Analysis scales TE6101, TE12000 Sartorius 
Sequencer ABI Prism 3730 Capillary-Sequencer  Applied biosystems 
Sonicator Probe UW2070, micro tip MS72 Bandelin Electronic 
Ultrasonic wave Heated wave water bath JSP 
UV Transilluminator Molecular Imager Gel Doc XR System  BioRad 
Vortex Vortex-Genie 2  Scientific Industries Inc. 
Water Baths TE31025, TE12000 Sartorius 
 
II.1.3 Media, stock solutions and buffers  
All stock solutions and standard buffers were prepared according to standard protocols using 
deionized water (dH2O). Solutions were sterilized for 25 mins in an autoclave (121°C/ 2 bar). 
Antibiotics were filter-sterilized (0.2 µm) and prepared as stock solutions, prior to addition. 
Finally, 1-5 M HCl or NaOH was used to adjust the pH of the buffers. Listed below are the 
compositors of the commonly used buffers. 
Table 3. Standard buffers and media stock solutions. 
Buffer Composition Concentration 
2xYT Bacto Tryptone  
Yeast Extract  
Sodium chloride 
1.6  
1  
0.5  
% (w/v) 
% (w/v) 
% (w/v) 
4x Incubation Buffer  NaH2PO4, pH 8.0 
NaCl 
Imidazole 
200 
1.2 
40 
mM 
M 
mM 
5x Orange G Loading Buffer Orange G  
Glycerol  
TAE 
0.01 
30    
1x 
% (w/v) 
% (v/v) 
v 
5x TGS  
 
Tris-HCl (pH 8.3)  
Glycine  
SDS  
125  
960 
0.5 
mM 
mM 
% (w/v) 
5x Non-Reducing Protein Loading Buffer Tris-HCl (pH 6.8)  
Glycerol  
SDS  
Bromophenol blue  
62.5 
30 
4    
0.05  
mM 
% (v/v) 
% (w/v)  
% (w/v) 
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5x Reducing Protein Loading   Buffer Tris-HCl (pH 6.8)  
Glycerol  
SDS  
Bromophenol blue  
ß-Mercaptoethanol  
62.5 
30  
4    
0.05  
10  
mM 
% (v/v) 
% (w/v) 
% (w/v)  
% (v/v) 
10x PBS (pH 7.4) NaCl  
KCl  
Na2HPO4 x 12H2O  
KH2PO4  
1.37 
27  
81 
15 
M 
mM 
mM       
mM 
10x PBS-Tween 20 (pH 7.6) Tween 20 
NaCl  
KCl  
Na2HPO4 x 12H2O  
KH2PO4  
0.5 
1.37 
27  
81 
15 
% (v/v)  
M 
mM 
mM       
mM 
10x TBST (pH 7.6) NaCl  
Tris 
Tween 20  
9 
0.5 
0.5 
% (w/v) 
M 
% (v/v) 
10x TBE Electrophoresis Running Buffer Tris-HCl 
H3BO3 
EDTA (0.5 M) 
0.685  
0.9      
0.02  
M 
M 
M 
50x TAE Electrophoresis Buffer  
(pH 7.5) 
Tris 
Glacial acetic acid  
EDTA  
2      
5.7 
50  
M 
% (v/v) 
mM 
AP Buffer (pH 9.6) 
 
Tris-HCl 
NaCl 
MgCl2 
100 
100 
5 
mM 
mM 
mM 
Blotting Buffer (pH 8.3) Tris-HCl 
Glycine 
Methanol 
25 
192 
20 
mM 
mM 
% (v/v)  
Coomassie Staining Solution Coomassie b. G-250  
Methanol   
Glacial acetic acid  
0.25 
50    
9      
% (w/v) 
% (v/v) 
% (v/v) 
Coomassie Destaining Solution Methanol  
Glacial acetic acid  
10    
10 
% (v/v) 
% (v/v) 
ELISA Coating Buffer Na2CO3 
NaHCO3 
0.2 
0.3 
% (w/v) 
% (w/v) 
ELISA pNPP buffer  (pH 10.4) Glycine 
MgCl2 
ZnCl2 
0.1  
1  
1  
M 
mM 
M 
Elution Buffer (pH 8.0) NaH2PO4 
NaCl 
Imidazole 
50 
300 
10-500 
mM 
mM 
mM 
LB - pH 7 NaCl 
Peptone 
Yeast extract 
1 
1 
0.5 
% (w/v) 
% (w/v) 
% (w/v) 
Lyophilisation Buffer (pH 7.5)  NaH2PO4 
NaCl 
10 
150 
mM 
mM 
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II.1.4 Immunohistochemistry substrates 
All the immunostaining substrates were prepared freshly and filtered (0.2 µm) prior to use.  
Table 4. Immunohistochemistry substrates. 
Lysis Buffer NaCl 
NaH2PO4  
Protease inhibitor 
Imidazol 
300 
50 
1 
1 
mM 
mM 
Tablet 
mM 
Protein Extraction Buffer (pH 8.0) Tris-HCl 
NaCl 
DTT 
EDTA 
Glycerol 
Protease inhibitor  
75 
300 
5 
10 
10  
1 Tab. 
mM 
mM 
mM 
mM 
%(v/v) 
50ml 
PBST 
 
PBS (pH 7.4) 
Tween 20  
1x 
0.05 
v 
% (w/v) 
SDS PAGE (Separating gel) 
 
Acrylamide  
Tris-HCl (pH 8.8) 
SDS (10%) 
TEMED 
APS (20%) 
30 
375 
0.1    
0.1 
0.1  
µl 
mM 
% (w/v) 
% (v/v)  
% (v/v) 
SDS PAGE (Stacking gel) Acrylamide 
Tris-HCl (pH 6.8) 
SDS  
TEMED 
APS 
5 
150 
0.1  
0.1 
0.1  
µl 
mM 
% (m/v) 
% (v/v) 
% (v/v) 
SOC  Peptone 
Yeast extract 
NaCl 
KCl 
MgCl2 
MgSO4 
Glucose 
2 
0.5 
10 
25 
10 
10 
20 
%(w/v) 
%(w/v) 
mM 
mM 
mM 
mM 
mM 
TB Medium  
 
Glycerin  
3PO4 
ZnCl2 
Kanamycin 
1.3 
2 7
0.8 
0.1  
0.5 
25         
 (w/v)  
 (w/v) 
% (v/v) 
% (v/v) 
µg/ml 
TfbI Buffer RbCl 
MnCl2 
Potassium acetate 
CaCl2 
Glycerin 
1 0 
50  
30 
10 
15  
 
mM 
mM 
mM 
% (v/v) 
TfbII Buffer  RbCl 
MOPS 
CaCl2 
Sterile glycerin  
10 
10 
75 
15 
mM 
mM 
mM 
% (v/v) 
Substrates  Enzyme Composition 
AEC  Horseradish Peroxidase Acetic acid 1.4 ml 
3-amino-9-ethylcarbazol 0.4 % (w/v) 
N,N Dimethyl formamide 100 µl 
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II.1.5 Enzymes and reaction kits 
Restriction and ligation enzymes, as well as T4 DNA ligase, DNA polymerase, BSA (bovine 
serum albumin) and related buffers were purchased from New England BioLabs (Frankfurt 
am Main) and Roche Molecular Biochemicals (Mannheim). The kits were used according to  
manufacturer’s instructions. 
Table 5. Name of the kits and their suppliers. 
Kit Supplier 
QIAprep Spin Miniprep Kit Qiagen, Hilden 
Dynabeads FlowComp™ Human CD14 Invitrogen, Karlsruhe 
EAE Induction kit Hooke laboratories, Lawrence, USA 
QIA quick gel extraction kit Qiagen, Hilden 
 
II.1.6 Antibodies 
Antibodies were used for diverse experiments, such as detection of recombinant proteins in 
western blot or detections of receptors on cells by flow cytometry and to further stain selected 
cells through their receptors in immunohistochemistry (Table 6). 
Table 6. List of antibodies. 
Antibody Detection Origin 
8.18-C5 Hybridoma Extracellular domain of MOG Provided by Prof. C. Linington1 
Anti-FITC AP FITC molecule A1812, Sigma 
Anti-Human CD14 PE Human CD14 marker 12-0149-41, eBioscience 
Anti-Mouse MΦ F4/80 
 FITC 
Mouse macrophage marker 11-4801-82, eBioscience 
Fast Blue BB Base  
          
Alkaline phosphatase Fast blue salt 10 mg 
N,N Dimethyl formamide 250 µl 
Naphtol AS MX 10 mg 
Levamisole 2 mM 
Tris 0.1 M 
New Fuchsin Alkaline phosphatase N,N Dimethyl formamide 1 ml 
NaNO2 50 mg 
Naphtol-ASBI 50 mg 
New Fuchsin 4 % (w/v) 
Levamisole 2 mM 
Tris 0.1 M 
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Biotin anti mouse Gr1 Mouse Gr1 13-5931, eBioscience 
Goat anti Mouse IgG, AP Mouse IgG A3562, Sigma 
Goat anti mouse IgG, HRP Mouse IgG A4416, Sigma 
Goat anti-rat IgG, HRP Rat IgG, monoclonal 3050-05, Southern Biotech 
Goat anti-rat IgG, AP Rat IgG, monoclonal 3050-04, Southern Biotech 
Goat anti-Mouse MOG Mouse MOG AF2439, R&D systems 
Mouse anti-His  Histidine tag Qiagen 
MOMA 2 Mouse macrophage marker Provided by Dr. Georg Kraal2 
Mouse anti-Human CD64 
FITC (FcγRI) 
CD64 receptor, human 
macrophages,  
MCA756F, AbD serotec 
Rabbit anti-Goat AP   Goat IgG 605-4502, BioMol GmbH 
Rabbit anti-human 
CCL18/MIP4-Biotin 
CCL18 chemokine, polyclonal ABIN116284, Antibodies 
online 
Rabbit anti-human    
CCL1-Biotin 
CCL1 chemokine, polyclonal ABIN116046, Antibodies 
online 
Rabbit anti-human 
CCL20/MIP3-Biotin 
CCL20 chemokine, polyclonal AHP788, AbD serotec 
Rat anti-Mouse CD3 Mouse CD3 complex 16-0032-85, eBioscience 
Anti-Mouse CD11b Biotin Mouse CD11b 13-0112-82, eBioscience 
Rat anti-Mouse CD14 
FITC 
Receptor for the complexes of 
LPS, M1 macrophages, 
monocytes 
11-0141-82, eBioscience 
Rat anti-Mouse CD19   
Biotin  
CD19 B-cell receptor 13-0193-85, eBioscience 
Rat anti-Mouse CD36 Mouse CD36, M1 macrophages 14-0361-82, eBioscience 
Biotin anti-mouse CD115 Mouse CD115 135508, BioLegend 
Rat anti-Mouse CD273 
(B7-DC) 
Mouse CD273, M2 macrophages, 
dendritic cells 
12-9972-81, eBioscience 
Rat anti-Mouse CD205 Dendritic cells 14-2051-82, eBioscience 
Rat anti-Mouse CD206 
FITC 
Mannose receptor on M2 
macrophages 
MCA2235FA, AbD serotec 
Rat anti-Mouse CD301 
Alexa Fluor688 
M2 macrophages, dendritic cells MCA2392A488, AbD serotec 
Sheep anti-FITC-AP FITC labeled antibody 6400-04, Southern Biotech 
Streptavidin HRP Biotin labeled antibody 016-030-084, Jackson IR. 
Streptavidin AP Biotin labeled antibody 016-050-084, Jackson IR. 
 
1University of Glasgow, Institute of infection, immunity and inflammation, UK 
2VU University Medical Center, Amsterdam, The Netherlands. 
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II.1.7 Recombinant proteins and blocking serums 
Immunostaings were blocked by either goat or sheep serum. Further more, H22-SNAP and 
MOG were used in EAE related experiments, which will be described later (Table 7). 
Table 7. Recombinant proteins and serums. 
Protein Use Origin 
Mouse MOG (35-55) MEVGWYRSPFSRVVHLYRNGK 60130-5, AnaSpec  
H22(scFv)-SNAP  CD64 receptor PPD, Fraunhofer IME [153],[172] 
Goat Serum Blocking G9023, Sigma 
Sheep Serum Blocking S3772, Sigma 
 
II.1.8 Bacterial strains 
E. coli DH5α and XL1-Blue strains were used as an intermediate recipient for transformation 
and DNA amplification, while BL21(DE3) was used for recombinant protein expression 
(Table 8). 
Table 8. Bacterial strains and their genotype 
Strain Genotype                                                          Origin 
DH5α F– Φ80lacZΔM15 Δ(lacZYA-argF)-               (Stratagene, California, USA) 
U169 recA1 endA1 hsdR17 (rK–, mK+)-  
phoA supE44 λ– thi-1 gyrA96 relA1 
XL1-Blue endA1 gyrA96 (nalR) thi-1 recA1-                    (Stratagene, California, USA) 
relA1 lac glnV44 F’[Tn10 proAB+ lacIq - 
 Δ(lacZ)M15] hsdR17(rK- mK+) 
BL21 (DE3) F– dcm ompT hsdS(rB– mB–) gal λ(DE3)        (Novagen, Wisconsin, USA). 
 
II.1.9 Eukaryotic cell lines 
The following cell lines were used for antibody extraction and binding analysis: 
8.18-C5: Hybridoma cell line, expressing αMOG Ab, provided by Prof. Linington, University 
of Glasgow, UK.  
Bo9: PV reactive Hybridoma cell line, producing IgG1, donation by Borstel research center, 
Sülfeld, Germany 
L540: Human Hodgkin-lymphoma cell line (DSMZ Nr. ACC 72). 
U937: Human lymphoma derived cell line (ATCC Nr. CRL-1593.2). 
 
  
34 
II.1.10   Plasmids 
The pMT vector is a low copy plasmid and derivate of the pET vector system. In pMT, the 
expression of the recombinant proteins is controlled by T7 promoter, which is induced by 
IPTG. The translocation of the expressed protein into the periplasmic space is carried out by 
pelB leader sequence. This plasmid contains a 10x polyhistidine tag for purification (N-
terminal). The following plasmids were used for the expression of recombinant protein [230], 
[231],[232], [233].   
Table 9. Plasmid variations 
Plasmid Derivate Origin 
pMT-PV-ETA pET27b  Novagen, Madison, USA 
pMT-PV pET27b  Novagen, Madison, USA 
pMS-L-eGFP-PV pSecTag2 plus IVS/IRES-eGFP-sequence 
from the pIRES-EGFP vector  
Clontech, Mountain view, 
USA 
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II.2 Methods 
II.2.1 DNA cloning techniques 
II.2.1.1 Restriction of DNA 
Restriction of DNA (II.2.1.1) was performed according to the manufacturer’s instructions. 
The restriction endonucleases and corresponding buffers were purchased from New England 
BioLabs (NEB). Double restriction was performed with the recommended buffers if 
necessary. 1U/µg of DNA was used. 
II.2.1.2 Dephosphorylation of restricted vectors  
Dephosphorylation of the restricted plasmid DNA (II.2.1.1) was carried out using calf 
intestinal phosphatase (CIP, Roche Diagnostics GmbH, Mannheim) following the 
manufacturer’s instructions. CIP catalyzes the 5’-phosphate of DNA and prevents the re-
ligation of the DNA fragments. 
II.2.1.3 Ligation of restricted DNA 
DNA fragments (II.2.1.1) were ligated using T4 DNA Ligase (400,000 U/ml; NEB) in an 
appropriate ligase buffer, following the manufacturer’s instructions in a final volume of 20 µl. 
6 times molar excess of insert DNA to vector DNA was used to ensure a successful ligation. 
The mixture was then incubated for 30 minutes at room temperature followed by 
transformation in E. coli. The required volume of the restricted vector  (II.2.1.2) was 100 ng. 
II.2.1.4 Rubidiumchlorid (RbCl) competent cells 
A colony of E. coli was inoculated in 20 ml LB medium and was incubated overnight at 37˚C. 
Later the culture was diluted (1:100) and when reaching 0.8 on OD600, it was centrifuged for 5 
min/4000 rpm/4°C. After 10 minutes incubation on ice, the ice-cold cells were again 
centrifuged (5 min/4000 rpm/4°C) and the bacterial pellet was suspended in 30 ml TfbI, 
centrifuged and again resuspended in 4 ml TfbII. The competent E. coli cells were frozen by 
liquid nitrogen and stored at -80°C. 
II.2.1.5 Transformation of bacteria with plasmid DNA 
Plasmids were transformed into competent (II.2.1.4) DH5α E. coli cells (50 µl aliquots), using 
5 µl of the ligation reaction (II.2.1.3). Competent cells were thawed on ice, mixed gently with 
plasmid DNA (II.2.1.3) and incubated for 30 minutes on ice, 90 seconds at 42°C and 
immediately placed on ice for 5 mins. Afterwards, the sample was centrifuged at 2000 rpm/ 5 
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mins, 800 µl of the supernatant was discarded and 800 µl SOC medium including kanamycin 
was added to the cells and incubated for 30 mins at 37°C while shaking. The transformed and 
cultured bacteria were then plated on LB-Kanamycin (25 µg/ml) agar and incubated at 37°C 
for 16 h. The identification of recombinant clones was verified by plasmid mini-preparation 
(II.2.1.7), control digest of plasmid DNA (II.2.1.1) and subsequent agarose gel electrophoresis 
(II.2.1.8). 
II.2.1.6 Culturing of bacterial cells 
E.coli bacteria were cultured in LB medium overnight on a shaker (37°C, 225 rpm). To allow 
selective growth of recombinant clones after transformation (II.2.1.5), ampicillin (100 µg/ml) 
or kanamycin (25 µg/ml) was respectively added to the media. Glycerol stocks were prepared 
by addition of 800 µl overnight culture to 800 µl glycerol (40%). The glycerol stocks were 
shock-frozen in liquid nitrogen and stored at -80°C. For inoculation of agar plates either a 
single colony or glycerol stocks were used. Plates were subsequently incubated over night 
(ON) at 37°C. For culturing of bacterial cells in suspension, a 5 ml pre-culture was inoculated 
with a single colony and incubated ON at 37°C while shaking at 225 rpm.  
II.2.1.7 Isolation of plasmid DNA from E. coli 
For mini-preparation of plasmid DNA recombinant clones of transformed E. coli (III.2.1.6) 
were grown over night at 37°C in 5 ml LB medium supplemented with kanamycin or 
ampicillin. The bacterial cultures were then pelleted by centrifugation (7000 g/5 min/RT) and 
the DNA was extracted using QIAprep Spin Kit (Qiagen) following the manufacturer’s 
instructions. These plasmids were further transformed into E. coli BL21, for protein 
expression. 
II.2.1.8 Agarose gel electrophoresis 
Isolated plasmids (II.2.1.7) and DNA fragments (II.2.1.1) were separated by 0.8-1.2 % (w/v) 
agarose gel electrophoresis. Samples were loaded with OrangeG Loading buffer (NEB) on the 
appropriate slots of the gel in TAE buffer and were run for 30 minutes at 100 V.  
For fragment determination, 3 µl (1 µg/10 µl) of DNA marker (2-Log DNA Ladder, NEB) 
was used as size and concentration standard. Subsequently DNA bands were visualized with a 
UV transilluminator at the wavelength of 302 nm [48], [56], [158], [234], [235] and were 
evaluated using a Molecular Imager Gel Doc XR System (BioRad). 
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II.2.1.9 Estimation of DNA concentration 
For the determination of size and concentration of plasmid DNA (II.2.1.7) or restricted 
fragments (II.2.1.1) on agarose gel (II.2.1.8), the fluorescence intensity of the loaded DNA 
fragments were compared with the DNA marker (2-Log DNA Ladder, NEB) of known 
concentration.  
II.2.1.10 DNA extraction from agarose Gel  
After gel electrophoresis was performed (II.2.1.8), DNA was visualized on a UV 
transilluminator. The appropriate DNA band was cut out with a scalpel and purified using 
QIAquick gel extraction kit (Qiagen) following the manufacturers instruction. The 
concentration of the purified DNA was determined by agarose gel electrophoresis (II.2.1.9). 
II.2.1.11 DNA sequencing 
DNA sequencing was performed at the Fraunhofer IME sequencing facility using an ABI 
Prism 3700 Capillary-Sequencer (Applied Biosystems), according to the chain-terminator 
method of Sanger [79], [201], [236]. A standard PCR method including denaturation step 
(98°C, 10 sec), primer-annealing step (52°C, 10 mins) and elongation step (59°C, 3 mins) was 
performed and140–160 ng/kb plasmid DNA together with 2 µl sequencing primers were filled 
up with dH2O to a final volume of 30 µl. The sequences were analyzed by Lasergene 
software. 
Table 10. Used primers. 
Plasmid Primer name Sequence 
PMS-MOG pMS-Nb GGCAGTACATCAAGTGTATCATATGCC 
PMS-MOG H6-forward TTAAACTCAATGATGATGATGATGATG 
PMT-MOG T7 forward AATACGACTCACTATAG 
PMT-MOG T7 terminator GCTAGTTATTGCTCAGCGG 
 
II.2.2 Protein Techniques (Expression, Purification and Characterization) 
II.2.2.1 Protein expression under osmotic stress condition 
Recombinant proteins were expressed in bacteria under osmotic stress conditions [4% NaCl 
(w/v), 0.5 M sorbitol], and in the presence of compatible solutes [6], [237]-[239]. The proper 
folding, stability and solubility of the recombinant proteins were increased regarding the 
presence of chaperons, which supports the folding of proteins in the periplasmic space. A 
freshly transformed single colony of recombinant E. coli BL21 (II.2.1.6), was grown in a 5 ml 
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overnight culture (28°C, 225 rpm) in TB kanamycin medium, supplemented with 10:1 
potassium phosphate buffer and 0.5 mM zinc chloride. On the next day, the main culture (500 
ml) was inoculated 1:100 and incubated on a shaker (26°C, 225 rpm) until an OD600 was 
higher than 1.6. Osmotic stress was induced by the addition of 0.5 M Sorbitol, 4% (w/v) 
NaCl, 10 mM Glycin-Betain and 100 ml TB/ZnCl2 media, incubated for 30 mins at 26°C. The 
expression of recombinant proteins was induced by addition of 2 mM IPTG. The cultivation 
was continued for 16 h at 26°C and 225 rpm. Finally bacteria were harvested (30.000 g, 10 
mins, 4°C) and the pellet was stored at -20°C. The thawed pellet was suspended in 40 ml lysis 
buffer and sonicated (70% sonication duty cycle, sonotrode 76, 6x60 sec). Afterwards the 
bacterial lysate from centrifugation (30.000 g/25 min/4°C) was discarded and the periplasm 
supernatant was desalted using either PD-10 desalting columns (Amersham biosciences) or 
dialysis membrane (Spectra/Por, Spectrum Laboratories, USA), which depends to the pore 
and protein sizes. 
II.2.2.2 Protein expression using 2xYT medium 
Recombinant MOG protein was expressed in 2xYT enriched medium, while a single colony 
was transferred into a 50-100 ml culture (28˚C, 225 rpm ON). The day after, 10 ml of culture 
was transferred to a 500 ml fresh medium and 0.5 mM IPTG was added when the E600nm 
was 3, followed by addition of 100 ml media (28˚C- 225 rpm overnight). The harvest of the 
pellet and the purification steps were same for both expression methods.  
II.2.2.3 H22-ETAʹ′  fermentation  
The H22(scFv)-ETA´ immunotoxin was expressed in Escherichia coli BL21-pMT using high-
density fermentation method (Applikon bioreactor, Schiedam, Netherlands). The bacteria 
were grown until they reached the minimum E600nm of 50. Further 125 mM sorbitol, 40 mM 
betain and 300 mM NaCl were added and the temperature was reduced from 37˚C to 28˚C, to 
allow a correct protein folding. After 30 mins, 0.5 mM IPTG was induced to initiate the 
protein expression for 24 h (350-950 rpm). Finally 480 g pellet was collected from 3750 ml 
medium and was resuspended in preparation buffer and sonicated as described before [70], 
[240]. 
II.2.2.4 Protein purification 
Recombinant proteins were purified using talon resins (Qiagen, Hilden, Germany) in an 
immobilized metal affinity chromatography (IMAC) method [241], [242]. The principle of 
IMAC is based upon the chelate formation of histidine residues with bivalent cations such as 
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Ni2+, Cu2+ and Zn2+. Imidazole was also used as a strong competitor against histidine. 
According to its concentration; it releases the low affinity bounded proteins and then the his-
tagged ones. To purify the expressed protein from 500-2000 ml culture, the sonicated 
supernatant was mixed with 1 ml talon beads and stirred for 1 h in 4˚C. Then the mixture was 
applied to a gravity column (Qiagen), equilibrated, while the flow through was collected. The 
talon column was then washed using different concentrations of wash buffer (including 10–40 
mM imidazole). Finally the protein was collected using 250 mM imidazole in 10 ml elution 
buffer. The elution fractions were collected and sterile filtered (0.22 µm; whatman) in a 1.5 
ml Eppendorf tubes, freezed or lyophilized.  
Table 11. Purification buffers 
Buffer NaH2PO4 NaCl Imidazole 
Binding buffer (pH 7.8) 50 mM 300 mM 1 mM 
Wash buffer 1 (pH 7.8) 50 mM 300 mM 10 mM 
Wash buffer 2 (pH 7.8) 50 mM 300 mM 40 mM 
Elution buffer (pH 7.8) 50 mM 300 mM 300 mM 
 
II.2.2.5 Fast Performance Liquid Chromatography (FPLC) 
For protein purification of the fermented product, self-packed IMAC column (Ni-charged 
IMAC-Sepharose 6 FF, GE-Healthcare) was used on Äkta Purifier System (GE-Healthcare), 
following the manufacturer’s instructions. The bacterial lysate was centrifuged (30000 g) 
prior loading onto an XK16-20 column, at a flow rate of 3 ml/min. For washing and elution 
steps, two different pumps were used to prepare the appropriate imidazole concentrations (25-
500 mM) and the elution profile was monitored by UV absorbance at 280 nm. The eluted 
protein was concentrated using a 30K Vivaspin Ultrafiltration device (Sartorius-Stedim) and 
sterile filtered. 
II.2.2.6 Size exclusion chromatography (SEC) 
For further purification of the immunotoxin (II.2.2.3), SEC was carried out on a Äkta Purifier 
System using an XK16-70 column packed with SuperdexTM 75 (GE Healthcare) at a flow 
rate of 1.0 ml/min. The protein elutions were monitored at A280 nm, collected in 10 ml 
fractions for further analysis (characterization), finally the protein was filter-sterilized (0.2 
µm; whatman), stored at -20°C or lyophilized and stored in -80°C. 
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II.2.2.7 SDS-PAGE gel electrophoresis  
The SDS-PAGE was performed for the detection and separation of the expressed recombinant 
proteins [42], [243], [244]. Proper gels were prepared and incubated at room temperature for 
20 mins. Afterwards, 5x loading buffer was added to the sample, which was denaturized at 
100°C for 5 mins and loaded on the gel (150 V) for 50 mins in the mini Protean protein gel 
electrophoresis equipment (BioRad).  For the detection of the proteins, one gel was blotted 
onto nitrocellulose membrane and detected with specific antibodies. The other gel was stained 
with Coomassie Brilliant Blue G250 for 30 mins and destained in Coomassie destainer ON 
[245], [246]. 
Table 12. SDS-PAGE gel preparation 
Material   Stacking gel Separating gel 
dH2O 
Tris (1M, pH 6.8) 
Acrylamide (30% w/v) 
SDS (10% w/v) 
TEMED 
APS (20% w/v) 
  3.6 ml 
  625 µl 
  830 µl 
  50 µl 
  5 µl 
  15 µl 
2.1 ml 
3.75 ml 
4 ml 
100 µl 
10 µl 
30 µl 
 
II.2.2.8 Western blotting 
Western blotting was carried out in mini transblot tank (BioRad) for 60 mins at 250 mA in 
4°C [247], [248]. The membrane was blocked using 1x Roti-Block (Roth) for 1 h at RT. Then 
it was incubated with the corresponding antibodies for another hour while shaking (1:1000 
dilution, RT). Between each incubation step, the membrane was washed 3 times by PBST. 
The protein of interest on the nitrocellulose membrane was detected by αMOG (from 8.18-C5 
cell supernatant) or αHis antibody, followed by addition of secondary enzyme-conjugated 
antibody, such as anti-mouse AP (1:1,000; Sigma). Finally the membrane was incubated in 
NBT/BCIP (Life Technologies) substrate for 10 mins in the dark, to develop the color 
reaction. The protein size was estimated by comparing it to the standard protein marker (New 
England BioLabs).  
II.2.2.9 Dialysis of recombinant proteins 
The purified protein (II.2.2.6) was dialyzed in 1 x PBS (350 mM NaCl) to remove the 
remaining imidazole from the elution buffer. Therefore, an appropriate membrane was 
selected (Spectra/Por, Spectrum Laboratories, USA) and the samples were gently rotated in 
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PBS buffer over night at 4°C. Afterwards, the sample was transferred into a fresh 1.5 ml tube, 
sterile filtered (0.22 µm; Whatman) and processed for further storage (II.2.2.10). 
II.2.2.10 Determination of protein concentrations 
Protein concentrations were determined using Roti-Quant solution (Roth, Karlsruhe) in 
Bradford assay [249], [250]. For non-pure proteins (degradations/bacterial debris), AIDA 
image analyzer was used to estimate the concentrations after the protein was separated on a  
SDS-PAGE gel. For Bradford assay, the standard protein of 1 mg/ml BSA (Sigma) in PBS 
was prepared and 0.5-7 µg of BSA standard (sigma) plus a triplet of the analyzed samples (20 
µl) were transferred to the wells of a microtiter plate (triplicates). 200 µl Roti-Quant solution 
was added and the plates were measured at 460 nm using the ELISA reader. The Bradford 
values of BSA standards were then used to construct a standard curve to determine protein 
concentration using Microsoft Excel. 
II.2.2.11 Buffer exchange and lyophilization of the purified proteins 
The purified proteins were concentrated using Vivaspin concentrators (Sartorius-Stedim) with 
a 10 kDa molecular cut of weight (MWCO). The samples were centrifuged at 3500 g in 4°C. 
Overall, the proteins were concentrated (10 times) and reduced to a volume of 500 µl, while 
imidazole was removed and the buffer was changed to PBS. After sterilized filtration, the 
proteins were stored at 4°C, -20°C or lyophilized, regarding to their application and the 
duration of incubation. BenchTop manifold freeze dryer was used to lyophilize 250 µl protein 
portions. The protein vials were restored in PBS each time prior to use (according to the 
manufacturer’s instruction). 
II.2.2.12 Stability test 
The stability of 2xYT expressed MOG protein was tested after two weeks of incubation in 
different conditions, as follows: 
Table 13. MOG protein stability, tested in different conditions. 
MOG Protein  Storage (2 weeks) Defrosting method 
2xYT Freezer 4 hrs on ice 
2xYT Fridge 4 hrs at RT 
2xYT Freezer 4 hrs at 37˚C 
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II.2.2.13 Flow cytometry 
To evaluate the cell binding affinity of H22-ETAʹ′, FACS (fluorescence activated cell sorter) 
analysis was performed. 1x105/ml U937 cell suspension (II.1.9) was washed with PBS in a 
cell washer (Dade Serocent) and incubated for 30 min on ice with 1 µM recombinant protein 
of interest (II.2.2.2-3) in 50 µl of PBS, containing 0.5% BSA. Then it was washed twice by 
PBS in a cell washer (Dade Serocent) and incubated by anti-Penta-His Alexa Fluor 488 
antibody (1:100; Qiagen) for 30 minutes on ice in dark. Further it was washed twice with PBS 
(pH 7.4) in the cell washer. Measurements were performed using FACS Calibur flow 
cytometer (Becton Dickinson) and the data were evaluated using WinMDI2.8 software.  
The binding affinity of H22 (scFv) to mouse granulocytes was also measured by flow 
cytometry. During one of the EAE treatment procedures, after the 4th injection of the 
immunotoxin (II.2.2.3), 1x105/ml cell suspension was prepared from mice blood. The cells 
were incubated with the same amount of H22-SNAP as H22-ETAʹ′ (10 µg) for 10 mins, which 
was calculated for 30 µl blood (0.05 µg/animal). After washing steps, the measurements were 
performed as described before (II.2.2.13).  
II.2.2.14  Enzyme Linked Immunosorbent Assay (ELISA) 
To detect immune responses in EAE induced mice and to monitor the immune response after 
MOG protein injection, blood samples were analyzed for anti MOG IgG response. High 
binding ELISA plates were coated ON with 200 ng MOG (1-125; 2xYT) per well in a mixture 
of 25 µl PBS and 25 µl coating buffer at 4°C. Plates were then washed 3x with PBST and 
blocked with 1% (w/v) milk powder (200 µl) in PBS for 30 min shaking at RT. After 
washing, samples were prepared from 1:100 to 1:3200 dilutions in PBS. To allow binding of 
the MOG specific antibodies, plates were incubated for 1 h shaking at RT. After washing, AP 
labeled Goat anti Mouse antibody (50 µl; 1:1000; Sigma) were added and plates were further 
incubated for 1 h shaking at RT. For detection, para-nitrophenyl phosphate (pNPP) substrate 
tablets (20 mg/tablet; Sigma) diluted in 20 ml pNPP-buffer were added. Plates were incubated 
with 50 µl substrate solution for 45 minutes shaking at RT in darkness. Substrate reaction was 
then measured with an ELISA reader at 405 nm.  
II.2.3 Cell Culture Methods 
II.2.3.1 Culturing and maintenance of eukaryotic cells 
All cell lines, including MOG specific 8.18-C5 hybridoma cells (provided by Professor C. 
Linington, University of Glasgow, Department of Clinical Neuroscience, UK) were cultured 
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in RPMI 1640 medium (Gibco, Karlsruhe) supplemented with 10% (v/v) fetal calf serum 
(FCS) and 50 µg/ml penicillin/streptomycin (Invitrogen) each. The cells were split twice a 
week, using 1 ml cell suspension mixed with 20 ml fresh culture medium. Cell cultures were 
maintained in vitro at 37°C in a 100% humidified atmosphere containing 5% CO2.  
II.2.3.2 Purification of recombinant eukaryotic proteins   
The purification of proteins from eukaryotic transfected 293T cells (293T-pMS-MOG) was 
performed, using Ni-NTA beads (Qiagen). Prior to purification, cell culture supernatant 
(collected for 2 weeks at 4°C) was filtered (0.22 µm; Whatman) and centrifuged (2000 rpm/2 
mins). Then 38 ml of supernatant was taken and mixed with 12 ml of 4x incubation buffer 
(II.1.3; table 5) and 100 µl nickel matrix, followed by incubation on a rotary shaker (1 hour at 
RT). The matrix was washed with 750 µl binding buffer (II.2.2.4; table 11) and the 
supernatant was discarded. The bound protein (matrix) was washed with 10/40 mM imidazole 
washing buffer and finally the protein was eluted with 500 µl/300 mM imidazole buffer 
(II.2.2.4; table 11). After centrifugation the protein was eluted in PBS and stored at -20°C. 
II.2.3.3 Cell proliferation assay 
The cytotoxic effect of H22(scFv)-ETAʹ′ on the target cells was assessed by measuring the 
conversion of XTT to a water soluble orange formazan dye as previously described [23], [85], 
[251]. Briefly, a total of 5 x 105 target cells were seeded into a 96-well microtiter plate and 
various dilutions of the recombinant protein were added to the wells. Then it was incubated 
for 72 h at 37°C containing 5% CO2. The plates were checked for chromogen development by 
addition of 50 µl XTT/phenanzine methosulfate (100:1, Serva and Sigma-Aldrich) and further 
incubation at 37◦C for 4 hrs. The absorbance was measured at 450 and 630 nm using an Epoch 
Microplate Spectrophotometer (BioTek) [252], [253]. Further, the required concentration of 
the immunotoxin (IC50) to reduce 50% of the cells was calculated using the GraphPad Prism4 
software. 
II.2.4 Macrophage analysis (Plasticity and Kinetics) 
II.2.4.1 Monocyte isolation through Ficoll gradient   
The isolation of peripheral blood mononuclear cells (PBMCs) requires separation of whole 
blood by density gradient centrifugation [254], [255], using Ficoll (VWR) as a synthetic 
sucrose polymer. According to its density, the PBMCs locate in the interphase between Ficoll 
and the plasma layer, containing the erythrocytes. Concerning the adherent capacity of the 
monocytes to plastic surfaces, later they were isolated from the total PBMCs. Buffy coats 
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were obtained from the “transfusion medicine” department of the University Hospital Aachen. 
Prior to centrifugation, the buffy coat was diluted with equal amount of serum free RPMI (20 
ml total) and overlaid by 20 ml of Ficoll (density 1.077 g/ml). Then it was centrifuged for 30 
mins, 700 g at 4˚C. The white colored interphase between the plasma fraction and the Ficoll 
fraction was transferred into a fresh tube and was washed twice with PBS. The cells were then 
suspended in cell culture flask with fresh RPMI (FCS, Pen/Strep). Finally the monocytes were 
let to adhere for 2-4 h to the flask, while the non-adherent lymphocytes were washed away 
and a pure monocyte culture was obtained. 
II.2.4.2 Monocyte isolation through CD14 magnetic kit 
Dynabeads® FlowComp™ (Invitrogen) human CD14 contains uniform, super paramagnetic 
beads (2.8 µm diameter) that enable easy isolation of human CD14+ monocytes directly from 
any sample. According to the manufacturer’s protocol, the FlowComp™ human CD14 
antibody (25µl) was mixed with 4 ml buffy coat. After the antibody was bound to the target 
CD14 monocytes (10 mins/4°C), the FlowComp™ Dynabeads® were used to capture them 
and separate them from the unbound cells using a magnet.  
All CD14 negative cells were removed during the wash cycles (8 ml isolation buffer/3 mins 
incubation on magnet) and the CD14+ monocytes were released from the beads by adding 1 
ml FlowComp™ Release buffer (10 mins/4°C).  
II.2.4.3 Macrophage polarization 
Adherent monocytes were cultured for 5 days in a complete culture medium supplemented 
with either 50 ng/ml recombinant human GM-CSF to generate M1 or 50 ng/ml recombinant 
human M-CSF to generate M2 macrophages. On day 6 macrophages were harvested, counted 
and seeded in duplicate at 1 × 106 cells/ml on a 12-well plates [39], [256]. Macrophages were 
primed with fresh medium supplemented with different stimuli to obtain a gradient of polarity 
phenotypes. M1 phenotype (classically activated macrophages) was induced by 1 µg/ml LPS 
(Sigma) and 20 ng/ml of IFN-γ for 24 h were as the M2 macrophages were differentiated by 
addition of 20 ng/ml IL-4 (Peprotech) for 24 h. 
II.2.4.4 Macrophage kinetics 
To establish the best treatment schedule with highest efficacy, the macrophage kinetics were 
studied. In total 8 EAE induced, non-treated mice were sacrificed on days 6, 8, 10 and 12 of 
the disease induction. Infiltration of the macrophages and other immune cell populations were 
studied through immunohistochemistry (II.2.6.2) and FACS analysis (II.2.2.13) of the blood.  
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II.2.5 Animal Experiments 
II.2.5.1 Mice strain, background and breeding  
hCD64 transgenic and non-transgenic DBA1 mice were obtained from the animal facility 
(Institut für Versuchstierkunde) of the University Hospital Aachen. In addition, C57BL/6 
transgenic hCD64 male mice were bred heterozygous in our animal facility and were mated 
with 8 weeks old C57BL/6 females, purchased from Taconic (Hudson, New York, USA). Six 
generations were bred and the hCD64 expression was screened through FACS (II.2.2.13) and 
PCR in newborn populations of 4-5 weeks old mice. Briefly, 10–12 weeks old female 
transgenic hCD64 mice (F ≥ 6) were used for EAE experiments. Furthermore, sex and age 
matched, non-transgenic littermates were used as control. The experiments were performed 
according to the policies of animal ethics Committee and the experiments were approved by 
the “Landesamt für Natur, Umwelt und Verbraucherschutz NRW” (Reference number: AZ 
8.87-50.10.35.08.015). 
II.2.5.2 EAE induction 
EAE was induced according to the manufacturers protocol, using the emulsion provided by 
Hooke Laboratories [257] (Hooke Kit™, EK-0114) containing MOG (35-55) protein 
emulsified with Complete Freund’s adjuvant (CFA) and supplemented with killed 
mycobacterium tuberculosis, injected subcutaneously. The pertussis toxin was injected 
intraperitoneally (IP) after 2 and 24 hours, post immunization. The mice were daily monitored 
for the development of the disease signs and weight changes. Developed immune response 
and presence of anti-MOG antibodies were additionally studied, by taking blood on days 10 
and 12 of EAE induction. The binding ability of anti-MOG antibody to MOG protein (1-125) 
was developed using ELISA (II.2.2.14) technic. 
EAE scorings were established as follows: 0.5-1: Limp tail (slight to complete), 1.5-2: partial 
hind legs paralysis or complete one leg paralysis, 2.5-3: Complete hind legs paralysis or one 
hind leg and one front leg, 3.5-4: Complete hind and partial front leg paralysis, 5: Moribund.  
II.2.5.3 Immunotoxin as a therapeutic agent 
Different EAE experimental groups were threated starting from different days using variable 
doses of H22-ETAʹ′ (4.2-20 µg, 4.7x10-7 - 1.61x10-6 M per animal in total). But according to 
our experiences and all the necessary data that we collected during these procedures, the final 
experiment was designed as follows; 10 µg of H22-ETA IT (0.8x10-6 M per animal in total) 
was injected intravenously (IV) into the eye socket, behind the eye orbit, starting from day 6 
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of the EAE induction [regarding macrophage kinetic studies (II.2.4.4)]. The effect of H22-
ETAʹ′ was additionally studied on healthy, non-EAE induced animals. 
The injections were repeated every second day and after 4 IV injections, another 4 injections 
were applied as IP. The animals were sacrificed on day 21-23, while day 6 treated group was 
kept until day 29.  
II.2.6 Immunohistochemistry Analysis 
II.2.6.1 Slide preparation and tissue fixation  
Brain, spleen, liver, kidney and lung tissues of mice were removed, snap freezed in liquid 
nitrogen and stored in −80°C prior to use. According to the gained experiences during this 
project, frozen sections of 8 µm were prepared from mid part of the cerebellum area in the 
brain [69],[258]. This area was selected as it had larger cell infiltrates. The sections were 
then prepared by Leica CM3050S cryostat and mounted on the super frost, coated slides 
(Menzel). The slides were sealed in a box containing silica gel (Roth) and stored overnight to 
remove any possible moistness. 
II.2.6.2 Immunohistochemistry 
The cryosections (II.2.6.1) were fixed for 7 mins in dry acetone, air dried and circled with 
Dako pen. Regarding the selected secondary antibody, they were blocked either by 5-10% 
(v/v) sheep or goat serum (Sigma) for 1 h. Sections were incubated with different antibodies 
including macrophage [CD64-FITC (1:40; AbD Serotec), F4/80 (1:80; eBioscience), CD14-
FITC (1:40; eBioscience), CD301 (1:80; AbDserotec)] and other cell markers [T-cell marker 
(1:100; CD3-eBioscience), B-cell marker (1:40; CD19-eBioscience), dendritic cell marker 
(1:40; CD273-eBioscience)] in a humidified chamber for 45 mins RT or in 4°C ON. Then it 
was washed 3x by PBST and incubated 30 mins with the secondary antibody such as; 
streptavidin AP/HRP (1:3000; Jackson IR), sheep anti-FITC AP/HRP (1:400; Southern 
Biotech) or Goat anti-rat AP/HRP (1:400; Southern Biotech). After 2x wash by PBST and 1x 
wash by TBST for 10 mins, the AP activity was measured using naphthol AS MX phosphate 
(Sigma) as substrate and fast blue BB base (Sigma) as chromogen, resulting in a blue staining. 
Also pink color was developed using naphthol AS BI (Sigma) as substrate and new fuchsin 
(Merk) as chromogen. Endogenous AP activity was inhibited by addition of levamisole (350 
mg/l, Sigma) to the reaction mixture. For HRP-conjugated antibodies, AEC substrate was 
used to develop brownish red color. Endogenous HRP activity was inhibited by addition of 
hydrogen peroxide (300 µl/l Sigma). Finally the slides were counterstained with haematoxylin 
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and embedded by glycerol-gelatin mounting medium (pH.7), which was prepared using 1.7% 
(w/v) gelatin powder mixed with 90% (v/v) glycerin and dissolved in 60 ml water (50˚C). 
II.2.6.3 Human brain immunostaining 
Fresh human brain tissue from one multiple sclerosis patient was stained by the Netherlands 
Brain Bank in Amsterdam (kindly donated by Dr. Inge Huitinga). Immunohistochemistry 
(II.2.6.2) was performed on paraffin sections of human MS brain tissue. CD64 receptor was 
stained, using 1/100 dilution (1 mg/ml) of our expressed H22 single chain (same scFv clone 
as used for production of immunotoxin), followed by secondary incubation of mouse anti-his 
antibody (1/100 dilution). The detection of the staining was identical to the frozen slides 
(II.2.6.2). Conclusively, the binding efficiency of H22 (scFv) to human brain tissue was also 
established. 
II.2.6.4 Image processing and statistical analysis 
The most infiltrated area from each section of cerebellum was selected, according to the 
staining intensity seen under the microscope. 10-20 images of 10-40x magnifications were 
taken, using Leica DM2000 microscope, and these images were further stitched together and 
blended to obtain a large field of view with high resolution. Those pictures were processed by 
image J and CS4 Adobe Photoshop, and the total stained area per field of view, average 
infiltrate size and percentage of area fraction per field of view were calculated per brain 
section of animal. Moreover the white matter, granular and molecular layers of the brain 
cerebellum, were analyzed and the layers were draw and painted separately by Photoshop and 
flattened on the original image (Figure 9) that was already processed with Image j; to present 
a better overview of the infiltrates on different parts of the brain cerebellum. Statistical 
analysis was performed using two-tailed, unpaired t-tests and two-way ANOVA, processed 
by GraphPad (prism4) software. P<0.05 was considered significant. 
 
  
48 
 
  The chart of immunohistochemistry slide analysis. The processing of the images is presented in this Figure 9.
chart. The C57BL/6 EAE induced mice were treated by H22-ETAʹ′ IT. Sections of 8 µm were prepared and 
immunostained for different markers. The images taken by microscope were stitched together and the specific 
stained markers were converted to black with white background in Photoshop. A threshold range of 0–185 
(8bit images has 1-256 shades of grey) and saturation range of 0-255 were defined to exclude the extra 
unspecific black dots of the processed images. After analysis of the stained area, the area fraction, size and 
average infiltrated range of the markers were calculated. The original stained pictures were additionally pained 
to differentiate the three areas of the brain cerebellum (white matter, granular layer, molecular layer). These 
images were later flattened with the processed black and white colored, image j analyzed, images to get a 
better understanding of the images. Finally they were statistically compared to each other. 
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 Results III.
III.1 Cloning, expression, and characterization of recombinant proteins 
III.1.1 Cloning of myelin oligodendrocyte glycoprotein (MOG) 
MOG sequence (1–125) was cloned using pMS-L-EGFP-MOG as insert and pMT-PV as 
vector. The plasmids were restricted using SfiI and NotI restriction enzymes, and MOG and 
pMT fragments were extracted from the gel, ligated, and transformed in DH5α. To analyse 
the bands, the plasmid was digested again using XbaI and NotI (Figure 10). The final plasmid 
products were then transformed into E. coli BL21, as described previously (II.2.1). As shown 
in Figure 10, gel a., the 385 bp MOG insert, and 5325 bp pMT vector were extracted from the 
gel, and after ligation, its size and quality were checked on gel b. Finally, prior to 
transformation, the proper sized miniprep products were checked on gel c. All the bands had 
the right sized digested fragments, and the final pMT-MOG product was 5710 bp, as 
expected. 
 
 
 a. MOG and pMT fragments (II.1.10) restricted by SfiI and NotI restriction enzymes were extracted Figure 10.
from the 1.2 % (w/v) agarose gel (II.2.1.10); b. after ligation (II.2.1.3), the plasmids were digested again using 
XbaI and NotI. c. The plasmid minipreps (II.2.1.7) were checked, prior to transformation from E. coli BL21, 
the expression strain. 
III.1.2 Expression and purification of MOG 
The 20 kDa MOG-his protein was fermented (II.2.2.3) in BL21 E. coli strain by adding 2 mM 
IPTG when E600nm was 30. Prior to purification, the protein extract was detected in a 425-g 
pellet with goat anti-MOG antibody (1:400; R&D Systems) by western blot (II.2.2.7). Then, 
the protein was eluted after sonication in a streamline Ni-NTA IMAC column at a flow rate of 
8 ml/min (II.2.2.4). However, all of the protein was lost in the flow-through and wash steps of 
imidazole. The flow-through was re-purified manually using a Ni-NTA column, but as 
considerable amounts of protein were already lost, it was not possible to purify it. Therefore, 
protein expression was repeated using two different protocols: the enriched 2xYT expression 
method and TB/PS stress expression, as described previously (II.2.2.1-2). The pellets were 
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collected through centrifugation and sonicated, and the supernatant was purified as described 
previously (II.2.2.4), using talon beads. The flow-through, wash, and elution fractions were 
run on SDS gel (II.2.2.6) to monitor the amount and purity. In Figure 11, the band of 20 kDa 
size protein is fainter in the flow-through, wash 1, and wash 2 lanes, because the protein was 
bound to the talon resins and thus, was missing in those lanes. A small amount of protein was 
released in wash 3, and one to four elutions contained purified bands of 20-kDa MOG. In the 
elution fractions, some other bands that were released together with the protein of interest 
were also observed. The samples were further purified using Ni-NTA beads, following the 
same protocol used for the talon-based purification (II.2.2.4).  
 
 
 Protein purification of MOG (II.2.2.4), expressed in 2xYT medium [(II.2.2.2), (red box)]. Left to Figure 11.
right: Flow-through, wash by binding buffer (W1), wash by 10 mM imidazole (W2), wash by 40 mM 
imidazole (W3), and elutions using 250 mM (E1, E2) and 500 mM (E3, E4) imidazole to release the proteins. 
The purified proteins from both samples (2xYT and TB/PS) were then compared on the gel 
and detected through western blot (II.2.2.7-8) by using goat anti-mouse MOG Ab (1:400; 
R&D Systems), followed by rabbit anti-goat AP antibody (1:1000; BioMol), (Figure 12).  
 
 
 
 The purified proteins from 2xYT and TB/PS mediums were compared on a. SDS-PAGE (II.2.2.7); Figure 12.
and b. Western blot (II.2.2.8). Lanes 1–4 are the purified protein, expressed in 2xYT medium; lanes 5–7 are 
the purified protein using stress expression protocol (red arrows). kDa: standard protein marker. 
There were some degradations of MOG protein, expressed in TB/PS medium under osmotic 
stress conditions (II.2.2.1) (Figure 12, a., lanes 5–7), which were detected in the western blot  
as well (Figure 12, b., lanes 5–7). The protein concentrations were higher in the 2xYT-
expressed elutions, and very faint colored bands of degradation were visible in the gel 
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(Figure 12, a., lanes 1–4). However, those degradation bands were no longer detected by 
western blot, but the pure intense bands of MOG protein were detected by anti-MOG 
antibody (Figure 12, b., lanes 1–4). The purified 2xYT-expressed protein was 90% pure. 
III.1.3 Protein dialysis and concentration  
Excess salts and imidazole were removed from the protein solution through an overnight 
dialysis, as described previously (II.2.2.8), and the total protein concentration was calculated 
according to Bradford assay (II.2.2.9). A total of 5.6 mg/l protein was expressed and purified 
from the 2xYT culture, and 1.5 mg/l total purified protein was expressed from the TB/PS 
medium. The expression rate was three times higher in the 2xYT medium, and the eluted 
protein was further concentrated using Vivaspin concentrators (Sartorius). Afterward, 100-µg 
concentrated aliquots were prepared, lyophilized, and stored at -20°C for further analysis 
(II.2.2.10). 
III.1.4 Binding affinity through ELISA 
ELISA assay was performed as described previously (II.2.2.13) to compare the binding 
abilities of different MOGs (2xYT and TB/PS) to 8.18C5 anti-MOG antibody (hybridoma 
8.18C5 cells; centrifuged 2000g 2min, diluted 1 in 5), followed by goat anti-mouse AP 
(1:1000; Sigma) and goat anti-MOG antibody (1:400; R&D Systems), followed by rabbit 
anti-goat AP (1:1000; BioMol) (Figure 13).  
 
 
 
 The binding properties of the expressed MOG proteins were assessed. Left: the binding of goat anti-Figure 13.
MOG antibody to different MOG proteins (II.2.2.14). Right: the binding of anti-MOG antibody produced by 
8.18C5 cells (II.1.9) to different MOG proteins. The black bars represent MOG expressed in 2xYT medium 
[(II.2.2.2), (200-50 ng dilutions)], the blue bars represent MOG expressed in TB/PS medium [(II.2.2.1), (200-
50 ng dilutions)], and the last bar (third) is the negative control after each set of dilutions.  
The binding affinity of the antibodies produced by 8.18C5 cells to both MOGs was slightly 
higher than the binding affinity of the commercial goat anti-MOG Ab to MOG proteins. The 
binding affinity of anti-MOG Ab (8.18C5) to 2xYT-expressed MOG was lower than its 
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affinity to the MOG expressed in TB/PS medium (Figure 13, right). This result might be due 
to the effect of incubation time or quantity, as the 200-ng samples showed a similar binding 
profile. The data provided from the binding of anti-MOG antibody to both MOG proteins 
presented no difference.  
III.1.5 MOG stability test 
After two weeks of storage in a refrigerator or freezer, the purified protein (2xYT) was 
analyzed for stability. The MOG protein was defrosted on ice, left at room temperature (RT), 
and to mimic body temperature (BT), left at 37°C for four hours (II.2.2.11). After 30 mins 
(RT), the protein samples were centrifuged and run on the gel to compare the quality of the 
bands and their stability. The samples were of high quality, with no observable degradation or 
precipitation, and they were 99% pure (Figure 14, red arrow).  
 
 
 Expressed MOG protein stability in different conditions (II.2.2.12), from left to right:  MOG from Figure 14.
freezer, defrosted on ice for four hours, before and after centrifugation (Ice, 2); MOG from refrigerator, stored 
at room temperature (RT) for four hours, before and after centrifugation (RT, 4); MOG from freezer, placed at 
37°C (body temperature; BT) for four hours, before and after centrifugation (BT, 6).  
III.2 Fermentation and characterization of H22-ETAʹ′   
H22-ETAʹ′ immunotoxin was expressed in Escherichia coli BL21 through high-density 
fermentation (II.2.2.3). The bacteria were harvested from periplasm after IPTG induction and 
suspended in preparation buffer, followed by cell disruption from a 485-g pellet. The protein 
was purified using Ni-NTA Sepharose (II.2.2.5) and size exclusion chromatography (SEC) as 
described previously (II.2.2.6). The purified immunotoxin was evaluated by SDS-PAGE and 
western blot (the 65 kDa bands). The binding (Figure 15) and proliferation assays were 
established as described previously (II.2.3.2-3). H22-ETAʹ′ was quantified, and its IC50 of 8.4 
ng/ml was calculated. Finally, the immunotoxin was filter sterilized (0.22 µm; Whatman) and  
lyophilized in vials of 270 µg/ml for further use. 
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 Expression and characterization of H22-ETAʹ′, left: SDS-PAGE (II.2.2.7) and western blot (II.2.2.8) Figure 15.
of H22-ETAʹ′, detected by anti His antibody (1:100; Qiagen) followed by goat anti-mouse AP (1:1000, Sigma); 
some degraded bands were observed. Right: binding affinity (II.2.2.13) and specificity of H22-ETAʹ′ to HL60 
and U937 cells (II.1.9), confirming the specific binding of H22-ETAʹ′ to CD64-presenting cells. No unspecific 
binding was developed to CD64-negative L540 cells. 
III.2.1 Expression and purification of MOG-ETAʹ′  
Because MOG was expressed successfully using 2xYT medium (II.2.2.2) and it had a high 
protein yield, the 58-kDa MOG-ETAʹ′ was also expressed in 2xYT medium and further 
purified by talon-NTA column, as described previously (II.2.2.4). The expression was 
confirmed by SDS-PAGE, and the detection was carried on using western blot (Figure 16) 
using goat anti-MOG antibody (1:400; R&D systems) followed by rabbit anti-goat AP 
(1:1000; BioMol). MOG-ETAʹ′ was detected in all elutions; however, some were lost in flow-
through and 10-mM and 40-mM imidazole washes (Figure 16, left gel, marked by red arrow). 
In the western blot analysis, a very intense band was detected in flow-through, which is 
marked by a red arrow on the western blot image in Figure 16.  
 
 
 
 
 Expression and characterization of MOG-ETAʹ′ in 2xYT medium, left to right: Expressed MOG-Figure 16.
ETAʹ′ on SDS-PAGE (II.2.2.7); some amounts of the protein were lost during purification (II.2.2.4), which are 
observable in 10 and 40 mM imidazole washes, while intense bands of MOG-ETAʹ′ can be seen in the elution 
fractions (red arrow on the left gel). The western blot (II.2.2.8) was developed after 3 mins that confirms the 
presence of MOG-ETAʹ′ and shows an intense band in the flow-through. The right gel is MOG-ETAʹ′ after 
dialysis (II.2.2.9) and concentration [(II.2.2.11), (red arrow)]. 
Due to an excess amount of MOG-ETAʹ′, the protein did not bind to the talon resins properly 
and it was lost. However, the total purified volume of expressed protein was 0.5 mg/l, and it 
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was further concentrated after dialysis. The quality was rechecked before lyophilization; no 
degradation was observed, and the bands were pure. Small faint bands of degradation were 
seen in the last gel, which is normal upon expression of EAE proteins (Figure 16). Finally, the 
protein was prepared as 100 µl aliquots of 300 µg/ml concentration and lyophilized. 
III.2.2 Binding analysis of MOG-ETAʹ′  
The 8.18C5 hybridoma cell line was used to determine the specific binding of MOG-ETAʹ′ 
and its difference (if existed) compared to the binding ability of MOG protein alone, using 
FACS analysis. The results showed that MOG and MOG-ETAʹ′ developed similar specificity 
and binding ability to the 8.18C5 cell line, due to the proper folding of both proteins. No 
bindings were observed against the control Bo9 cell line (Figure 17). 
 
 
 
 
 Development of specific binding properties of MOG and MOG-ETAʹ′, left: Specific binding ability Figure 17.
of MOG and MOG-ETAʹ′ (II.2.2.13) to 8.18C5 hybridoma cell line (blue line: MOG-ETAʹ′; pink line: MOG). 
Right: There were no unspecific bindings of the proteins to the Bo9 hybridoma cell line that was used as a 
negative control. 
 
 
III.3 Macrophage studies 
III.3.1 Monocyte isolation from PBMCs 
Monocytes were isolated from whole blood using CD14 magnetic FlowComp Dynabeads 
(Invitrogen) as described (II.2.4.2), or prepared from peripheral blood mononuclear cells 
(PBMCs) of buffy coat (received from Transfusion Medicine Department, Uniklinik Aachen) 
by density gradient centrifugation using Ficoll (VWR) (II.2.4.1). After centrifugation, the 
samples were transferred to a culture flask, and five washing rounds were carried out. The 
monocytes were selected and separated according to their adherent specificity to plastic 
surfaces. The rest of the cells were washed away, and the remaining monocytes were further 
cultured by the addition of cell culture medium (II.2.3.1).  
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According to the FACS analysis of the two different monocyte isolation protocols (Ficoll and 
Dynabeads), both procedures were reliable. They had similar separated monocyte populations 
and nearly the same number of events on the graphs (Figure 18). The discarded supernatant 
from the Ficoll isolation was also checked to determine whether there was any CD14 
population lost during this procedure. There was a small amount of cells remained in the 
supernatant, proving the high quality of both methods.  
 
 
 
 Monocyte isolation using different methods, a. FACS analysis (II.2.2.13) of monocytes isolated Figure 18.
using CD14 positive magnetic Dynabeads (Invitrogen) from PBMCs of buffy coat (II.2.4.2). b. Monocytes 
isolated from PBMCs using the Ficoll gradient method (II.2.4.1), after four rounds of monocyte harvesting. c. 
Monitoring of the remained monocyte population in the supernatant after CD14 was isolated, using the Ficoll 
gradient method (the discarded cell population). 
III.3.2 Macrophage polarization and CD64 expression 
The purified monocytic cell cultures were further proliferated to macrophages through proper 
stimulating factors, as described previously (II.2.4.3). One group was classically activated 
through IFNγ/LPS to M1, while the other was alternatively polarized to regulatory M2 
macrophages using IL-4 (Figure 19). 
 
 
 
 
 CD64 expression on M1 and M2 macrophage populations, a. FACS analysis (II.2.2.13) indicates Figure 19.
expression of CD64 on M1 macrophages polarized by IFNγ and LPS (II.2.4.3). b. CD64 expression on M2 
polarized macrophages using IL-4 (II.2.4.3), shows a smaller population of CD64 expressing cells on M2 
compared to M1 cells. CD14 was also expressed on M1 macrophages but there was no shift in the M2 
polarized group that indicated CD14 expression on these cells.  
The polarized populations were studied for the expression of both CD14 and CD64 receptors 
through FACS analysis in M1 and M2 populations. Anti-human CD64, FITC labeled (1:40; 
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AbD Serotec) and anti-human CD14, PE labeled (1:40; eBioscience) antibodies were used. 
Macrophages treated by LPS showed a higher expression of CD64 compared to macrophages 
treated by IL-4, confirming that CD64 was highly activated and upregulated on M1 
macrophages rather than the M2 subtype (Figure 19). 
III.4 EAE induction and immunohistochemistry (Setup) 
III.4.1 EAE induction 
To select the proper mouse strain for our experiments and to develop a homogenous group of 
EAE-induced mice followed by immunohistochemical staining, human CD64 transgenic 
(hCD64) DBA1 and C57BL/6 mice were obtained from the animal facility of Aachen 
University Hospital (Uniklinik). After full-length MOG (1-125) was cloned, expressed, and 
purified (III.1.1), EAE was induced using a mixture of 150 µg MOG, together with complete 
Freund’s adjuvant (CFA), supplemented by 4 mg/ml killed Mycobacterium Tuberculosis. The 
mixture was injected intraperitoneally (IP) into the subcutaneous of the mice, followed by 
injections of 200 ng pertussis toxin (PT) on days 0 and 2 of EAE induction. The dose of PT 
was 2x increased in the second injection to elicit a stronger immune response. EAE induction 
was repeated three times in both the DBA1 and C57BL/6 transgenic mice strains (hCD64); 
however, no signs of EAE developed (Table 14), even though MOG purity was higher than 
95% prior to injection, and the widely used EAE induction protocol was followed [78].  
Table 14. EAE experimental setup using two different MOG, two mouse strains, and variable doses of PT 
 
 
 
The mice were monitored twice daily for development of EAE signs (II.2.5.2), and they were 
euthanized after 20 days. After brain preparation (II.2.6.1), the sections were analyzed for the 
presence of lesions and infiltrates. To solve the EAE induction problem, recombinant ready-
to-use MOG (35-55) was purchased from AnaSpec. MOG 35–55 (MEVGWYRSP-
FSRVHLY-RNGK) was the necessary immunogenic sequence to induce EAE in the C57BL/6 
mice, and MOG 79-96 (GKVALRIONVRFSDHGGY) was the sequence for EAE induction 
in the DBA1 mice. However, even the purchased MOG could not overcome the EAE inducti- 
on complications, even in the C57BL/6 mice. 
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III.4.1.1 Serum antibody titration 
After the EAE inductions failed, and during one of the experimental cycles, blood samples 
were taken from the hCD64, DBA1 and C57BL/6 mice on days 10 and 12 after EAE 
induction. Although no clinical signs had developed after 15 days of EAE induction, ELISA 
analysis revealed an antibody response against MOG proteins (II.2.2.14). The immunogenic 
antibody response of the C57BL/6 mice was more intense than that of the DBA1 mice (Figure 
20). The mice were euthanized after 20 days, and the brains and spleens were removed for 
immunohistochemistry (II.2.6.1-2). The serum antibody titers in the C57BL/6 mice were 
relatively equivalent at different antibody dilutions and time points (Figure 20). However, 
lower antibody amounts were observed in the sera of the DBA1 mice (day 10), indicating a 
weaker immune response compared to C57BL/6. The brains of the C57BL/6 mice were 
further analyzed through immunohistochemistry for the presence of immune infiltrates. 
 
 
 
 Antibody titration of anti-MOG Ab in mouse serum (II.2.5.2), using MOG (1-125) and AP labeled Figure 20.
goat anti-mouse antibody (1:5000; Sigma). The day 12 samples from the DBA1 mice had measurement 
failure; therefore, it was excluded from the graph. 
III.4.1.2 Immunohistochemistry of spleen (EAE mice) 
Initially, the brain sections of the hCD64 and C57BL/6 EAE-induced mice were stained with 
hematoxylin to observe the areas of demyelination. In addition, the spleen sections were 
immunostained for CD3 [T-cells, (1:100; eBioscience)], CD64 [(10.1), M1 macrophage 
marker, (1:40; AbD Serotec)], CD115 [receptor for macrophage colony stimulating factor M-
CSF, (1:400; eBioscience)], CD11b [common myeloid marker, (1:400; eBioscience)], and 
Gr1 [myeloid differentiation antigen, (1:1000; eBioscience)] receptors. Double stainings of 
CD115/CD64, CD11b/CD64, and Gr1/CD64, and co-stainings of CD3/Gr1 and CD3/CD11b 
receptors were also carried out (Figure 21). Corresponding stainings were established 
primarily by using different antibody dilutions until consequently proper dilutions were 
configured, ranging from 1:40 for CD64 to 1:1000 for Gr1. The proper dilutions for 
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secondary antibodies were varied; for example, streptavidin AP/HRP-labeled antibodies were 
best used at 1:3000, while goat anti-rat AP/HRP and sheep anti-FITC AP developed the best 
staining when used at a 1:400 dilution. Although the mice did not develop EAE, the antibody 
titration indicated an immune response against the antigen in the blood, and the 
immunostainings revealed no infiltrates in the brain sections. However, in the spleen sections, 
the populations of CD11b, Gr1, and CD3 were increased in the EAE-induced mice compared 
to the healthy mice (non-EAE induced). A minor difference was also seen in the CD115 
populations. Comparing the total stainings of all the markers, the CD64 cell population had 
the lowest staining, as the macrophages might not have been fully polarized at that time. 
 
 
 
 Immunohistochemistry of EAE-induced hCD64 C57BL/6 mice, using different antibodies and Figure 21.
substrates (II.2.6.2). The stainings are spleen sections, as follows: 1. CD64/CD11b (red/blue); 2. CD64; 3. 
CD11b; 4. CD3; 5. CD64/Gr1 (red/blue); 6. CD64; 7. CD11b; 8. Gr1; 9. CD64/CD115 (red/blue); 10. CD64 
(blue); 11. CD3/Gr1 (red/blue); 12. CD3/CD11b (red/blue). Immunostainings were as described in II.1.4 and 
II.2.6.2.  
III.4.2 EAE induction in C57BL/6 mice  
The EAE induction experiments and their related antibody response in the C57BL/6 mice, 
developed by ELISA (Figure 20), as well as the immunohistochemistry results (Figure 21), 
led us to continue the experiments, selecting the hCD64 C57BL/6 mouse model. The antibody 
titration presented a stronger immune response against the same MOG (1-125) fragment in the 
C57BL/6 mice than in the DBA1 mice. In addition, because the immunogenic sequence of 
MOG in C57BL/6 mice is 35-55, we were able to purchase it directly from AnaSpec, which 
saved us time and costs, as self-produced MOG is pricey and time consuming to express, 
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purify, and characterize. The C57BL/6 mouse is also known as the most suitable model for 
macrophage-related studies in EAE disease. Considering all of these factors, the C57BL/6 
mice were selected as the proper model for the rest of our experiments. 
We continued to face many problems while inducing EAE, but finally, after several efforts 
using different materials (MOG and CFA) and protocols (such as variable injection places and 
PT doses), EAE was developed in one out of six mice (hCD64, C57BL/6). The weight 
changes and clinical signs were monitored daily. When the mouse had a score of 0, it weighed 
19.8 g (day 15), and after five days (day 20), with a score of 3, the weight was down to 15.2 
g. The EAE score increased to 4 on day 22, after which the mouse partially recovered back to 
score 2; however, the weight changes and the disability in walking had not recovered 
completely by day 28, when the mouse was euthanized.  
III.4.3 EAE induction via Hooke Laboratories kit 
After trying several different EAE protocols and variable MOG and PT doses, we concluded 
that EAE induction was not repeatable in the group. The EAE scores were highly variable; 
some mice did not even develop EAE, and therefore, were not reliable for the treatment 
experiments. Thus, we decided to try an EAE induction kit, produced by Hooke Laboratories.  
Two different EAE induction kits were obtained as a sample from Hooke Laboratories. The 
kits were different (0-112 and 0-114) regarding the amounts of PT and mycobacterium 
tuberculosis. After trying each in four mice (C57BL/6, hCD64, 12 weeks old), very slight 
(score 1–2, using kit 0-112) to moderate (score >2, using kit 0-114) immune reactions 
developed after day 13 of EAE induction. Three mice from the group immunized by kit 0-112 
developed scores of 1–2 (Figure 22), while in the other EAE induced group, using kit 0-114, 
two mice developed a score of 1 and the rest developed scores of 3. The EAE clinical scores 
were given as follow: 0.5–1, limp tail (slight to complete); 1.5–2, partial hind leg paralysis or 
complete paralysis in one leg; 2.5–3, complete hind leg paralysis or one hind leg and one front 
leg; 3.5–4, complete hind and partial front leg paralysis; and 5, moribund. These mice were 
not studied further for immunohistochemistry and brain infiltrates, as the groups were very 
small, and the purpose of this experiment was to test the quality of the EAE induction kits. 
Therefore, kit 0-114 was selected as an appropriate EAE induction kit for further experiments, 
as higher scores developed with that kit, and they were more applicable for the treatment 
strategy. With kit 0-114, it would have been easier to notice the effect of the immunotoxin 
when testing the treated and non-treated groups during the next EAE induction experiments. 
After we had the proper EAE induction kit in hand and selected the suitable mouse model, 
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large groups of animals were needed in order to plan an efficient treatment schedule. 
Therefore, we initiated the mouse breeding. 
 
 
 EAE-induced C57BL/6, hCD64 transgenic mouse, using kit 0-114 from Hooke Laboratories. Limp Figure 22.
tail and complete paralysis of one hind leg (score 2) was developed on day 15 of EAE induction (II.2.5.2).  
III.5 Mouse breeding (C57BL/6)  
Because the age, sex, generation, and availability of the mice was very essential for the 
experiments and the C57BL/6 (hCD64) breeding pair in Uniklinik Aachen was already too 
old, we initiated the breeding in the animal facility of Fraunhofer IME, as described 
previously (II.2.5.1). To reach the required generation and quantity of animals as quickly as 
possible, two hCD64 transgenic male mice were obtained from the University of Utrecht and 
mated with ten purchased six-week-old female mice from Charles River (C57BL/6NCrl-027). 
The mouse database was created, and all the necessary information, including age, generation, 
breeding, pregnancy, and background information was stored therein (Figure 23).  
 
 Sample of breeding database, including cage number, sex, background, hCD64 transgene, date of Figure 23.
birth, pregnant mouse number, breeding date, and number of delivered pups (II.2.5.1). As seen in the table, 
there were some difficulties, especially with the primary breeders, such as bleeding and death of the pregnant 
mouse or the mother eating the delivered pups due to stressful conditions. 
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Because the mice were from different backgrounds, which could be problematic in the 
experiments, the breeding was carried out to the sixth generation (F>6) in order to obtain a 
homogenous background. After reaching the sixth generation, the breeding continued to 
provide the required number of mice for the EAE experiments. To manage each set of 
experiments, 3–4 months’ time was needed for breeding and screening and for the mice to 
reach the proper age (12 weeks old). Only hCD64 female mice were suitable for our 
experiments, which would be 25% of the offspring (Mendel’s law); therefore, many breeding 
pairs were needed to provide the required number of mice (for example, n=36), because if 
during one experiment, the mice were not matched by age and generation, the results would 
not be reliable. After all of the described preliminary EAE induction experiments, 
immunohistochemistry, and breeding setups were completed, the preliminary EAE induction 
experiments, followed by H22-ETAʹ′ treatment, were initiated and carried out. 
III.6 EAE induction and H22-ETAʹ′  treatment (preliminary exp. 1) 
To set up the first preliminary treatment experiment, EAE was induced in ten C57BL/6 
transgenic mice (seven treated and three non-treated), using the 0-114 EAE induction kit. The 
treatment was started on day 13 of the EAE induction, upon monitoring of the first EAE signs 
in both groups. After three injections, there was no effect on score reduction, and the dose of 
immunotoxin was increased to 12.6 µg per animal for another three injections. The mice were 
euthanized when they reached the highest scores on day 23. The brains and spleens were 
removed and prepared for immunohistochemistry as described previously (II.2.6.1).  
 
 
 The brain cerebellum consists of three layers: cerebral white matter (W) or arbor vitae, which forms Figure 24.
sensory and motor information and contains myelinated axon strips; the granular layer (G), which includes 
granule cells; and the molecular layer, which is the demyelinated axons of the granular cells that are vertically 
raised to the upper molecular layer. The EAE or MS infiltrates are mostly in the myelinated white matter area 
(II.2.6). 
In Figure 24, the cerebellum of the brain and the area from which the sections were prepared 
are circled in red, and the three different layers of the cerebellum are shown. White matter is 
the area where the infiltrates of EAE and MS can be seen the most, because it is the zone that 
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contains the myelinated axons of the neurons; therefore, the stained infiltrates are expected to 
be seen there. 
III.6.1 Immunohistochemistry analysis (hCD64) 
During this experiment (preliminary 1), EAE onset was variable, and the animals had 
different scores at different time points and when euthanized (Table 15). The onset date of 
EAE was also variable; some of the mice had disease signs on day 13, and the others 
developed them on day 15 of EAE induction.  
Table 15. Analysis of stained areas, calculated by ImageJ. CD64 count was the number of black spots detected 
by ImageJ on a threshold image; therefore, the counted spots could be composed of one single cell or a 
number of cells gathered together. Total area stained per image is simply the size of the infiltrates in each 
section of brain per mouse, and area fraction is the percentage stained in the whole section. The treated 
group is highlighted in gray (II.2.6.4). 
 
 
 
After the treatment, the mice were euthanized and the hCD64 macrophage population of the 
brain was studied through immunohisto-chemistry and statistical comparison of treated vs. 
non-treated groups (Figure 25). The immunohistochemistry was carried out using 10.1 anti-
human CD64 FITC labeled antibody with new fuchsine substrate for pink color development 
of CD64 (II.2.6.2). Twelve images per slide were taken by microscope and stitched together 
(Figure 25), and the staining results were further analyzed statistically according to previously 
described methods (II.2.6.4), (Figure 26). The treatment had no effect on the progress of EAE 
signs, as the mice in both groups developed severe disease signs. However, the CD64 
population was reduced considerably in the treated group (Figure 25, 1-5T), while the brain 
sections of the non-treated group were full of stained infiltrates and areas of demyelination 
(Figure 25, 1-3Nt). 
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 Immunohistochemistry of EAE induced, treated vs. non-treated mice. Each image is the Figure 25.
immunohistochemistry (II.2.6.2) of a cerebellum section from a single mouse brain, which is composed of 12 
images stitched together (II.2.6.4). The first three images are the non-treated mice (1–3, Nt), which had scores 
of 3, 2, and 2. The treated mice had scores of 0, 2, 1, 1, and 3 (1–5 T). Stainings were carried out using 10.1-α 
CD64 FITC/α FITC AP, developed with a new fuchsine substrate and hematoxylin counterstain. There are 
some lighter areas in the white matter where hematoxylin staining is absent; the highest CD64 cell 
accumulation is around these areas, which are demyelinated areas (marked by red arrows). The drawing of 
each stained image is next to its original one. Pink: white matter area; dark blue: granular layer; and light blue: 
molecular layer. The black spots are the counted CD64 stained areas, which were analyzed by ImageJ 
software. This image was prepared using Photoshop to present a better perspective of the CD64 stained areas. 
The white line is drawn as a border to separate the treated and non-treated groups. 
III.6.2    Statistical analysis  
The total stained area was calculated per each sample in the same size images from the brain 
cerebella of both treated and non-treated animals. The average stained area of the non-treated 
group was 38873.33 µm2, while that of the treated group was 2256.42 µm2, indicating a 
reduction in CD64 cells in the treated group (Figure 26, 1). The area fraction was also 
calculated per image to provide a better overview of the total percentage, stained per slide. 
The area fraction in the non-treated group was 1.3–2%, while that of the treated group was 0–
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0.4% per image (Figure 26, 3). Two mice that had scores of 0 had area fractions of 0 as well 
(Table 15).  
 
 
 Statistic analysis of hCD64 staining in seven treated and three non-treated mice (II.2.6.4). 1. CD64 Figure 26.
stained area (µm2) presented a larger hCD64 macrophage population in the non-treated group compared to the 
treated one. The maximum total stained area was 7261 µm2 in the treated group and 48,650 µm2 in the non-
treated group. 2. The statistical studies of hCD64 staining were calculated by two-way ANOVA test, using 
Prism 4; ***P<0.0005. 3. Area fraction indicates percentage of stained area per section. The three non-treated 
animals (371, 391, and 395) presented higher percentages of stained area (0–0.4%) compared to the treated 
animals (1.3–2%). 4. Average CD64 stained area (spot size) in each sample; the largest spot is the biggest 
group of hCD64-stained cells that were clustered together and detected as one single dot by ImageJ. gray: 
treated; black: non-treated.  
As seen in Figure 26 (4), the average sizes of the CD64 stained areas were not related to the 
H22-ETAʹ′ treatment. The stained population of CD64-positive cells was clustered together or 
present as a single cell, which was independent of the treatment (Figure 26, 4). It should be 
noted that treatment had no effect on the manner in which the infiltrates appeared.  
After CD64 staining and analysis of the sections, the difference between the treated and non-
treated groups became more obvious, the statistical studies were significant at p<0.005, and 
the stained differences were statistically relevant (Figure 26, 2). Although the non-treated 
mice had a milder version of the disease, the CD64 cell population was larger in this group, as 
the CD64 macrophages were considerably reduced in the treated mice (Figure 26, 1). 
The processed data were manually re-analyzed (Table 16), and the analysis showed that the 
lesion sizes were reduced in the treated group, and the mice that scored 0 were completely 
lesion-free (Table 16, mice 1 and 4). The hCD64 staining showed cell reduction in the treated 
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samples, as the mice with higher scores in the treated group also had a smaller cell population 
compared to the mice with lower score but in the non-treated group (Table 16, treated mouse 
6 vs. non-treated mouse 3). There was less cell accumulation in the treated group, whereas in 
the non-treated group, the cells were closer to each other (cell clusters). The stained hCD64 
macrophage population was mostly in the white matter area (arbor vitae) of the brain in the 
treated group, whereas the hCD64 cells were stained even in the granulocyte layer of the brain 
in the non-treated group (Table 16).   
 
Table 16. This Table was counted manually in a blinded fashion; it confirms the results of the analyzed ImageJ 
images from the seven treated and three non-treated mice. The maximum score and score when euthanized 
are important, as the mice euthanized with a score lower than their maximum might have fewer inflammat-
ory cells than the mice sacrificed at their score peak. The treated mice are highlighted, and red lines mark 
the number of lesions and hCD64 stained cells. The reduction in the treated group is observable. 
 
 
III.6.3 Immunohistochemistry analysis (M1/M2, dendritic cells, and T cells) 
After observing the reduction in hCD64, additional immunostaining was carried out using 
CD36 (M1 marker) and CD301 (M2 marker) with CD64 as double-stained cells, plus CD3 (T 
cell marker) and CD205 (dendritic cell marker) as single-stained cells.  
The double staining of CD36/CD64 was developed using blue base substrate for the detection 
of blue colored CD64, and AEC substrate for the detection of red colored CD36. Large 
populations of CD64 and CD36 were seen in the non-treated mice, and these populations 
were considerably lower in the treated group. In fact, the CD36 population was composed of 
few cells in the treated samples. Some double-stained cells were observed to have a dark blue 
color, indicating that the cells were expressing both CD64 and CD36 receptors (Figure 27, a.). 
There were more CD64 stained cells than CD36 stained cells. 
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 Immunohistochemistry of EAE-induced hCD64 C57BL/6 mouse brain, using different antibodies Figure 27.
and substrates (II.2.6.2). a. CD64/CD36 (blue/red); b. CD64/CD301 (blue/red); c. CD3; d. CD205. T: Treated; 
Nt: Non-treated. The immunostainings were carried out as described previously (II.1.4 and II.2.6.2). Each pair 
of images is similar staining from two different mice. 
T cell (CD3) staining showed a large population in the spleen sections of both treated and 
non-treated mice. However, in the brain sections of the treated group, they were mostly 
clustered around vessels or areas of inflammation (Figure 27, c. T). Animals with lower 
scores had even fewer CD3 stained cells, while T cells were distributed all over the white 
matter area in the non-treated group. In addition, the CD3 population was as large as the 
CD64-stained population (Figure 27, a. and c.). The dendritic cell marker (CD205) was also 
lower in the brain and spleen sections of the treated group. In the non-treated group, the white 
matter of the brain was full of CD205-stained cells, while in the treated group, 4–5 cells were 
seen in the infiltrated areas of the brain’s white mater (Figure 27, d.). 
CD301, as a marker of the M2 population, was double stained with CD64. Reduction of M2 
was observed in the treated group, which shows the intermediate phase of these cells, in that 
both CD64 and CD301 were expressed on them (Figure 27, b.). In the treated group, M2 cells 
were mostly gathered as small clusters but in the non-treated mice, they were distributed all 
over the section. In addition, more double-stained cells were observed in the non-treated 
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group, whereas in the treated group, the cells were stained blue or red, individually, for each 
marker. The microscopic images were processed in Photoshop by selecting each color 
separately. Figure 28 presents the overview of this staining; CD64 is shown as blue, CD301 is 
shown as red, and double-stained cells are shown as black (Figure 28).  
 
 
 
 Double immunostaining of CD301 & CD64 receptors. The blue color indicates CD64, the red color Figure 28.
indicates CD301, and the black color indicates cells that were double-stained for both receptors (II.2.6.2). 
III.6.4 Manual scoring of the immunohistochemistry 
The immunohistochemistry stained slides were further manually counted to check the results 
(Table 17). In general, mice with a 0 score had very limited infiltrates (Table 17, mice 1 and 
4). The CD301, CD36, CD3, and CD205 populations were all lower after treatment.  After 
analyzing the immunohistochemistry results (Tables 15–17) of this experiment (III.6), we saw 
that the general immune cell populations were reduced, next to CD64, in the treated mice. 
Although the treatment was targeted against the hCD64 receptor of the macrophages, its 
effect was observed in the reduction of different cell populations as well. Because the 
treatment had no effect on the disease scores, another experiment was planned with an earlier 
treatment time point (day 8), and an increased dose of the IT (20 µg).  
Table 17. Manually scored results of immunohistochemistry, treated (highlighted) vs. non-treated mice. Six 
different areas per cerebellum section were selected, and the stained cells were counted manually. The 
difference between the two groups is observable. 
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III.7 EAE induction and H22-ETAʹ′  treatment (preliminary exp. 2) 
Another EAE induction was carried out using kit 0-114, followed by H22-ETAʹ′ treatment (20 
µg) starting on day 8, repeated on day 9, and every second day thereafter. This time, we tried 
to maximize the quality of the treatment schedule and the number of the animals. Therefore, 
the inclusion of nine mice in each group and the early treatment (beginning on day 8 with 20 
µg of IT) were the highlights of this experiment. At the onset of the disease, there were 
considerable differences between the treated and non-treated groups. The treated group was 
healthy, without EAE signs, while the non-treated group already developed EAE on day 13 of 
the EAE induction. However, after two days (day 15), the treated group developed a strong 
reaction to the treatment.  
Table 18. Three groups of mice (n=9) including 1: CD64 positive and treated; 2: CD64 negative and treated; and 
3: CD64 positive and non-treated. Of four mice that died (group 1), three were healthy, without EAE signs, 
and suddenly developed a reaction. The remaining mice from the same group (1) developed high scores on 
day 16 of EAE induction. The number of injections, doses, and days are provided here. 
 
	  	  Mice	  group	   CD64	   H22-­‐ETAʹ′ 	  (Treatment	  days)	   PBS	   Death	  1	   +	   8,9,11,13,15	  (20µg),	  17	  (10µg)	   -­‐	   4	  2	   -­‐	   8,9,11,13,15	  (20µg),	  17	  (10µg)	   -­‐	   -­‐	  3	   +	   -­‐	   +	   -­‐	  
 
Four of the mice died immediately after the IT injection, and the remaining mice developed 
high EAE scores, progressing suddenly from score 0 or 1 to score 3 (Figure 29, a.). Therefore, 
the last injection dose of IT was reduced to 10 µg on day 17 (Table 18). The cause of death 
was unknown, and the hCD64-negative and treated group did not develop any signs of 
weakness or reaction after the injections. For further analysis, the mouse brains were prepared 
for immunohistochemistry as previously described (II.2.6.1-2). 
III.7.1 Immunohistochemistry of brain cerebellum 
The brain and spleen sections were immunostained for hCD64 receptor. After analyzing the 
stitched images, we noticed that the lesion size, number of infiltrates, and furthermore, 
hCD64 expression, were higher in the treated group rather than in the non-treated group. In 
addition, the stained cells were distributed in the whole cerebellum, including the granular and 
molecular layers, and the lesion sizes were larger compared to the non-treated group (Figure 
29, b.). The mice blood was further analyzed to detect any abnormalities. 
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 Development of EAE scores in the treated and non-treated groups (II.2.5.2). a. The statistical studies Figure 29.
(II.2.6.4) between the groups (each day) showed the scoring differences on days 13, 14, and 15, before the 
sudden deaths of several mice and worsening of the disease. ***P<0.0001 and **P<0.001. b. Results of CD64 
staining in the treated (highlight) and non-treated mice show more stained cells and larger lesions in the treated 
mice. Mice 1 and 2 of the treated group, did not develop EAE, but they had small lesions and cell infiltrates. 
III.7.2 CD64 population 
Before euthanizing the animals, blood samples were taken from the remaining five treated 
mice (day 20). Interestingly, a very large hCD64-positive granulocyte population was 
observed in all samples, as analyzed by FACS. While skin ulcers and emulsion bumps could 
have been the explanation, it was necessary to examine this finding further. Therefore, to 
understand the reason for the large hCD64 and granulocyte populations in the treated group, 
and to recognize whether it was related to H22-ETAʹ′ itself or other influencing factors, a few 
additional experiments were designed: examining the direct effect of H22-ETAʹ′ on healthy 
non-EAE induced mice; studying the population of granulocytes in brain sections; and 
developing the macrophage immune kinetics. 
III.8 H22-ETAʹ′  effect  
To further evaluate the effect of the IT on mice, similar to the previous treatment schedule 
(Table 18), the same dose of immunotoxin (20 µg) was applied in non-EAE induced, 
C57BL/6 transgenic (hCD64) mice. The mice were euthanized on day 16 after eight injections 
of H22-ETAʹ′, and the spleens kidneys, and livers were removed for further 
immunohistochemistry and analysis (II.2.6.1-2). hCD64 (human macrophage), F4/80 (mouse 
macrophage), and CD3 (T cell) populations were analyzed in these samples and compared to 
the control mice, which were not injected with H22-ETAʹ′ (Figure 30, lined and marked as H).  
After comparing the hCD64 staining of H22-ETAʹ′-injected mice with the healthy control 
mice, the results revealed similar CD64 expression in the kidneys, spleens, and livers of all 
the mice (Figure 30, a., d.), as CD64 is normally present and expressed in those tissues, and 
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F4/80 is a normally expressed receptor in the liver’s Kupffer cells, the kidney cells 
(residential macrophages), and the red pulp of the spleen. F4/80, as a mouse macrophage 
marker, was stained in all tissues, and it had a very large population in the spleen, as expected. 
No differences in F4/80 staining were detected between the groups of animals (Figure 30, b., 
e.).  
 
 
 Evaluation of H22-ETAʹ′ effect on healthy non-EAE induced animals. a. Immunohistochemistry of Figure 30.
hCD64, b. F4/80, and c. CD3 in spleen sections. d. CD64, e. F4/80, and f. CD3 staining of kidney sections. 
The stainings were compared between three H22-ETAʹ′-injected mice vs. one H22-ETAʹ′ non-injected “marked 
as H” mouse. No difference was seen between the animals [(II.2.5.3), (II.2.6.2)].  
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The presence of polymorphonuclear cells (PMNs), such as granulocytes, was also checked in 
these slides, as an increased PMN population is expected in the case of inflammation. Thus, 
an AEC substrate was prepared, without blocking the endogenous H2O2, for red staining of 
PMNs. After this stain check, no granulocyte population was distinguishable, and all the 
CD64 stained cells were detected as macrophages. 
CD3 was also stained normally in the spleens, and few cells were stained in the kidneys of the 
mice; no differences were seen in these samples (Figure 30, c., f.). When analyzing all the 
samples, we observed that the staining intensity of the hCD64 and F4/80 receptors were 
higher in the spleen and kidney sections of the healthy, non-EAE induced or no-H22-ETAʹ′ 
injected mice (H), because in the H22-ETAʹ′-injected mice the population of macrophages was 
slightly lower, due to the IT injections. The most abundant staining in these mice was F4/80, 
while CD3 had the smallest stained cell population (Figure 30). We determined that H22-
ETAʹ′ had no effect on the healthy, non-EAE induced mice, and we decided to apply a similar 
treatment protocol once again, with minor dose changes (10 µg) in the EAE-induced mice.  
III.9 Freund’s adjuvant effect 
After the effect of H22-ETAʹ′ was tested on non-EAE induced mice, another experiment was 
carried out using a reduced dose (10 µg) of IT. EAE was induced in three groups as described 
previously (II.2.5.2), using the Hooke Laboratories 0-114 EAE induction kit, and the 
treatments were initiated on day 6 of EAE induction.  
Similar to the previous time (III.2), the mice developed a strong reaction and four mice died 
in less than 5 minutes after the fourth injection. Blood was taken immediately from all the 
mice and screened by FACS (Figure 31). An abnormal increase in the granulocyte population 
(nearly seven times) was observed in the blood samples (Figure 31).  
To determine the reason for these results, the effect of H22 and its binding to the granulocytes 
was tested. Two days after the fourth IT injection, blood samples were taken from the mice 
and incubated for 0–5 mins with H22-SNAP (the same dose and time as H22-ETAʹ′, 0.05 µg 
per animal). Because H22-SNAP is similar to H22 and it targets the same receptor as H22-
ETAʹ′ but lacks the toxin part, it was used to evaluate the H22 binding effect on the 
granulocytes. In addition, the SNAP tag is a 19-kDa polypeptide that was fused to H22, and it 
could further be tagged by suitable ligands such as fluorescent dyes. After incubation, the 
samples were immediately analyzed using FACS; the results presented a sudden decrease in 
the granulocyte population after incubation with H22-SNAP, whereas the controls were 
unaffected (Figure 32).  
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Our results indicate that the binding of H22-SNAP to CD64-positive granulocytes and their 
further lysis caused anaphylactic shock in the mice. The non-EAE induced, H22-ETAʹ′-treated 
mice were used as controls, and the granulocyte population was checked in those mice as well 
as the other mice (Figure 31, control).  
 
 
 Blood screening of the EAE induced mice after day 14 of EAE induction. The FACS analysis Figure 31.
(II.2.2.13) showed a large granulocyte population in eight treated mice after the fourth injection, vs. a control 
mouse (H22-ETAʹ′ injected but not EAE induced). The difference in the granulocyte population between the 
control and the rest of the animals is obvious. 
 
 The experimental groups and the blood screening of the EAE induced and treated mice, before and Figure 32.
after incubation with H22-SNAP, left: Three groups of EAE-induced mice. The days of H22-ETAʹ′ injections 
are marked on the table. After four injections of H22-ETAʹ′, five transgenic mice died within a few minutes. 
The hCD64 group, which was not treated, and the hCD64-negative but treated group showed no reaction. Ts: 
transgenic; D6-T: day 6 treated; n-t: non-treated; n-Ts: non-transgenic. Right: FACS analysis (II.2.2.13) of 
hCD64, H22-ETAʹ′-treated mice on day 10 of treatment. Dark blue and black lines are the hCD64-positive 
granulocytes in the blood of the treated group, and the light blue and gray lines are the same blood after 
incubation by H22-SNAP. The difference in granulocyte population between the H22-SNAP-incubated and 
non-incubated populations is distinguishable.  
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These experiments show that the large granulocyte population was caused by CFA effect 
induced as a consequence of EAE induction injected subcutaneously in the mice. After the 
reason for the large granulocyte population was determined in the EAE-induced mice, we 
were finally able to design a suitable IT injection protocol that avoided the CFA effect (Figure 
32). Before planning the last EAE induction and treatment experiments, we decided to 
establish the macrophage infiltration time point into the brain, in order to design a more 
accurate treatment schedule. 
 
III.10 Immune kinetics 
III.10.1 Macrophages (CD64) 
As we wanted to study the role of macrophages in the development of EAE, and as we 
encountered problems, we developed a set of experiments to establish a protocol that suited 
our treatment strategy (EAE inductions, III.6 and III.7). During these preliminary 
experiments, we observed that there were many variable factors affecting the outcome of EAE 
induction and treatment. Therefore, to establish an effective macrophage targeted therapy, it 
was essential to know the exact course and nature of the inflammation, including the infiltrate 
compositions and the time of invasion.  
To estimate the macrophage kinetics in the brain lesions (II.2.4.4), EAE was induced in eight 
10-week-old female mice (II.2.5.2), and two each were euthanized on days 6, 8, 10, and 12. 
The brains were removed, sectioned, and stained for CD64-expressing macrophages, as 
previously described [(II.2.6.2), (Figure 33)]. Healthy mice were also checked for the 
expression range of hCD64, marked as day 0 (normal) in Figure 34. a. The staining on day 6 
was similar to that of day 0, with only a few cells stained (<5); on day 8, the macrophage 
population increased slightly, to 15–30, and from day 10 to 12 the stained area was larger 
(Figure 34.b.). The size (µm2) of the total stained area was calculated for CD64, CD14, 
CD301, and CD3 receptors (Figure 35). 
The FACS results were similar to those of the immunostaining. Blood samples were taken 
from two mice on days 6, 8, 10, and 12 of EAE induction and stained by FACS. In Figure 
34.a., there is a clear distinction between the positive and negative cells (after day 6); the cell 
count of the hCD64 population was 16 on day 0 and 32 on day 6, and then increased to 64 on 
day 8 and further increased to 128 on days 10 and 12 of EAE induction. The day 0 samples 
were those of healthy, transgenic, non-EAE-induced mice. The CD14, CD3, and CD301 
kinetics were also developed and analyzed further to assist us in developing an appropriate 
treatment schedule (Figure 35). 
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 Immunohistochemistry of macrophage kinetics (II.2.4.4) on days 6, 8, 10, and 12 of EAE-induced Figure 33.
mice. Stainings show hCD64-expressing cells in the white matter area of the mid cerebellum. Most of the 
infiltrates are in the white matter area, where it is filled by axons and the myelin layer around it. Usually the 
places with high infiltrate cell numbers have a lighter hematoxylin staining, due to a loss of myelin in those 
areas, as in the last two images. Each two stainings in one line are representative of two mice euthanized on 
the same day. The staining was carried out using mouse anti-human CD64 FITC (1:40; AbD Serotec), 
followed by sheep anti-FITC AP (1:400; Southern Biotech); the pink color of AP-labeled antibodies was 
developed using the new fuchsine substrate as described previously (II.1.4), (II.2.6.2). On the right side, the 
threshold was prepared using adobe Photoshop, which is a prerequisite for ImageJ picture analysis and 
calculation of the stained area per image, as well as further plotting of the related graphs.  
III.10.2 T cell and M1 and M2 immune kinetics 
The brain sections from the EAE-induced mice were stained for the presence of CD14, 
CD301, and CD3 markers. The infiltrates were then statistically analyzed from day 6 to day 
12. In Figure 35, CD14 and CD3 presented profiles similar to that of CD64. The populations 
of both increased after day 8, on day 10, and further on day 12. The CD301 population was 
low in the beginning until day 10, after which it increased. However, the T cell marker (CD3) 
presented a very small stained area, even on days 10 and 12, compared to the area stained by 
the other immune cells (Figure 34.b.).  
As stated in the description of the experiments, we were finally able to design an optimal 
protocol for EAE induction followed by H22-ETAʹ′ treatment. The optimized version of the 
EAE induction and treatment were then tested on four groups of mice. 
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 a. Macrophage kinetics (II.2.4.4) from blood samples, tested through FACS analysis (II.2.2.13). Figure 34.
Each two graphs on one line are from two mice euthanized on the same day (same arrangement as fig.34.b.). 
The experiments were planned on days 0, 6, 8, 10, and 12 of EAE induction. According to the absorbance and 
the cell counts, the population increased slightly until day 8, followed by a sudden increase on days 10 and 12. 
b. Macrophage kinetics and CD64-stained area per µm2, from day 6 to 12. The macrophage infiltrates 
appeared in the stainings after day 8 of EAE induction and they grew further to a larger population on day 12, 
although it was prior to the development of clinical EAE signs (II.24.4) and (II.2.6.4).  
 
 Immune cell kinetics (II.2.4.4) of hCD64, CD14, CD3, and CD301 markers; stainings are from days Figure 35.
6, 8, 10, and 12 of EAE induction. All infiltrates increased after day 8, except the CD301 population, which 
remained nearly the same or increased slightly until day 10. The CD64 and CD3 populations increased 
suddenly on day 10, while CD14 and CD301 had a slight increase from day 8 to day 10, and a major shift on 
day 12. 
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III.11 EAE induction and optimized H22-ETAʹ′  treatment 
After finishing all of the preliminary experiments and having the prerequisite data for 
macrophage-targeted therapy, the optimal EAE induction protocol and treatment schedule 
were planned, and the final experiment was performed. Four groups of mice were immunized 
(Table 19) using a Hooke EAE induction kit (II.2.5.2). The disease signs developed after day 
13 of EAE induction [79]. The treatment was started on day 6 of EAE induction, which was 
planned according to the macrophage and immune cell kinetic studies (3.8). One of the groups 
was treated from day 13, upon score development, as a control to evaluate the importance of 
timing of the treatment. The determined dose of H22-ETAʹ′ was 10 µg per animal, as it was 
the safe dose determined by the H22-ETAʹ′ studies (III.7.2.1) (Table 19).  
 
Table 19. Four groups of mice (n: 9) were studied in this experiment. 1: hCD64, treated from day 6 (hCD64 
transgene); 2: hCD64, treated from day 13 (hCD64 transgene); 3: hCD64, not treated (hCD64 transgene); 
and 4: hCD64 negative, treated from day 6 (wild type litter mates). EAE was induced (II.2.5) in all groups 
on day 0, and the treatment protocol was followed according to this table. The “x” indicates the day the 
group was euthanized. Ts: transgene; D-t: day treated; nt: non-treated; n-Ts: non-transgene.  
 
 
 
 
The place of injection was chosen as IV in the plexus of the eye socket, behind the eye orbit, 
for the first four injections; then, after observing the results of the experiments that presented 
the CFA effect on granulocytes and their reaction to H22-scFv (III.7.2.2), the injection place 
was changed to IP and continued in that manner until the end of the experiments (Table 19). 
III.11.1 EAE scoring 
The non-treated and non-transgenic treated mice developed EAE on day 13 of EAE induction, 
while the treated groups started to developed EAE signs on day 14. The progression of the 
disease was similar in all groups until day 17, after the fifth injection of H22-ETAʹ′, when the 
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mice were suffering from score 1.5. After day 18, the treated group started to show signs of 
recovery, and on days 20–21, the mice (day 6 treated) were back to a healthy condition. The 
scores of the treated group all went back to 0 or 0.5 until the end of the experiments. The 
hCD64 non-treated, CD64 negative/treated, and hCD64 day 13 treated groups were all 
euthanized on days 21–23, as they developed severe clinical scores and inappropriate life 
conditions. However, the hCD64 day 6 treated group was kept until day 29, as their scores 
decreased to 0–0.5 and their clinical signs disappeared (Figure 36).  
 
 
 
 
 
 Development of clinical disabilities in four EAE induced experimental groups, including hCD64 Figure 36.
day 6 treated; hCD64 day 13 treated; hCD64 non-treated; and CD64 negative, day 6 treated (II.2.5.2-3). The 
clinical signs decreased and exacerbation of the disease was prevented in the hCD64 day 6 treated group, 
while the clinical scores of the other groups increased during the same time, without recovery. Statistical 
analysis between the hCD64 day 6 treated and the other groups was calculated with a two-way ANOVA test 
(II.2.6.4), and the difference was considered significant; ***P<0.0005. 
III.11.2 Immunohistochemistry  
The mouse brains and spleens were removed and prepared for immunohistochemistry as 
described previously (II.2.6.1). The CD64, CD14, CD301, CD273, CD3, and CD19 stainings 
were carried out (II.2.6.2) to indicate the staining differences between the nine treated (day 6) 
and nine non-treated mice (Figures 37-39). Qualitatively, CD64 staining was reduced in the 
treated group compared to the non-treated one. In some treated mice, stainings were rarely 
seen, while in others, single cells were spread around the lesions. In the non-treated group, 
stained cells were mostly gathered next to each other around an inflamed area of the 
cerebellum (Figure 37). The macrophage staining intensity was reduced after the H22-ETAʹ′ 
treatment began on day 6. In addition, developed lesions and demyelinated areas were hardly 
seen in the treated group compared to the non-treated group (Figure 37, red arrows). 
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CD14 (M1) and CD3 (T cell) stainings both decreased in the treated group, showing similar 
reactions to the treatment as CD64 (Figures 38-39).  
The only unaffected staining was CD301, the marker of M2 macrophages. Furthermore, the 
CD273 receptor, present on M2 macrophages and dendritic cells, was noticeably increased in 
the treated group compared to the non-treated group. 
 
 
 Immunohistochemistry (II.2.6.2) of hCD64 cells in the treated vs. non-treated groups: a, white Figure 37.
matter area; b, molecular layer; c, granulocyte layer. Reduction of CD64 staining is noticeable in the white 
matter area of the treated group. Arrows show the areas of demyelination in white matter, where the 
hematoxylin staining is faint and the macrophage infiltrates are larger, including more cells. The stainings 
were carried out using mouse anti-human CD64 FITC (1:40; AbD Serotec), followed by sheep anti-FITC AP 
(1:400; Southern Biotech). The pink color was developed using the new fuchsine substrate as described 
previously (2.1.4), (2.2.6.2). 
 
 
 Immunohistochemistry (II.2.6.2) of CD14 expressing macrophages, in the treated vs. non-treated Figure 38.
groups. Reduction of CD14 staining is noticeable in the treated group. Areas of demyelination in the white 
matter area, where the haematoxylin staining is faint and full of CD14 infiltrates, are visible. The stainings 
were carried out using anti-mouse CD14 FITC (1:40; AbD Serotec), followed by sheep anti-FITC AP (1:400; 
Southern Biotech). The pink color of AP-labeled antibodies was developed using the new fuchsine substrate as 
described (II.1.4), (II.2.6.2). 
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 Immunohistochemistry (II.2.6.2) of CD3/CD19 cells in the treated and non-treated groups. The Figure 39.
stainings were carried out using rat anti-mouse CD3 (1:100; eBioscience) followed by goat anti-rat AP (1:400; 
Southern Biotech) and rat anti-mouse CD19 (1:40; eBioscience) followed by goat anti-rat HRP (1:400; 
Southern Biotech). For red color development of HRP-labeled antibody, AEC substrate was used; for blue 
color development of AP-labeled antibody, fast blue base substrate was used; and for pink color development 
of AP-labeled antibody, new fuchsine was used (II.1.4). 
III.11.3 Statistical analysis 
The processed immunohistochemistry images were analyzed using ImageJ and completed 
using GraphPad Prism (II.2.6.4). The statistical analysis further confirmed that the CD64, 
CD14 (M1 markers), and CD3 (T cell) stainings were significantly different (Figure 40; 1, 2, 
3) between the day 6 treated and non-treated groups (p<0.0005). A statistically significant 
increase in the CD273 (M2 marker) population was also observed (p<0.005) (Figure 40; 4). 
The CD301 (M2 marker) had a nearly similar profile in both the day 6 treated and non-treated 
groups; only one sample had more receptors stained in the non-treated group; therefore, the 
difference was not considered significant (Figure 40; 5). 
The day 13 treated group was also compared to the non-treated one, and the decreases were 
not statistically significant. However, the total infiltrate number was reduced, and the CD3 
decrease was considered significant (p<0.005) (Figure 40; 3). When comparing the day 6 
treated group with the day 13 treated group, the infiltrate reductions were very obvious in all 
samples, except in CD273 staining; the day 6 treated group had a larger CD273 stained area 
than the day 13 treated group did (Figure 40; 5). 
The results also showed that although the clinical scores and symptoms in the day 13 treated 
group were not affected upon treatment, the total number of infiltrates was still slightly 
reduced (Figures 36 and 40). 
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 The immunohistochemistry (II.2.6.2) differences between the day 6 treated, day 13 treated, and non-Figure 40.
treated groups were statistically analyzed (II.2.6.4) using Prism 4; ***P<0.0005; **P<0.005; *P<0.05; ns, not 
significant. M1 markers (1: CD64 and 2: CD14) and the T cell marker (3: CD3) significantly decreased in the 
day 6 treated group. The other M2 markers increased or remained unaffected (4: CD301 and 5: CD273). The 
CD64 population of day 13 treated group changed slightly (just two samples), while CD14 was not affected at 
all. Except for a decrease in CD3 population, the M2 markers were also statistically unaffected. 
Finally, all the microscopy results from the stainings of CD64, CD14, CD301, CD3, CD19, 
and CD273 that were processed by ImageJ were further approved individually through the 
whole sections by blinded manual counting and scoring of the stainings (Table 20), (III.10.2).  
 
 
 
  
81 
Table 20. Manually scored immunostainings (II.2.6.2) of CD64, CD14, CD301, CD3, CD19, and CD273; day 6 
treated (highlight), day 13 treated, and non-treated. 
 
 
III.12 Immunohistochemistry of the human MS brain (CD64) 
To present a better understanding of CD64 expression in human tissue, CD64-expressing 
macrophages were stained in human MS patients’ brains (Figure 41). The Netherlands Brain 
Bank (NBB) in Amsterdam collects fresh human brain tissues from donors with a variety of 
neurological disorders, as well as from non-diseased donors.  
 
 Macrophage staining in human brain sections of MS patients (II.2.6.3) tissue, stored in Netherlands Figure 41.
Brain Bank. CD64 was stained using H22-scFv (provided by Fraunhofer IME, Department of Pharmaceutical 
Product Development) in paraffin-embedded sections. Stainings were carried out using H22-scFv (1:100) 
followed by mouse anti-his HRP (1:100), and further developed using AEC substrate.  
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The brains are collected directly after death, which makes it possible to isolate the living cells 
and macrophages from the lesions and choroid plexus. Paraffin-embedded sections of human 
MS brains were stained, using H22 single chain, provided by our group (Pharmaceutical 
Product Development, Fraunhofer IME), and the same clone as was used to generate H22-
ETAʹ′. Here, we present the first data of CD64-expressing macrophages in MS patients’ brain 
lesions (Figure 41). These data confirmed that anti-CD64 treatment could also be used to 
target macrophages in the human brain. 
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 Discussion  IV.
Multiple Sclerosis (MS) is a complex neurological disorder of the central nervous system, 
most likely caused by environmental influences in genetically susceptible people. The disease 
can range from benign to partially disabling and proceeds to clinical deterioration. MS 
involves an immune-mediated cascade initiated in the peripheral immune system, targeting 
the CNS. The reactive infiltrated immune cells seek out the myelin sheath to destroy it and 
disrupt the signal transfer. Therefore, causes interruption in the body’s ability to communicate 
with the CNS. Subsequently, wide range of physical, mental, and psychiatric problems could 
be developed in a patient suffering from MS [81].  
Considering the complex immunopathology of MS, the available therapies in the market 
attempt to partially improve the body’s function after an attack, or to further avoid new 
attacks. Following IFN’s announcement in 1993 as the primary registered drug [82], 
enormous efforts have been made to develop more specified immuno-targeting drugs. It 
appears, the more specified the field of immunotherapy is getting, the greater its efficacy is 
becoming [83]. One of the recently developed ideas of immunotherapy is the interest to 
inhibit the reactive autoimmune cell functions, those attacking the myelin layer [84], such as; 
Rituximab that depletes B cells (anti-CD20 antibody) or Alemtuzumab that depletes T cells 
(anti-CD52 antibody) [23], [59], [85]. Several modulatory therapeutics are under phase III of 
clinical investigation, designed to block the reproduction of T cells and shift pro-
inflammatory Th-1 to anti-inflammatory Th-2 population, as Laquinimod and Teriflunomide 
[23], [39], [86]. Some other therapeutics are under examination phase to treat MS through 
reduction of the BBB’s permeability, [87], [88]. Agrawal et al., showed that suppression of 
both matrix metalloproteinase-2 (MMP-2) and MMP-9, reduced the leukocyte penetration 
across the BBB, thereby inhibiting EAE development [89]. And according to deBoer et al., 
IFNβ increased the tightness of the BBB [90]. Additionally blocking the inflammatory agents, 
such as TNFα or IFNγ cytokines, which contribute towards the BBB’s breakdown was proved 
to develop a therapeutic efficiency [91]. 
One of the promising targets of immunotherapy in MS, is the rapidly recruiting monocytes to 
the inflamed areas of CNS, while their inflammatory activity hinders the resolution of the 
complicated disease cascade [92]. Despite the important role of macrophages next to the other 
immune cells in Multiple Sclerosis [59], up-to-date the majority of the treatments were 
focused on anti-inflammatory, symptom reducing drugs through elimination or inhibition of T 
or B cells, while no therapies are yet developed against macrophages [23]. Additionally, the 
majority of the approved therapeutics are partially suitable for relapsing-remitting MS models 
  
84 
but not for the progressive phase [86]. Thus the lack of an effective, disease-inhibiting 
treatment, explains the necessity of new therapeutical investigations.  
Our focus was laid on introducing a new therapeutic strategy, which could be potentially used 
for MS treatment, through targeting the reactive inflammatory monocyte populations. Here, 
human CD64, C57BL/6 transgenic mice (F>6) were used to estimate the role of hCD64 
positive macrophages, that whether depletion of these cells in EAE chronic model would be 
an advantage or not [93]. To develop the best therapy schedule, some additional requirements 
and experiments were carried out, such as macrophage kinetic studies, the effect of H22-ETAʹ′ 
on healthy non-EAE induced animals, and the effect of Freund’s adjuvant on granulocyte 
population, which was increased upon adjuvants injection. Furthermore, different therapeutic 
protocols were tested, in terms of time, dose of application, and place of injection, to enable 
the designing of an optimized protocol.  
IV.1 Expression of required protein products for EAE induction 
To provide the required proteins for EAE induction followed by the treatment, both EAE 
inducing MOG [94], [95] and the therapeutic H22-ETAʹ′ proteins were expressed and 
characterized [96]. Different methods and protocols were used and compared together, in 
terms of protein purity, quality and yield. Concerning those procedures, MOG was 
successfully expressed in 2xYT medium, since TB/PS medium resulted in a low yield and 
degraded protein bands in the purified samples (Figure 12). MOG expression through 2xYT 
medium increased the protein yield 3 times, comparing to the normal stress expression 
method. Additionally, the purification results shows that talon resins developed stronger 
affinity to his-tagged proteins, comparing to nickel resins [97]. Primarily, Nickel resins were 
used for MOG purification but upon using talon resin, the proteins had higher purity, 
therefore the purifications were further carried out using talon resin [98]. There were no bands 
of degradation or contaminated proteins except the purified MOG product (figure 12). The 
stability test showed that the protein structure was stable and when kept in fridge over a week 
or at room temperature for one hour, it was not degraded (Figure 14). Furthermore, the 
specific biding of MOG to anti MOG antibodies produced by 8.18C5 cells was established 
(Figure 13) and following an overnight dialysis, the pure protein was confirmed to be suitable 
for EAE inductions. 
When MOG-ETAʹ′, expressed in TB/PS medium was purified, upon presence of degraded 
bands in the final purified product and its problematic expression, it was additionally 
expressed in 2xYT medium and further purified using talon resin. During the purification 
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procedure, large amounts of the protein were lost either in the flow through and “low 
concentration” imidazole, washing buffer (Figure 16). This could have been explained as the 
consequence of insufficient talon beads (the volume). If the beads reached their maximum 
binding capacity in comparison to the total volume of the expressed protein, they could no 
longer bound to the extra protein, as 1 ml talon beads could purify 1.5 mg of protein. 
Moreover, reduced binding affinity of the proteins could have been also explained as the 
result of an undefined protein folding. However, the binding studies of MOG-ETAʹ′ and 
further its characterization by FACS analysis confirmed the protein’s appropriate folding 
[(Figure 16; western blot), (Figure 17)]. Indeed, upon false folding, no binding could have 
been seen in FACS and western blot. Thus, insufficient volume of the purification beads was 
the major reason of the protein loss.  
After expression and purification of H22-ETAʹ′ [99], [70], the protein was further 
characterized. Accordingly, the IC50 was 8.4 ng/ml, and the protein was considered highly 
pure with specific binding abilities against CD64 positive HL60 and U937 cells (Figure 15), 
therefore suitable for injections. In addition, the degraded, small ETAʹ′ bands (>30 kD) were 
removed during the dialysis procedures [100], [101]. Kasper et al., showed that by using the 
low background strain (LOBSTR), the background contamination of proteins expressed in 
E.coli BL21 (DE3) could have been further minimized, since the contaminating co-expressed 
proteins were eliminated after purification, and the affinity of the expressed proteins were 
reduced [102]. However, here by dialysis and purification via talon resins the protein product 
quality was optimized. 
IV.2 Preliminary EAE inductions 
The initial EAE inductions were applied (III.4.1.1), using various MOG products, 
supplemented with complete Freund’s adjuvant (CFA) and pertussis toxin (PT), however 
EAE did not developed and consequently the brain immune infiltrates were missing. The 
immunohistochemistry of spleen and antibody titrations of mice serum approved the immune 
response against MOG (Figure 20), since EAE is an antibody mediated demyelinating disease 
[103]. Upon comparing the immunostainings of EAE induced vs. healthy, non-EAE induced 
mice, the reactive immune cell populations of EAE induced mice were increased in the spleen 
sections (CD115, CD11b, Gr1 and T cells) [104]. However, in the brain sections, no 
infiltrates were present, which could have been referred to the structure of BBB. Because 
upon BBB’s break down, the immune infiltrates should have been seen in the CNS and 
therefore in the brain sections [105]. Subsequently this could have demonstrated that the BBB 
  
86 
prevents the infiltration of those reactive immune cells to the immune privileged area of the 
CNS. And consequently, inhibits the EAE development, even if immune response was 
developed, the reactive immune cells were observed and increased in the periphery (Figure 
20). Therefore this could additionally demonstrate that destruction of the BBB is one of the 
important features of the EAE development [106]. Which is known as a prerequisite event for 
EAE development, and is further associated with the influx of inflammatory cells from 
periphery to CNS [88], [107]. As based on developed studies, BBB could inhibit the disease 
development [87], since in EAE the auto-immune response initiates in the periphery and 
further infiltrates the CNS via BBB. In EAE induction, pertussis toxin is the responsible agent 
that breaks down the BBB, therefore to promote EAE onset, the injected dose of PT was 
further increased in the following experiments. 
IV.3 EAE induction and remyelination 
Following many efforts, EAE was finally induced successfully in hCD64, C57BL/6 mice; 
using Hooke laboratories kit (0-114) [108], [109], and further treated using 4.2 µg H22-ETAʹ′. 
After brain cerebellum sections were prepared, the CD64 staining and analysis presented 
major differences between the treated and non-treated groups [(Figure 25), (Table 15, 16), 
(p<0.0005)]. The CD64 stained cell population was reduced while the progress of the clinical 
disabilities and the disease scorings were not affected by this treatment.  
In Figure 25, mice 1 and 3 from the non-treated group, developed large areas of 
demyelination, while the hCD64 population was mostly observed as cell clusters around the 
infiltrated areas [111]. However, this was rare in the treated samples, since mice 1, 2 and 4 
from the treated group developed demyelinated areas as well, but the surrounding macrophage 
population was reduced and small (Figure 25). The manual scoring showed reduced lesion 
numbers in the treated group comparing to the non-treated ones (Table 16). 
Additionally, the highest hCD64 stained cell number was 230 in the non-treated group, while 
it was reduced to 23 in the treated group. The EAE clinical scorings were variable, while 
despite the reduced infiltrates in the treated mice; the disease scores were still high and 
unaffected. Further difference between these groups was the position of the hCD64 stained 
cells. In the treated group the immune cell infiltrates were limited to the white matter area of 
the brain, while in the non-treated group, CD64 cells were located additionally in the granular 
layer of the brain cerebellum, which could be referred to the presence of microglial cells [113] 
(Figure 25). 
Additionally, the CD36, CD301, CD3 and CD205 immunostainings showed reduction of 
these populations (Figure 27) [115], [116]. The influence of the treatment was clearly 
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observed on the double stained samples shown in Figure 27, including CD36/CD64 (a) and 
CD301/CD64 (b) stainings. In those samples, the cell populations were large, as both single 
and double stained cells were present in the non-treated group, while in the treated group, 
double stained cells were reduced and typically single stained CD36 or CD301 cells were 
observed. Furthermore, depletions of the double stained cells were developed as the 
consequence of CD64 expression on them. The CD64 single stained cell populations were 
considerably reduced in the treated group (Figure 27). These data were additionally confirmed 
by manual counting (table 17). Moreover, the CD3, CD36, CD205 and CD301 stained cell 
numbers were reduced from 60-180 in the non-treated group to 0-16 in the treated group 
(Table 17) [118], [120], which presented less inflammation in the brain. 
In total, the CD64 stained areas were reduced significantly in treated group comparing to the 
non-treated group (p<0.0005). The largest stained area was 48650 µm2 in the non-treated 
group, while it was reduced to 7261 µm2 in the treated group (Figure 26). In addition, the 
stained area fraction covered 1.3-2% of the stained image in the non-treated mice, while it 
was reduced to 0-0.4% in the treated group. The manual cell counts approved the calculated 
results by image j and microscopy (Table 15). During this experiment the disease severity was 
not changed, even though the treated group presented less number of macrophage and 
immune cell infiltrates, since they were treated from day 13 of the EAE induction. 
The late treatment and presence of already developed lesions, did not allow H22-ETAʹ′, to 
prevent the disease onset. Subsequently, the developed lesions and areas of demyelination 
were observed even in the treated mice (Figure 27, d.T), though the infiltrates were reduced to 
1-10 cells. Therefore late H22-ETAʹ′ therapy was able to reduce the inflammation and the 
immune cell attack, by reducing the infiltrated cells, but it couldn’t promote remyelinating 
condition, during such a short time [122]. Noticeably, the entrance of the monocytes to the 
sites of inflammation could have been before development of the disease and prior to lesion 
formation [124], therefore late treatment had no effect on the clinical symptoms, even though 
that an inhibitory effect was established on the disease progress. In a comparable situation, 
once the demyelinated lesions are formed, the destructed myelin layer should further be 
repaired to help resolving the clinical disabilities. Since the disabilities are developed as the 
consequence of myelin damage and disruption of signal conduction. And additionally the 
lesion volume directly correlates with macrophage recruitment, demyelination and acute 
axonal damage [125].  
Considering the immunopathology and the neurological dysfunctions of the MS [127], to 
overcome the physical disabilities, a condition should have been provided to promote myelin 
regeneration [129]. One of the therapeutic strategies currently under development is the 
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transplantation of the oligodendrocyte precursor cells (OPCs), to promote remyelination 
[129], [66]. Since OPCs are activated in the presence of regulatory cytokines, chemokines and 
growth factors that further assists their differentiation into remyelinating oligodendrocytes 
[133]. According to some studies, during the inflammatory phase of MS and after 
oligodendrocyte loss, large number of fresh oligodendrocyte precursor cells (OPCs) enter the 
corpus callosum [135], [136], and migrate to the areas of demyelination. Thereafter, during 
the remission phase, the M2 macrophages produce anti-inflammatory mediators, including 
growth factors [138], which proliferate the OPCs to oligodendrocytes and remove the myelin 
debris. They further engaged the recruited oligodendrocytes with demyelinated axons to 
differentiate them to remyelinating oligodendrocytes, producing the required myelin sheath 
[140]. Failure in myelin repair often happens because of a failure in differentiation of the 
precursor cells, rather than a failure in their recruitment, as the consequence of, regulatory 
cytokines and growth factors unavailabilities [142]. Therefore, on one hand, one of the major 
considerations that should have been focused on is the schedule and the initiation time point 
of the treatment. To reach an optimized therapy, the therapeutic should have been applied 
early enough, prior to demyelination, lesion formation and development of the physical 
disabilities [144]. On the other hand providing the regulatory cytokines and growth factors 
produced by M2 macrophages would also be and advantage. 
IV.4 Preliminary EAE inductions and treatment optimization 
In a successful therapy, reduction or prevention of the clinical scores should have been 
established. Therefore, additional experiments were planned, with an earlier treatment time 
point, while the IT doses were increased to 10 and 20 µg per animal [(preliminary 1 and 2 
EAE inductions), (III.6 and III.7)], [146]. During these experiments, the treatments were 
initiated from day 8 of the EAE induction. During both experiments, 4-5 healthy mice died 
each time following the 4th injection of H22-ETAʹ′. While, large population of granulocytes 
was observed in the FACS analysis of the mice blood samples (Figure 31) [148]. Initially, the 
skin ulcers and bumps of emulsion at the sites of injection were the suspicious reason of 
developing large granulocyte population (III.7.2). Because it actually happened in the mice 
with developed wounds and emulsion bumps, at the injection sites (preliminary exp. 1). But 
during the other experiments (preliminary exp. 2), no wounds were seen in the mice, died 
after the 4th IT injection.  
Additionally, prior to the sudden death, the disease scoring differences between the treated vs. 
non-treated groups, presented an effective treatment (Figure 29.a.). As the EAE scores of the 
treated mice were lower on days 13, 14 and 15 (p<0.005). But after the “sudden death”, the 
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scores of the remaining mice in the same group increased unexpectedly. Moreover, the brain 
sections were analyzed for the presence of the granulocytes, while the hCD64 population of 
the brain was composed of macrophages and no granulocytes were seen there. However, in 
both groups treated by 10 µg or 20 µg of H22-ETAʹ′ (III.6 & III.7), similar reactions 
happened, and indeed the treated group with higher dose of H22-ETAʹ′ (20 µg), developed a 
stronger and quicker reaction (III.7). Subsequently, two alternatives were possible; the mice 
death happened as an unspecific effect of the H22-ETAʹ′, or it was developed as the 
consequence of H22-ETAʹ′, binding to blood granulocytes and leading to degranulation [150]. 
Therefore, to provide an answer, initially the direct effect of the H22-ETAʹ′ immunotoxin was 
examined on the normal non-EAE induced mice. Accordingly, the same dose of H22-ETAʹ′ 
(8x 20 µg, IV shots) was injected in hCD64, healthy and non-EAE induced female mice. 
Afterwards the mice were sacrificed and the kidney, lung and spleen sections were prepared, 
stained and analyzed (Figure 30). The outcome confirmed that no unspecific reaction was 
developed against the therapeutic protein in the mice.  
Furthermore the staining results presented no difference between the H22-ETAʹ′ received and 
H22-ETAʹ′ non-received mice, since the CD64, CD3 and F4/80 receptors were normally 
expressed and stained on the tissues (Figure 30). This experiment approved that H22-ETAʹ′ 
spontaneously, was not the reason of mice death, even if high doses of 20 µg were applied. 
Additionally during all experiments, the CD64 negative littermates, injected by H22-ETAʹ′ 
were present as control groups, since H22-ETAʹ′ cannot target the macrophages of this group. 
Therefore, any unspecific effect will immediately establish an unclear reaction. However, 
during these experiments, the control groups did not develop any reaction to the IT. 
To understand the reason of the large granulocyte population further and the IT reaction 
[152], a similar protein was used to establish the effect of H22 (scFv), when binding to 
granulocytes (without toxin moiety). Thus, same amount of H22-SNAP was used to evaluate 
its binding effect. H22-SNAP contains the same identical binding domain, binding affinity 
and molecular weight as H22-ETAʹ′, while the functionality and the toxicity of ETAʹ′ is 
missing [153].  
Therefore the mice blood was incubated by H22-SNAP (same amount and incubation time as 
H22-ETAʹ′). Following the incubation, FACS analysis showed that the population of the 
granulocytes was considerably reduced after incubated with H22-SNAP, while prior to 
incubation the granulocyte population was 7 times larger (Figure 32). Accordingly, H22 
single chain was immediately detected by the granulocytes; therefore binding and 
consequently degranulation was the reason of the anaphylactic shock in the mice [155]. 
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Since our targeted receptor was additionally expressed on the granulocytes, therefore these 
cells were affected upon binding to H22-ETAʹ′. The Complete Freund’s adjuvant (CFA) effect 
was described previously [148], [157], which could increase the granulocyte population. But 
since, no research was carried out for the development of any therapeutic, having similar 
properties to target a receptor on the granulocytes, this reaction was unknown until now. 
Indeed, it was valuable to know; when a therapeutic candidate, against macrophages, has to be 
examined in EAE model, the presence of the targeted receptor on the granulocytes should 
have been validated and considered as an important issue. If the target is expressed by the 
granulocytes, then a special treatment schedule should have been designed to inhibit the 
possible interactions between the therapeutic and the granulocytes. Furthermore, according to 
a personal communication with Dr. Suzana Marusic, the president of Hooke laboratories Inc., 
this reaction was described as a typical response to protein therapeutics. Accordingly, this 
happens in EAE models, 8-14 days after the first injection of the therapeutic protein, and the 
death depends on the injection dose of the therapeutic. Additionally, the mice death due to 
anaphylactic reaction could have been happened more often in the mice, without EAE clinical 
signs. This was comparable to what happened in the treated group (III.7). However, the 
reason of that, happening in the mice, without clinical scores or very low scores, is still 
unknown.  
In the EAE models, the immune response to the therapeutic protein is enhanced by the 
presence of Freund’s adjuvant (needed to induce EAE), therefor the protein itself would not 
induce anaphylactic reaction in normal mice (III.8), but it will, in mice injected with CFA. 
Some data presented the effect of subcutaneously or intraperitoneally injections of CFA, 
which resulted in an increased blood and bone marrow granulocytes [148].  
Upon performing these experiments, it was known that this reaction was developed because 
of the combination of the therapeutic with the complete Freund’s adjuvant effect (increased 
granulocytes) upon EAE induction. However, if immunotoxin or similar therapeutic is applied 
in humans, it has the advantage that MS disease does not initiate upon CFA or any other 
external adjuvant injections (indeed it is forbidden to use adjuvants in human). Therefore, the 
population of the granulocytes is expected to increase in MS comparable to other immune 
cells, but in a normal range, and as a regular immune response to the available auto antigens. 
Thus, the humans will be safe from CFA’s effect. 
The experiments established that H22-ETAʹ′, on its own has no side effect on healthy mice 
(III.8). After performing mentioned experiments [(H22-ETAʹ′ effect; III.8) and (granulocytes 
effect; III.9)], it was concluded that the death was caused because of an anaphylactic shock 
and as the consequence of granulocyte degranulation in mice. Since after immediate binding 
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of the H22-ETAʹ′ to the available granulocytes (in the blood), they degranulated and released 
toxic materials (nitric oxide, superoxide) and enzymes (lysozyme), therefore the mice died 
upon toxic shock [160], [161].  
Subsequently, after determining the granulocytes effect on the preliminary experimental 
groups, a new therapeutic schedule was planned. We observed that after 4 IV shots, the 
inflammation was controlled, therefore continuing the treatment as an IP injection decreased 
the risk of the anaphylactic shock, while prevented the disease progress as well. During this 
procedure, the IT release could have been slower via IP injection, therefore its effect on the 
CD64 positive granulocytes was reduced either. Consequently, the increased population of the 
granulocytes could not immediately bind to the IP injected H22-ETAʹ′, as the full amount of 
the IT was not released directly in the blood. However, according to our previous 
experiments, treating mice just IP would not be sufficient, as the CD64 positive cells would 
have had enough time to regenerate and attack the myelin layer and exacerbate the disease. 
This experiment provided the necessary information to develop the most appropriate 
treatment schedule, without getting disturbed by the CFA’s effect.  
IV.5 Immune cell kinetics  
After obtaining valuable data regarding EAE induction and its complicated therapeutic 
strategy, we performed a kinetic study of the immune cells, infiltrating the brain after EAE 
induction. This indeed assists completing the experimental schedule.  
EAE was induced in 8 mice on day 0, while each 2 were sacrificed on days 6, 8, 10 and 12 of 
the EAE induction (III.10). The brain sections were prepared and the immunohistochemistry 
results were analyzed (Figure 33). The immunostainings showed that CD64 expressing 
macrophage infiltrates were seen after day 6 of the EAE induction [163], however, initially 
the macrophage population was limited to 2-5 cells, but thereafter, it was increased from day 
8 and further from day 10 to 12 (Figure 34.a.). Upon comparison between the CD64 
population of the EAE induced mice and CD64 population of the non-EAE induced mice 
(Figure 34.a.; normal), the increase of the macrophage population was obvious in the EAE 
induced group. 
Additionally, to analyze the immune kinetics, the CD64 stained area (µm2) of the 
macrophages and other immune cell infiltrates were calculated, using image j software [165]. 
The stained area of CD64 was smaller than 5 µm2 on samples of day 6 and 8, followed by an 
increase on day 10 (65 µm2), and further extension on day 12, presenting a stained area of 
nearly 150 µm2 (Figure 34.b.). The CD14 infiltrates developed a similar infiltration profile as 
CD64; however, the total population of CD14 was smaller comparing to CD64. The stained 
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area size (CD14) was calculated 20 µm2 on day 10 and was further increased to 120 µm2 on 
day 12 (Figure 35).  
The T cell population (CD3) was not comparable to the macrophage populations (CD64 and 
CD14). Indeed CD3 stained area was very small, even on day 12 of the EAE induction 
(Figure 35). This could be explained through the fact that T cell presence is increased in CNS, 
upon antigen (myelin particles) presentation by APCs or macrophages [167]. And it further 
describes the necessity of macrophage presence, for T and other immune cell attractions. 
Here, the T cell population was increased to a larger volume of 1 µm2 on day 12 of the EAE 
induction. Once comparing the T cell infiltration sizes on day 12 of the EAE induction 
(Figure 35) with the stained sample of the T cells on day 23 of the EAE induction (Figure 27; 
c.T); the large population of the T cells on day 23, proves that they certainly increased after 
day 12 of EAE induction, upon APC’s activity and availability of the myelin particles.  
Moreover, the CD301 infiltrates (M2) were increased from day 12 of the EAE induction, 
having a stained area of 90 µm2, which could have been due to the presence of the 
demyelinated areas (Figure 35). This demonstrated that the inflammatory phase has been 
already developed and thereafter the degraded myelin particles should have been cleaned, 
Thus M2 macrophages are required. Therefore, the regulatory signals were received from the 
microenvironment for prevention of demyelination and to promote ODC dependent 
remyelination [142]. Since in the initial steps of the disease, remyelination is normally 
happening and partial recovery is a normal procedure, while M2 macrophages are repairing 
the peripheral nerves [170].  
Additionally, Myelin debris regulates the inflammatory responses of M2 macrophages in both 
EAE and Multiple Sclerosis diseases [157]. When macrophages phagocyte the myelin, they 
additionally send regulatory signals to oligodendrocytes, and further direct them to initiate 
remyelination. However, usually in MS after some minor recovery, when the ODC’s are 
damaged by M1 macrophages, remyelination stopped and the absence of regulatory mediators 
directs the disease to its progressive phase.  
Furthermore, when comparing Figures 29 and 33, though the macrophages enter the CNS 
from day 6 but the disease onset initiates from day 13 of the EAE induction. This presented an 
early infiltration and initiation of the demyelination, prior to development of clinical signs. 
Thereafter, the progress of the demyelination and infiltration after day 13, leads to lesion 
formation, clinical disabilities and physical impairments. Additionally, Berger et al., 
demonstrates that EAE inflammation processes are clearly linked to early macrophage 
infiltration in the brain [163].  
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According to our kinetic studies, the M1 markers appear from day 6 of EAE induction, in the 
initial inflammatory phase of the disease, while M2 markers were seen from day 12 of the 
EAE induction (Figure 34-35), to phagocytosis and promoting regulating responsibilities after 
disease development. Our established data provide a new insight for initiation of an early 
treatment schedule that was designed to initiate upon cell infiltration, prior to lesion formation 
and disease onset; from day 6 of the EAE induction.  
For an additional comparison between early and not-early treatments, another group, injected 
by H22-ETAʹ′, starting from day 13 of the EAE induction was included, that was after the 
onset of the disease, and upon score development.  
IV.6 H22-ETAʹ′  and the clinical recovery of EAE induced mice   
The final optimized experiment was planned (III.11), including 4 groups of mice (Table 19). 
The treatment was started from day 6 of the EAE induction; after 4x IV shots the injections 
were continued as IP (Table 19). The non-treated and day 13 treated groups, developed a 
homogenous EAE onset, while they were suffering from severe disabilities and high scores of 
2.5-3 on day 21 of the EAE induction. The transgenic hCD64, day 6 treated group developed 
score 1.5 on day 16, which was the highest developed score by this group and thereafter they 
were recovered immediately after day 17 of the EAE induction (Figure 36). The range of 
weight changes in all groups was between 6-8 g loss, except the recovered group, which had 
an average weight loss of 1-3 grams. Excluding the treated group that was kept until day 29, 
the other 3 groups were sacrificed on day 21-23, because of high disease scores and 
developed disabilities.  
IV.6.1 The M1 macrophages and immune infiltrates of the CNS 
The M1 macrophage populations of the day-6 treated group (CD64, CD14) were considerably 
reduced in immunohistochemically stained sections of the brain cerebellum (Figure 37-38). 
While M2 population was increased (CD273) or not effected (CD301), (Figure 40) [170], 
[173]. The T and B cell populations were also reduced according to the evaluated 
immunohistochemistry data (Figure 39); indeed, B cells had the smallest cell population 
comparing to the other immune cells. A study showed that the anti-myelin antibodies that are 
produced from plasma cells, mostly enter from the cerebrospinal fluid (CSF) and peripheral 
blood to the sites of inflammation and demyelination [174], [58]. Therefore, B cells are 
expected to be active as plasma cells in the cerebrospinal fluid (CSF) and blood, rather than in 
brain lesions.  
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Furthermore, the immunohistochemistry images were analyzed using Photoshop and image j 
[165]. The size of hCD64 stained area (Figure 40; 1) was calculated between 100-400 µm2 per 
image in the non-treated group, while it was reduced to below 100 µm2 per image in the day 6 
treated group, having only 2 samples of around 150 µm2 (p<0.0005). The day 13 treated 
group, presented a slightly reduced population of CD64, while no effect on disease clinical 
progress and scorings was seen.  
Thereafter CD14 was the next M1 marker that had the largest stained area by occupying 40 to 
120 µm2 of the image, while it was reduced to smaller than 40 µm2 stained area per image, in 
the day 6 treated group (p<0.0005). Moreover, CD14 staining was not affected in day 13 
treated group compared to the non-treated group (Figure 40; 2). 
Subsequently, the T cell population was additionally decreased, which further could have 
leads to EAE score reduction [10]. T cell reduction was observed as the consequence of the 
inflammatory macrophage reduction, because the samples treated by anti-macrophage 
therapy, had a decreased T cell population (Figure 39). The T cell stained area size of 27 µm2 
in the non-treated group was reduced to 4 µm2 in the treated group [(p<0.0005), (Figure 40; 
3)]. Here, the total population of the T cells was obviously affected by the reduction of M1 
macrophages. Since M2 regulatory macrophages treated by IL-4, failed to present antigens to 
T cells, and M1 macrophages are required for T cell activation, consequently upon M1 
reduction T cell activation could no longer be induced by APCs [178]. In addition, reduced 
accessibility of the cytotoxic materials plus immunoattractants, as IL-1, IL-6 and IL-23 
secreted by M1 cells, give rise to Th-17 inflammatory cells. Therefore upon their absence, the 
interaction between M1 macrophages and T cells are normally reduced [143].  
In this experimental model, by depleting M1 macrophages the fundamental structure of the 
BBB could have also been supported. M1 macrophages are the inflammatory cytokine 
producers (TNFα and IFNγ) that lead to BBB disruption. Therefore, upon depleting the CD64 
expressing M1 cells, the major source of the inflammatory cytokines could have been 
additionally eliminated [87], [181]. Here it was demonstrated that by eliminating M1 
macrophages, the total infiltrated autoimmune cells, such as CD14, CD36 or CD3, were 
reduced in the brain cerebellum sections.  
In addition to deplete M1 macrophages in the brain, these cells could further be targeted in the 
periphery and eliminated before they enter CNS. There are numerous advantages regarding 
this therapeutic strategy; since inhibiting the entrance of the cytokine-activated, blood-derived 
macrophages to CNS, prevents the disease severity [130]. Therefore, the total immune cell 
population could no longer been attracted to CNS, by the inflammatory mediators, produced 
by macrophages. Additionally as macrophage-mediated reactive microglia, contributes in 
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disease exacerbation [132], [185] by preventing the entrance of the inflammatory blood 
derived monocytes to CNS, microglia can no longer trigger the disease progress [124]. Since 
the brain supporting microglia cannot be activated without stimulation of the infiltrated 
macrophages, thus microglia will retain its regulatory profile, until it is not altered through 
cytokines, produced by M1 macrophages [69].  
A therapeutic called Natalizumab, was developed earlier to inhibit the entrance of leukocytes 
to CNS, by blocking the interaction between α4 integrin and vascular cell adhesion molecule 
1 (VCAM-1) on epithelial cells of BBB [187]. However, serious side effects were developed 
among the patients, suffering from MS, and treated by Natalizumab [188]. As more than 400 
cases were diagnosed since 2005, having progressive multifocal leukoencephalopathy (PML), 
as the consequence of Natalizumab therapy [189]. PML is a deadly infection of the CNS, as it 
destroys oligodendrocytes, and develops multifocal areas of demyelination. Therefore, it was 
withdrawn from the market in 2005 and was back again in 2006, while was permitted to be 
prescribed only under exceptional conditions [190]. Treatment by Natalizumab blocked the 
entrance of the invasive immune cells, but the disrupted brain barrier leads to development of 
an infection by JC polyomavirus. PML was known as the major reason of death in people 
treated by Natalizumab [191].  
Therefore, considering all, in order to inhibit the entrance of the auto reactive immune cells to 
CNS, by depleting them in the periphery; a cocktail of therapeutic antibodies could have been 
prepared [193], to improve the BBB’s maintenance. For example, IFNβ that protects the 
BBB’s structure or other regulatory agents, such as growth factors, could have been applied 
next to an anti-macrophage therapy. Subsequently, eliminating the inflammatory cells, while 
preventing the BBB’s break down [181], [196], and providing an additional support for its 
maintenance, might enable us to deplete the monocytes in the periphery and to overcome the 
cycle of MS disease. 
IV.6.2 The M2 macrophages and the micro environmental shift  
We demonstrated that the total inflammatory cell populations were reduced during this 
experiment (III.11), while M2 cells were increased or remained unaffected (Figure 40; 4, 5). 
Accordingly, CD301, as one of the M2 markers, was not changed in the immunostained 
sections (Figure 40; 4). Previously it was shown that CD301 was co-expressed together 
(Figure 28) with CD64 receptor on the macrophages, during their intermediate phase of 
plasticity [158], [198]. Therefore, targeting macrophages by CD64 directed immunotoxin, 
could have had reduced the double stained cells and depleted the intermediate macrophages. 
This could explain the reason that these cells were not increased even if the inflammatory 
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environment was directed to regulatory environment [186]. Indeed only fully polarized M2 
macrophages were able to remain in the tissue, those lacking the CD64 expression. According 
to Mokarram et al., macrophages in an intermediate phase, are always present in the brain 
lesions of MS and EAE model, but their role on the peripheral nerve repair is still unknown 
[170].  
Comparing the treated groups, CD301 was slightly increased in the day 13 treated group, even 
though that it was not changed in the day 6 treated group (Figure 40; 4). This could have been 
associated with disease stage, and presence of the active lesions together with the availability 
of the myelin particles [201]. M2 cells actively phagocyte the myelin debris to clean up the 
environment [180], therefore, their presence in an area having myelin debris, or where there is 
an ongoing demyelination, is essential. During this experiment, the day 6 treated group was 
kept until day 29 of the EAE induction; the time point that mice were completely recovered 
from the disease signs, and experienced 9 days of healthy condition with partially or mostly 
recovered lesions. Therefore, less myelin particles could have been available to phagocyte and 
consequently less M2 cells were required, as it was observed (Figure 40; 4). On the other 
hand, in day 13 treated group, sacrificed on day 21, an ongoing inflammation was already 
developed at that time point, with active lesions and developed severe clinical disabilities, 
therefore larger population of M2 cells were required to clean up the environment.  
Furthermore, the total population of the CD273, an IL-4 induced receptor [169], expressed on 
regulatory macrophages and dendritic cells, was considerably increased in day 6 treated group 
[(Figure 40; 5), (p<0.0005)]. CD273 is a member of PD-L2 (programmed death ligand 2) 
family and it involves in suppression of T cell proliferation and activation, upon engagement 
with PD-1 (programmed death 1) receptor [207]. In addition, the alternatively activated 
macrophages could inhibit the T-cell proliferation through expression of PD-L2 [209]. 
Moreover, B cell population was also minimized (Figure 39), because antigen presentation, 
and therefore antibody production of B cells was interrupted. Subsequently the myelin attack 
was stopped upon reduction of “B cell-produced” antibodies.  
IV.6.3 The M2 macrophages and remyelination 
During this experiment, after the treatment, we observed that, decrease of M1 macrophages 
reduced the T cells. It is known that T cells and macrophages are capable of maintaining a 
local inflammation together, without the necessity of an external stimuli [64]. Therefore 
reduction of M1 macrophages could decrease the T cell trigger and promote the dendritic cells 
to regulate the T cell response and participate in the positive immune regulating cycles 
(Figure 40; 3) [48], [145], [79], [156]. Furthermore the treatment and reduced M1 population 
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stimulates the M2 macrophages (CD301, CD273) to clean up the environment and produce 
anti-inflammatory agents (Figure 40; 4, 5) [42], This alteration and stimulation could have 
provide an anti-inflammatory environment around the infiltrated areas of the brain, and 
develops a regulatory properties to promote nerve regeneration by ODC’s [170], because the 
presence of M2 macrophages could further develop a regulatory micro environment upon 
normal cellular activities [210]. 
In the context of MS therapy, before providing a condition to promote myelin regeneration 
[179], and to further overcome the clinical disabilities; the microenvironment should have 
been able to send immuno-regulatory, rather than inflammatory signals. [212]. Boven et al., 
demonstrated that phagocytosing M2 macrophages, have an anti-inflammatory M2 profile, 
and are producing anti inflammatory agents and growth factors [180], they could further 
affect the surrounding micro environment, and promote myelin regeneration by OPC’s [138]. 
Additionally, the microenvironment could automatically be balanced and shifted regarding the 
phase of the disease. For instance, in relapsing remitting MS, the nature of the disease 
suggests the presence of regulatory mediators, which can control the disease and prevent the 
expansion of the demyelinating lesions (the remission phase). While imbalance 
microenvironment and cytokines towards the M1 population, promote relapses [216] and 
further accelerate the disease progress to SPMS or PPMS. Interestingly, macrophages have 
the ability to control the balance of the anti and pro-inflammatory (damaging vs. repairing) 
mediators and contribute in the development of anti-inflammatory environment [218], [220]. 
Additionally, a key target to shift the total infiltrate compositions and their reaction to the 
chronic inflammation is to polarize the macrophage population, which could have been 
beneficial in many macrophage-mediated diseases, as well as in MS [156]. Therefore, 
according to these outcomes, modulation of the macrophage profile from M1 inflammatory to 
M2 regulatory [186], while depleting the M1 cells (comparable to CD64 targeted therapy), 
would also be an advantageous concern [170], [223] and could promote remyelination and 
further provide disease recovery [225]. 
As it was shown previously, CD64 was strongly expressed on M1 macrophages, isolated from 
the PBMC’s of human blood and polarized by LPS, (Figure 19). Therefore, targeting CD64, 
could not just deplete M1 macrophages that destroy the myelin producing oligodendrocytes 
[226], but the remaining or modulated M2 macrophages (Figure 40; 4, 5) could further 
contribute in the activation of the myelin generating oligodendrocytes [228] by secretion of 
proper cytokines and growth factors [180].  
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IV.7 The treatment timing  
H22-ETAʹ′ was able to reduce the inflammatory infiltrates before the mice reached score 2 of 
the clinical signs (III.11), giving them the chance of complete recovery (Figure 36). 
Therefore, it might have stopped many unwanted destructive actions and immune 
malfunctions, such as microglial activation, macrophage mediated demyelination [172], 
oligodendrocyte destruction and further production of inflammatory agents [230].  
Accordingly the most crucial concern for treatment of either mice or humans would be the 
initiating time point of the treatment. Since remyelination is possible only in the active lesions 
where still hard plaques are not formed (such as III.11) [232], otherwise treatments would not 
be efficient anymore (such as III.6).  
It is widely accepted that upon presence of progressed non active lesions and plaques 
remyelination could no longer happened [48], [56], [158], [235]. An active lesion contained 
abundant macrophage population, while the slowly expanding chronic plaques, revealed 
milder macrophage activation only at the lesion margins [79], [201]. Therefore depleting the 
macrophages only from active lesions might assist the disease regulation, as it was observed 
here as well.  
Currently the diagnosis of MS is not based on a single test or a physical symptom, and indeed 
multi-factors together with MRI analysis are now used as a mixture of diagnostic tools. 
Therefore in 95% of the patients, MS is diagnosed within the first year [6], [238], [239], 
[240]. Understanding the initial phase of the disease, and the relapses early enough, are the 
key prerequisites for the development of MS therapeutics. Studies provided evidence that in 
patients who were suggested of developing Multiple Sclerosis in future, an early therapy with 
IFNβ, delayed the onset of the clinically definite MS [241].  
In our experiments, late treatment had no effect on the remyelination phase, even though that 
the inflammatory immune cell populations were reduced (III.6). Since the first evidence of 
remyelination is the reduction of the clinical scores and recovery of the physical disabilities, 
which did not happened in that group (III.6), but when mice treated from day 6 (III.11) the 
clinical signs were disappeared as the consequence of healthy and correct signal transfer 
through the neurons of the brain. 
IV.8 Targeting CD64 in human brain 
Conclusively, to evaluate the possible efficiency of the H22 based immunotoxins in human, 
paraffin embedded, MS brain tissue sections were stained in the Netherlands brain bank 
(Figure 41), using H22 single chain (III.12). The outcome indicated that CD64 (the human 
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version in human brain) could be targeted by H22 single chain in human brain, and it could 
have the potential to be further studied for human macrophage targeted therapy.  
A recent study determined the cytokine profile of the patients who were in the progressing/ 
relapsing stage of the disease. The major detected bio-markers were macrophage 
inflammatory factor (MIF), CCL2 and TNF-α, which were all produced by macrophages [42], 
[244]. This study presented that the inflammatory agents, mostly produced by macrophages, 
were increased in the patients who were suffering from the progressing phase of the disease. 
Therefore, confirming the role of macrophages in both progressive stage and relapsing phase, 
prior attacks. Finally, combining this technology with our findings might enable us to design 
an efficient therapeutic strategy for humans.  
Relapsing–remitting MS in humans, which affects 85% of total patients, manifests as several 
cycles of attack and partial recovery that occur during the course of the disease. Therefore, 
H22-ETAʹ′ treatment could be started prior to each attack, once increases in macrophage-
related inflammatory agents are monitored [244]. The treatment time point in humans could 
thus be very important and could determine the efficiency of the therapeutic on the progress 
of the disease. Relapsing–remitting mice models are also available to provide a more relevant 
therapeutic strategy similar to that of humans, but that model needs additional setup and could 
be an option for future research. Berard et al., compared the differences in relapsing–remitting 
and chronic EAE models in the C57BL/6 mice using the same antigen. They observed that at 
the peak of the disease, and with similar clinical scores, chronic EAE is associated with 
increased lesion areas, myelin loss, axonal damage, and chemokine/cytokine expression 
compared to relapsing–remitting EAE. They also reported that inflammation and myelin loss 
continues to worsen in the later stages of chronic EAE, whereas these features are largely 
resolved at the equivalent stage in relapsing–remitting EAE [245]. Thus, this excluded the 
relapsing–remitting EAE from an appropriate MS related experimental model. These 
differences indicate that the chronic model is more suitable for therapeutic purposes, as the 
healing efficiency of the therapy is more accurately observed in chronic models than in 
relapsing models.  
Here, macrophage depletion prevented the progressive phase of the disease in the chronic 
EAE mice model. While no therapeutic has been introduced to date that can inhibit 
progressive MS, H22-ETAʹ′ was shown to be efficient in mice. However, the non-human 
immunogenic fused toxin part could prevent repeated administration in humans, due to the 
development of an undesired immune response. 
To avoid immunogenicity, prior to undertaking clinical trials, the ETAʹ′ toxin part should be 
replaced by a human-based toxin, such as granzyme B (Gb), which is an apoptosis-inducing 
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serine protease naturally expressed and secreted by cytotoxic T lymphocytes and natural killer 
cells [247]. Stahnke et al., fused Gb genetically to H22 and obtained H22-Gb, a fusion protein 
lacking the immunogenic properties of non-human immunofusions [249]. In conclusion, the 
use of H22-Gb in human MS clinical trials could be a promising step, as the complicated 
immunogenic responses would be depleted. 
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 Conclusions  V.
Regarding the available therapeutics in the market, new targeting strategies are required to 
further promote myelin repair, regulate immune functions, and preserve tissue for Multiple 
Sclerosis therapy.  
In this context, the CD64 directed immunotoxin was established as an effective therapy for 
EAE and other developed disease models [23], [85], [252]. The IT reduced the EAE clinical 
symptoms and scores, from severe to none, while the other groups were suffering from high 
disease scores and disabilities. Additionally, the IT therapy reduced the population of the 
other inflammatory immune cell infiltrates, as the consequence of M1 macrophage depletion, 
leaving the regulatory M2 macrophages un-effected or increased.  
Respectively, late treatment had no healing effect on the clinical disabilities and demyelinated 
areas, developed by the infiltrates.  
H22-ETAʹ′ was shown to be a potential candidate for further development, particularly if 
combined with another therapy. Indeed, a mixture of therapeutics could be applied against 
macrophages, combined with other T or B cell directed immunotoxins. While, in the first 
place, the possibility of the disease development will be reduced, and in the second place, the 
number of the infiltrates and the expanded lesions would also be negligible. However, M2 
macrophage polarization could additionally promote remyelination and if the BBB’s structure 
could be further stabilized, the auto reactive immune cells will be eliminated in the periphery, 
and will no longer infiltrate into the CNS. Therefore H22-ETAʹ′ will deplete the M1 
macrophages in periphery before they could activate the microglia and expand the brain 
lesions.  
Conclusively, our data showed that the inflammatory M1 macrophage depletion using IT, 
could be a valuable strategy for MS treatment. Since, considering the expression profile of 
CD64 and the established immunostainings of the human brain, H22 could correspondingly 
target CD64 expressing cells in the human brain. This provides an entire new insight into 
macrophage related therapies for human MS. 
 
 
 
 
  
102 
 Summary VI.
In order to evaluate the potential role of the inflammatory macrophages in the pathogenesis of 
the autoimmune diseases, especially MS [254], the highly expressed CD64 receptor on the 
M1 macrophages was targeted through H22-ETAʹ′ IT in EAE induced, transgenic mice.  
The prerequisite protein products were produced for EAE induction and treatment. MOG (1-
125) was cloned, expressed, purified and characterized as the essential immunogenic protein. 
Considering the variable factors that could influence EAE induction, different protocols were 
tried by using various expressed MOG, purchased MOG and EAE induction kits.  
EAE was successfully induced, using Hooke laboratory’s EAE induction kit [MOG (35-55), 
supplemented with complete Freund’s adjuvant and pertussis toxin], in hCD64 transgenic 
C57BL/6 mice.  
Concerning the ability of H22-ETAʹ′ immunotoxin, to eliminate the CD64 expressing M1 
macrophages [39], it was selected as the suitable therapeutic protein. The immunotoxin was 
fermented and purified while its binding and toxic abilities were further established. 
Thereafter, variable doses, time points and injections were attempted, which enabled the 
establishment of an optimized protocol. Furthermore, the kinetics of different immune cells, 
including macrophages were studied in an EAE induced mice, through immunohistochemistry 
of the brain sections in four different time points, starting from day 6 to day 12 of EAE 
induction. The effect of H22-ETAʹ′ therapy was additionally verified on healthy non-EAE 
induced animals separately, to investigate the safety of the immunotoxin. Moreover, the 
immunostainings were developed using wide range of antibodies and staining substrates.  
Besides, the CD64 expression was evaluated on macrophage subtypes. The peripheral 
monocytes were isolated from human blood’s PBMCs and polarized to M1 (by LPS) and M2 
(IL-4) macrophages. Thereafter CD64 expression was confirmed to be predominantly on M1 
macrophages, polarized by LPS. In addition, hCD64 transgenic mice were bred and further 
developed in our own animal facility center, followed by related examinations and preparation 
of transgenic vs. non-transgenic littermates for the experiments. 
According to the processed protocol, the human CD64 transgenic, C57BL/6, EAE induced 
mice were treated by H22-ETAʹ′ immunotoxin. The EAE scorings and therefore the clinical 
signs were recovered in the treated group, while the non-treated ones were suffering from 
severe clinical disabilities and the progressive deterioration of the disease. The 
immunohistochemistry data displayed reduction of cell infiltrates in the treated group 
comparing to the non-treated and late-treated controls.  
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Conclusively, the statistically evaluated data together with the clinical findings, confirmed the 
importance of CD64 targeted therapy as a candidate for further studies. Taken together, 
targeting macrophages could potentially be significant, as a new therapeutic strategy in MS 
disease. Furthermore, it has the potential to be developed as one of the disease modifying and 
effective therapies, against the human’s Multiple Sclerosis. 
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 Appendix VIII.
VIII.1   Abbreviations 
AA   Acrylamide 
AEC   3-amino-9-ethylcarbazole  
ADCC   Antibody dependent cellular cytotoxicity 
Ab   Antibody 
Ag   Antigen 
AML   Acute myeloid leukemia 
Amp   Ampicillin 
AP   Alkaline phosphatase 
APS   Ammonium persulfate 
APC   Antigen presenting cell 
ATCC   American Type Culture Collection 
bp   Base pair 
BBB   Blood brain barrier 
BSA                            Bovine serum albumin 
°C   Degree Celsius 
CCL   Chemokine ligands 
CD   Cluster of differentiation 
CFA   Complete Freund’s adjuvant 
CNS   Central nervous system 
CSF                            Cerebrospinal fluid 
dH2O                          Deionized water 
H2O2   Hydrogen peroxide 
DC   Dendritic cells 
DMF                           N,N-Dimethylformamide 
DNA   Deoxyribonucleic acid 
dNTP   Deoxynucleotide triphosphate 
DSMZ                        Deutsche Sammlung von Mikroorganismen und Zellkulturen 
DMSO  Dimethylsulfoxide 
EAE   Experimental autoimmune encephalomyelitis 
E. coli   Escherichia coli 
EDTA   Ethylenediaminetetraacetic acid 
eGFP   Enhanced green fluorescent protein 
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ELISA   Enzyme-linked Immunosorbent assay 
ETAʹ′   Pseudomonas exotoxin A (truncated) 
Fab   Fragment antigen binding 
FACS   Fluorescence activated cell sorting 
Fc   Fragment crystallisable 
FcγR   Fcγ-receptor 
FCS   Fetal calf serum 
FITC   Fluorescein isothiocyanate 
g   Gram 
GA   Glatiramer acetate  
Gb   Grenzyme B 
GAM   Goat anti mouse 
G-CSF   Granulocyte colony stimulating factor 
GL   Granular layer 
h   Hour 
hCD64  Human CD64 
h-mAb   Humanized monoclonal antibody 
His-Tag  Polyhistidine residue  
HRP   Horseradish peroxidase 
IC50   Inhibitory concentration at 50% survival 
IFNγ   Interferon γ 
IFNβ   Interferon β 
IgG   Immunoglobulin G 
Igκ-leader  Ig-kappa-signal peptide 
IHC   Immunohistochemistry 
IL   Interleukin 
IMAC   Immobilized metal ion affinity chromatography 
IP   Intraperitoneally injection 
IV   Intravenous injection 
IPTG   Isopropyl-beta-D-thiogalactopyranoside 
IT   Immunotoxin 
Kan   Kanamycin 
kb   Kilo base pair 
kDa   Kilo Dalton 
LB   Luria Bertani (broth) 
  
122 
LPS   Lipopolysaccharide 
m   Milli 
µ   Micro 
M   Molar 
mA   Milli ampere 
mAb   Monoclonal Antibody 
MBP   Myelin basic glycoprotein 
M-CSF                        Macrophage colony stimulating factor 
MHC   Major histocompatibility complex 
MIP   Macrophage inflammatory factor 
µg   Micro gram 
µl   Micro liter 
ml   Milli liter 
ML   Molecular layer 
µm   Micro meter 
mM   Milli molar 
MMP   Matrix metalloproteinase 
MOG   Myelin oligodendrocyte glycoprotein 
MS   Multiple sclerosis 
NAWM  Normal appearing white matter 
NBT/BCIP  Nitro blue tetrazolium chloride/5-bromo-4-chloro-3-indolyl-phosphate 
ng   Nano gram 
NBB   Netherlands brain bank 
NEB   New England Biolabs 
Ni-NTA  Nickel nitrilotriacetic acid 
Nt   Non treated 
ON   Over night 
OPC   Oligodendrocyte precursor cell 
PAA   Polyacrylamide 
PAGE   Polyacrylamide gel electrophoresis 
PBMCs  Peripheral blood mononuclear cells 
PBS   Phosphate buffered saline 
PBST   PBS with 0.05% (v/v) Tween 20 
PD   Programmed death 
PD-L   Programmed death ligand 
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pH   Common logarithm of the concentration of hydrogen ions 
PLP   Myelin proteolipid protein 
PML   Progressive multifocal leukoencephalopathy 
PMN   polymorphonuclear 
PPMS   primary progressive multiple sclerosis 
PT   Pertussis toxin 
RA   Rheumatoid arthritis  
rpm   Rounds per minute 
RRMS   relapsing remitting multiple sclerosis 
RT   Room temperature 
sec   Second 
scFv   Single chain fragment variable 
SDS   Sodium dodecyl sulphate 
SEC   Size exclusion chromatography 
SPMS   Secondary progressive multiple sclerosis 
T   Treated 
TAE   Tris acetate EDTA 
TCR   T cell receptor 
TEMED  Tetramethylethylenediamine 
TGF-β   Tumor growth factor β 
Th   T helper cell 
TLR   Toll-like receptor 
TNFα   Tumor necrosis factor alfa 
Tris   Tris-hydroxymethyl amino ethane 
Tween 20  Polyoxyethylene 20 sorbitan monolaurate  
U   Unit 
UV   Ultra violet 
v/v   Volume per volume 
VCAM-1  Vascular cell adhesion molecule 1 
VLA-4  Very late antigen 4 
w/v   Weight per volume 
WB   Western blot 
WM   White matter 
XTT Sodium 3'-[1-(phenylaminocarbonyl)-3,4-tetrazolium] -bis (4-methoxy-
6-nitro) benzenesulfonic acid hydrate 
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VIII.2    Sequences 
Myelin oligodendrocyte glycoprotein (MOG), extracellular domain (MOG 1-125). 
MOG sequence is displayed below, with the relevant restriction sites for cloning; including 
SfiI and NotI (marked in blue). The first, guanine (G) and last, valine (V) amino acids are 
marked in red.  
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